Pharma & Biotech Sector Financials, Performance and Ratios
-
Sector Score
35.4 /100
Rank 20 out of 27 Sectors -
Advance/Decline
171/477
-
No. of Companies648
-
Avg. Market Cap8,360
-
Price to Earning Ratio6.83
-
Price to Earning Growth Ratio0.92
-
Price to Book Ratio28.25
-
Return on Equity6.78
-
Return on Capital Employed-
-
Return on Assets3.42
-
Dividend yield 1 year %0.66 %
-
Net Profit Growth Annual YoY %13.60 %
-
Net Profit Growth Qtr YoY %99.21 %
-
Net Profit Growth Qtr QoQ %535.15 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Pharma & Biotech Sector Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Pharma & Biotech Peer comparison
Compare all stocks in Pharma & Biotech industry listed on stock exchanges
| Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AbbVie |
|
358,545.8
|
202.7
|
L
 -1.1%
H
202.0
207
|
L
 -0.6%
H
202.0
214.9
|
L
 -1.9%
H
190.8
214.9
|
L
 -9.3%
H
190.8
237.1
|
L
 8.3%
H
176.6
244.8
|
L
 36.9%
H
131.0
244.8
|
L
 74.6%
H
105.6
244.8
|
L
 224.3%
H
55.1
244.8
|
| Adc Therapeutics SA |
|
477.0
|
3.8
|
L
 -2.9%
H
3.7
3.9
|
L
 -0.8%
H
3.4
4.1
|
L
 2.2%
H
3.4
4.8
|
L
 -6.5%
H
3.4
5.0
|
L
 190.7%
H
1.2
5.0
|
L
 91.3%
H
0.4
6.0
|
L
 -83.4%
H
0.4
32
|
L
H
0.4
56.6
|
| Amneal Pharma Inc (Class A) |
|
4,376.7
|
13.7
|
L
 0.7%
H
13.5
13.8
|
L
 7.2%
H
12.4
13.8
|
L
 11.1%
H
12.0
13.9
|
L
 -5.5%
H
11.7
15.4
|
L
 91.1%
H
7.0
15.4
|
L
 614.6%
H
1.7
15.4
|
L
 137.4%
H
1.2
15.4
|
L
 -54.0%
H
1.2
35.2
|
| Annovis Bio Inc |
|
78.3
|
2.3
|
L
 -5.8%
H
2.3
2.4
|
L
 22.8%
H
1.9
2.4
|
L
 -3.8%
H
1.5
2.4
|
L
 -9.2%
H
1.5
3.0
|
L
 56.9%
H
1.4
5.5
|
L
 -84.2%
H
1.1
22.5
|
L
 -89.7%
H
1.1
132
|
L
H
1.1
132
|
| Bausch Health Companies Inc |
|
2,140.0
|
5.7
|
L
 1.4%
H
5.6
5.9
|
L
 2.5%
H
5.4
6.3
|
L
 5.9%
H
5.2
6.3
|
L
 -2.6%
H
4.9
6.3
|
L
 20.9%
H
4.4
8.7
|
L
 -1.7%
H
4.0
11.5
|
L
 -79.4%
H
4.0
32.5
|
L
 -80.8%
H
4.0
34.8
|
| Bristol-Myers Squibb |
|
114,866.5
|
56.3
|
L
 -0.6%
H
55.6
56.9
|
L
 -2.3%
H
55.6
60.8
|
L
 -5.2%
H
55.6
60.8
|
L
 -9.3%
H
55.6
62.9
|
L
 18.3%
H
42.5
62.9
|
L
 -17.4%
H
39.4
69.1
|
L
 -12.7%
H
39.4
81.4
|
L
 -21.0%
H
39.4
81.4
|
| Emergent Biosolutions Inc |
|
471.1
|
9.1
|
L
 0.3%
H
9.0
9.5
|
L
 14.3%
H
7.5
9.5
|
L
 12.7%
H
7.5
9.5
|
L
 -16.4%
H
7.5
11.5
|
L
 90.6%
H
4.7
14.1
|
L
 1.9%
H
1.4
15.1
|
L
 -85.0%
H
1.4
68.0
|
L
 -74.8%
H
1.4
137.6
|
| Elanco Animal Health Inc |
|
11,990.1
|
24.0
|
L
 -8.3%
H
23.5
26.2
|
L
 10.1%
H
21.8
26.3
|
L
 5.2%
H
21.6
26.3
|
L
 -4.7%
H
21.6
27.7
|
L
 152.5%
H
10.8
27.7
|
L
 157.9%
H
7.9
27.7
|
L
 -22.7%
H
7.9
37.5
|
L
H
7.9
37.6
|
| GSK PLC (ADR) |
|
101,379.4
|
50.5
|
L
 -0.1%
H
50.4
50.8
|
L
 -1.8%
H
50.0
52.6
|
L
 -10.4%
H
50.0
59.6
|
L
 -16.2%
H
50.0
61.7
|
L
 34.7%
H
35.5
61.7
|
L
 36.6%
H
31.7
61.7
|
L
 30.9%
H
28.5
61.7
|
L
 17.7%
H
28.5
61.7
|
| Johnson & Johnson |
|
535,629.8
|
222.5
|
L
 -0.9%
H
220.6
224.8
|
L
 -2.1%
H
220.6
231.2
|
L
 -7.7%
H
220.6
244.2
|
L
 -7.3%
H
220.6
251.7
|
L
 44.1%
H
146.1
251.7
|
L
 36.8%
H
140.7
251.7
|
L
 32.7%
H
140.7
251.7
|
L
 97.4%
H
109.2
251.7
|
| Eli Lilly |
|
869,412.2
|
975.0
|
L
 -1.2%
H
967.1
989
|
L
 14.5%
H
896.8
996.5
|
L
 5.2%
H
850.5
996.5
|
L
 -7.9%
H
850.5
1106.9
|
L
 25.8%
H
623.8
1134.0
|
L
 127.9%
H
419.8
1134.0
|
L
 402.8%
H
191.8
1134.0
|
L
 1206.9%
H
64.2
1134.0
|
| Merck & Company |
|
277,361.3
|
112.3
|
L
 -1.1%
H
111.1
113.8
|
L
 1.2%
H
108.6
114.6
|
L
 -7.1%
H
107.9
124
|
L
 -7.9%
H
107.9
125.1
|
L
 42.1%
H
73.3
125.1
|
L
 -4.6%
H
73.3
134.6
|
L
 51.3%
H
70.9
134.6
|
L
 119.6%
H
50.4
134.6
|
| Nuvation Bio Inc (Class A) |
|
1,674.9
|
4.8
|
L
 -4.6%
H
4.7
5.1
|
L
 10.8%
H
4.1
5.2
|
L
 8.1%
H
4.1
5.3
|
L
 -15.6%
H
4.0
6.1
|
L
 130.1%
H
1.6
9.8
|
L
 188.0%
H
1.0
9.8
|
L
 -56.4%
H
1.0
15.2
|
L
H
1.0
15.2
|
| Novo Nordisk (ADR) |
|
203,750.5
|
45.8
|
L
 0.1%
H
45.8
47.1
|
L
 13.7%
H
41.7
47.6
|
L
 24.9%
H
36.0
47.6
|
L
 -3.9%
H
35.1
51.1
|
L
 -30.9%
H
35.1
81.4
|
L
 -43.9%
H
35.1
148.2
|
L
 23.5%
H
35.1
148.2
|
L
 71.7%
H
15.5
148.2
|
| Novartis AG (ADR) |
|
277,417.5
|
145.4
|
L
 -2%
H
145.0
148.1
|
L
 1.7%
H
144.5
148.8
|
L
 -4.9%
H
142.3
156.5
|
L
 -7.1%
H
142.3
170.5
|
L
 31.5%
H
104.9
170.5
|
L
 38.8%
H
92.2
170.5
|
L
 66.4%
H
74.1
170.5
|
L
 125.1%
H
59.2
170.5
|
| Organon & Co. |
|
3,497.8
|
13.3
|
L
 -0.7%
H
13.3
13.4
|
L
 -0.2%
H
13.3
13.4
|
L
 120.2%
H
5.8
13.4
|
L
 62.2%
H
5.7
13.4
|
L
 45.9%
H
5.7
13.4
|
L
 -40.9%
H
5.7
24.1
|
L
H
5.7
39.5
|
L
H
5.7
39.5
|
| Prestige Consumer Healthcare Inc |
|
2,583.1
|
54.6
|
L
 0.5%
H
53.6
55.1
|
L
 -2.6%
H
53.1
56.8
|
L
 -1.0%
H
53.1
60.3
|
L
 -17.7%
H
51.2
71.1
|
L
 -32.6%
H
51.2
89.4
|
L
 -10.2%
H
51.2
90.0
|
L
 15.9%
H
45.9
90.0
|
L
 -3.7%
H
26.3
90.0
|
| Pfizer |
|
151,756.9
|
26.5
|
L
 -0.2%
H
26.2
26.7
|
L
 0.8%
H
26.0
26.9
|
L
 -4.9%
H
26.0
27.8
|
L
 -2.7%
H
26.0
28.7
|
L
 15.7%
H
22.0
28.7
|
L
 -31.2%
H
20.9
40.4
|
L
 -32.4%
H
20.9
61.7
|
L
 -16.8%
H
20.9
61.7
|
| Perrigo Co PLC |
|
1,625.6
|
11.7
|
L
 -4.4%
H
11.7
12.4
|
L
 3.8%
H
11.3
12.6
|
L
 10.7%
H
10.4
12.6
|
L
 -20.0%
H
9.2
15.0
|
L
 -52.5%
H
9.2
28.4
|
L
 -67.2%
H
9.2
40.3
|
L
 -72.5%
H
9.2
50.9
|
L
 -87.3%
H
9.2
111
|
| Arcus Biosciences Inc |
|
3,107.4
|
24.8
|
L
 -4.7%
H
24.6
25.9
|
L
 2.7%
H
24.1
26.7
|
L
 11.4%
H
20.3
28.7
|
L
 17.8%
H
18.5
28.7
|
L
 205.2%
H
7.1
28.7
|
L
 26.7%
H
6.5
28.7
|
L
 -17.8%
H
6.5
49.1
|
L
H
6.3
49.1
|
| Dr. Reddy`s Laboratories Ltd (ADR) |
|
11,181.7
|
13.4
|
L
 -0.2%
H
13.4
13.7
|
L
 -2.2%
H
13.2
13.8
|
L
 2.2%
H
12.8
14.2
|
L
 -4.6%
H
12.8
14.8
|
L
 -0.6%
H
12.8
16.2
|
L
 10.4%
H
10.6
74.9
|
L
 -5.0%
H
9.6
74.9
|
L
 60.3%
H
5.6
74.9
|
| Takeda pharma Co (ADR) |
|
52,569.0
|
16.6
|
L
 -0.5%
H
16.6
16.9
|
L
 2.1%
H
16.5
16.9
|
L
 -8.7%
H
16.2
18.8
|
L
 -7.0%
H
16.2
18.9
|
L
 9.7%
H
13.0
18.9
|
L
 -1.4%
H
12.6
18.9
|
L
 0.1%
H
12.3
18.9
|
L
 -30.8%
H
12.3
30.6
|
| Teva- pharma Ind Ltd (ADR) |
|
41,931.0
|
36.0
|
L
 -0.9%
H
35.6
37.0
|
L
 1.8%
H
34.5
37.0
|
L
 20.8%
H
28.9
37.0
|
L
 3.8%
H
27.9
37.0
|
L
 123.4%
H
15.0
37.3
|
L
 310.6%
H
7.1
37.3
|
L
 250.0%
H
6.8
37.3
|
L
 -28.4%
H
6.1
56.4
|
| Usana Health Sciences Inc |
|
358.3
|
19.5
|
L
 -2.8%
H
19.5
20.4
|
L
 4.0%
H
18.2
21
|
L
 11.1%
H
17.1
21
|
L
 -8.8%
H
16.6
22.5
|
L
 -31.7%
H
16.6
38.3
|
L
 -71.0%
H
16.6
69.6
|
L
 -80.2%
H
16.6
107.9
|
L
 -68.8%
H
16.6
138.0
|
| Zoetis (Class A) |
|
36,715.4
|
87.3
|
L
 -21.5%
H
85.3
91.6
|
L
 -23.3%
H
85.3
116.3
|
L
 -26.2%
H
85.3
123.3
|
L
 -31.5%
H
85.3
132.5
|
L
 -41.7%
H
85.3
172.2
|
L
 -53.1%
H
85.3
201.9
|
L
 -47.9%
H
85.3
249.3
|
L
 84.4%
H
45.3
249.3
|
| Biohaven Ltd |
|
1,466.5
|
9.7
|
L
 -3.0%
H
9.6
10.1
|
L
 5.9%
H
9.0
10.8
|
L
 6.5%
H
8.8
11.1
|
L
 -16.0%
H
8.0
13.1
|
L
 -49.2%
H
7.5
22.1
|
L
 -31.6%
H
7.5
62.2
|
L
H
5.5
62.2
|
L
H
5.5
62.2
|
| Whitehawk Therapeutics Inc |
|
194.7
|
3.9
|
L
 -5.1%
H
3.9
4.1
|
L
 -2.5%
H
3.8
4.3
|
L
 12.6%
H
3.3
4.4
|
L
 42.8%
H
2.7
4.5
|
L
 149.4%
H
1.6
4.5
|
L
 -51.1%
H
1.2
8.6
|
L
 -75.0%
H
1.2
49.8
|
L
H
1.2
101.3
|
| AbCellera Biologics Inc |
|
1,471.4
|
4.8
|
L
 -4.4%
H
4.7
5.2
|
L
 26.2%
H
3.8
5.2
|
L
 42.2%
H
3.2
5.2
|
L
 52.5%
H
2.9
5.2
|
L
 137.4%
H
1.9
6.5
|
L
 -19.5%
H
1.9
8.1
|
L
 -83.2%
H
1.9
36.1
|
L
H
1.9
71.9
|
| Abeona Therapeutics Inc |
|
328.2
|
5.8
|
L
 -4.0%
H
5.6
6
|
L
 8.1%
H
5.4
6.1
|
L
 21.2%
H
4.6
6.1
|
L
 12.5%
H
4.2
6.1
|
L
 0.2%
H
4
7.5
|
L
 75.9%
H
2.9
9.0
|
L
 -84.8%
H
2.2
48
|
L
 -90.4%
H
2.2
568.8
|
| Oruka Therapeutics Inc |
|
3,835.0
|
64.1
|
L
 -8.2%
H
63.5
70.2
|
L
 -5.9%
H
61.0
71.0
|
L
 13.7%
H
55.1
91
|
L
 93.9%
H
31
91
|
L
 589.7%
H
8.9
91
|
L
 153.1%
H
2.2
91
|
L
 72.8%
H
2.2
91
|
L
 -92.1%
H
2.2
848.9
|
| Acumen Pharma Inc |
|
178.4
|
2.5
|
L
 -3.9%
H
2.4
2.6
|
L
 5.6%
H
2.3
2.6
|
L
 -10.5%
H
2.3
3.0
|
L
 2.9%
H
2.2
3.6
|
L
 147%
H
1.0
3.6
|
L
 -53.3%
H
0.9
11.3
|
L
H
0.9
27.0
|
L
H
0.9
27.0
|
| Arbutus Biopharma Corp |
|
856.7
|
4.4
|
L
 -1.6%
H
4.3
4.4
|
L
 5.3%
H
4.1
4.5
|
L
 -2.5%
H
4.0
4.8
|
L
 13.3%
H
3.8
4.9
|
L
 31.0%
H
2.9
5.1
|
L
 67.3%
H
1.7
5.1
|
L
 55.4%
H
1.7
6.5
|
L
 4.8%
H
0.8
12.6
|
| ABVC BioPharma Inc |
|
28.2
|
1.1
|
L
H
1.1
1.2
|
L
 6.8%
H
1.0
1.2
|
L
 -20.9%
H
1.0
1.8
|
L
 -36.8%
H
0.9
1.8
|
L
 -4.4%
H
0.9
5.5
|
L
 -86.4%
H
0.4
9.6
|
L
 -97.7%
H
0.4
299.5
|
L
 -99.7%
H
0.4
378
|
| Acadia Pharma Inc |
|
3,862.6
|
22.6
|
L
 5.0%
H
21.5
22.8
|
L
 1.6%
H
21.4
23.1
|
L
 1.1%
H
21.0
23.1
|
L
 -4.2%
H
19.9
25.4
|
L
 55.2%
H
14.5
28.4
|
L
 2.9%
H
13.4
33.9
|
L
 7.7%
H
12.2
33.9
|
L
 -18.4%
H
12.2
58.7
|
| Adicet Bio Inc |
|
77.8
|
8.3
|
L
 -2.7%
H
8.2
8.7
|
L
 9.0%
H
7.5
8.9
|
L
 20.6%
H
6.1
8.9
|
L
 18.4%
H
6.0
8.9
|
L
 -13.8%
H
6.0
17.4
|
L
 -91.9%
H
6.0
120
|
L
 -96.3%
H
6.0
349.9
|
L
H
6.0
349.9
|
| Achieve Life Sciences Inc |
|
491.7
|
4.8
|
L
 -0.2%
H
4.7
4.9
|
L
 15.4%
H
4.2
4.9
|
L
 48.3%
H
3.1
5.3
|
L
 12.7%
H
2.6
5.3
|
L
 93.2%
H
2
6.0
|
L
 -45.0%
H
1.8
10.3
|
L
 -51.0%
H
1.8
10.4
|
L
 -99.8%
H
1.8
2904
|
| AC Immune SA |
|
297.2
|
2.9
|
L
 -1.7%
H
2.9
3.0
|
L
 -0.3%
H
2.9
3.2
|
L
 8.2%
H
2.8
3.5
|
L
 -7.0%
H
2.4
3.5
|
L
 80.3%
H
1.5
4
|
L
 40.4%
H
1.4
5.1
|
L
 -51.7%
H
1.4
12.6
|
L
H
1.4
20.0
|
| Aclaris Therapeutics Inc |
|
678.8
|
4.9
|
L
 1.7%
H
4.6
4.9
|
L
 8.7%
H
4.2
4.9
|
L
 27.9%
H
3.6
4.9
|
L
 36.1%
H
2.8
4.9
|
L
 279.7%
H
1.2
4.9
|
L
 -45.9%
H
0.6
11.1
|
L
 -79.6%
H
0.6
24.4
|
L
 -76.5%
H
0.6
33.3
|
| Acrivon Therapeutics Inc |
|
86.9
|
2.0
|
L
 -2.9%
H
2
2.1
|
L
 12.2%
H
1.8
2.2
|
L
 29.3%
H
1.4
2.2
|
L
 21.6%
H
1.3
2.2
|
L
 52.6%
H
1.1
3.6
|
L
 -83.8%
H
1.1
14.3
|
L
H
1.1
25.5
|
L
H
1.1
25.5
|
| Acelrx Pharma Inc |
|
14.9
|
0.9
|
L
 1.2%
H
0.8
0.9
|
L
 8.6%
H
0.8
1.0
|
L
 20.6%
H
0.7
1.0
|
L
 8.6%
H
0.7
1
|
L
 76%
H
0.4
1.6
|
L
 35.4%
H
0.4
1.6
|
L
 -96.1%
H
0.4
33.4
|
L
 -98.6%
H
0.4
115
|
| Grace Therapeutics Inc |
|
34.8
|
2.3
|
L
 -5.1%
H
2.2
2.4
|
L
 7.1%
H
2.1
2.6
|
L
 -44.7%
H
1.8
5.1
|
L
 -37.5%
H
1.8
5.2
|
L
 -23.7%
H
1.8
5.2
|
L
 -16.4%
H
1.7
5.2
|
L
 -88.4%
H
1.7
32.6
|
L
 -96.5%
H
1.7
161.1
|
| Acurx Pharma Inc |
|
6.1
|
2.1
|
L
 1.4%
H
2.0
2.1
|
L
 7.6%
H
1.9
2.3
|
L
 -40.1%
H
1.9
3.5
|
L
 -3.2%
H
1.3
7.5
|
L
 -68.9%
H
1.3
21
|
L
 -96.5%
H
1.3
176.4
|
L
H
1.3
176.4
|
L
H
1.3
176.4
|
| Adial Pharma Inc |
|
2.0
|
1.4
|
L
 -10.1%
H
1.4
1.6
|
L
 -8.4%
H
1.4
1.7
|
L
 -18.9%
H
1.4
1.8
|
L
 -54.5%
H
1.4
3.3
|
L
 -91.8%
H
1.4
18.9
|
L
 -99.3%
H
1.4
350
|
L
 -99.9%
H
1.4
3175
|
L
H
1.4
5900
|
| Adma Biologics Inc |
|
1,967.8
|
8.5
|
L
 -16.0%
H
7.5
8.6
|
L
 -20.1%
H
7.5
10.9
|
L
 -8.7%
H
7.5
11.4
|
L
 -48.5%
H
7.2
17.2
|
L
 -63.4%
H
7.2
24.0
|
L
 144.8%
H
3.1
25.7
|
L
 416.5%
H
1.0
25.7
|
L
 38.4%
H
1.0
25.7
|
| Adaptive biotech Corp |
|
2,284.6
|
14.7
|
L
 1.8%
H
14.2
15.1
|
L
 8.6%
H
13.0
15.1
|
L
 4.3%
H
12.4
15.6
|
L
 -6.9%
H
12
17.0
|
L
 66.7%
H
8.4
20.8
|
L
 131.3%
H
2.3
20.8
|
L
 -59.9%
H
2.3
43.4
|
L
H
2.3
71.3
|
| Aditxt Inc |
|
0.1
|
0.1
|
L
 -14.3%
H
0.1
0.1
|
L
 -45.5%
H
0.1
0.2
|
L
 -80%
H
0.1
0.5
|
L
 -97.7%
H
0.1
6.4
|
L
 -100.0%
H
0.1
1979.8
|
L
 -100.0%
H
0.1
9835520000
|
L
 -100.0%
H
0.1
10000000000
|
L
H
0.1
10000000000
|
| Agenus Inc |
|
155.8
|
3.8
|
L
 -3.6%
H
3.7
3.9
|
L
 -2.3%
H
3.7
4.3
|
L
 -0.5%
H
3.6
5.1
|
L
 27.6%
H
2.8
5.1
|
L
 26.3%
H
2.7
7.3
|
L
 -88.1%
H
1.4
196
|
L
 -93.2%
H
1.4
196
|
L
 -93.7%
H
1.4
196
|
| Agios Pharma Inc |
|
1,637.3
|
27.5
|
L
 2.0%
H
26.9
27.6
|
L
 -1.9%
H
26.5
28.7
|
L
 -20.9%
H
24.3
36.0
|
L
 3.8%
H
24.3
36.4
|
L
 -2.8%
H
22.2
46
|
L
 7.8%
H
19.8
62.6
|
L
 -50.0%
H
16.8
62.6
|
L
 -36.8%
H
16.8
99.8
|
| Aeglea BioTherapeutics Inc |
|
296.0
|
73.1
|
L
 0.1%
H
71.1
74.5
|
L
 1.7%
H
67.2
76
|
L
 49.2%
H
48.8
76
|
L
 108.1%
H
32.4
76
|
L
 381.6%
H
13.9
76
|
L
 1727.5%
H
2.7
76
|
L
 -59.9%
H
2.7
212.5
|
L
 -66.4%
H
2.7
300
|
| Akebia Therapeutics Inc |
|
316.5
|
1.2
|
L
 -20.3%
H
1.1
1.2
|
L
 -13.2%
H
1.1
1.5
|
L
 -10.6%
H
1.1
1.6
|
L
 -15.1%
H
1.1
1.6
|
L
 -49.1%
H
1.1
4.1
|
L
 8.3%
H
0.8
4.1
|
L
 -60.8%
H
0.2
4.3
|
L
 -85.9%
H
0.2
20.3
|
| Avalon GloboCare Corp |
|
3.3
|
0.4
|
L
 -2.4%
H
0.4
0.4
|
L
H
0.4
0.4
|
L
 -31.0%
H
0.3
0.6
|
L
 -37.5%
H
0.3
1.6
|
L
 -89.0%
H
0.3
4.7
|
L
 -79.2%
H
0.2
11.7
|
L
 -95.7%
H
0.2
15.7
|
L
H
0.2
135
|
| Aldeyra Therapeutics Inc |
|
104.4
|
1.7
|
L
 -0.6%
H
1.7
1.8
|
L
 15.3%
H
1.5
1.9
|
L
 12.3%
H
1.5
1.9
|
L
 -68.7%
H
1.1
5.7
|
L
 -17.6%
H
1.1
6.2
|
L
 -83.6%
H
1.1
12.0
|
L
 -85.6%
H
1.1
13.2
|
L
 -72.1%
H
1.1
16.7
|
| Alector Inc |
|
270.9
|
2.4
|
L
 -5.1%
H
2.4
2.6
|
L
 6.1%
H
2.2
2.7
|
L
 4.3%
H
2.2
2.7
|
L
 24.5%
H
1.8
2.7
|
L
 132.4%
H
1.0
3.4
|
L
 -67.1%
H
0.9
9.1
|
L
 -85.6%
H
0.9
43.3
|
L
H
0.9
43.3
|
| Aligos Therapeutics Inc |
|
37.3
|
6.0
|
L
 -5.3%
H
6.0
6.5
|
L
 1.0%
H
5.9
6.8
|
L
 -25.5%
H
5.9
9.0
|
L
 -17.6%
H
5.9
9.0
|
L
 31.7%
H
4.2
13.7
|
L
 -80.5%
H
3.8
46.3
|
L
 -99.1%
H
3.8
857.8
|
L
H
3.8
937.8
|
| Alkermes PLC |
|
5,883.3
|
35.4
|
L
 0.2%
H
35.3
36.3
|
L
 5.0%
H
33.1
36.6
|
L
 3.9%
H
32.5
36.6
|
L
 1.4%
H
27
36.6
|
L
 16.6%
H
25.2
36.6
|
L
 20.2%
H
22.0
36.6
|
L
 60.8%
H
21.2
36.6
|
L
 -7.5%
H
12.0
71.2
|
| Allogene Therapeutics Inc |
|
783.2
|
2.3
|
L
 -1.7%
H
2.3
2.4
|
L
 7.6%
H
2.1
2.4
|
L
 -12.7%
H
1.9
4.5
|
L
 34.3%
H
1.6
4.5
|
L
 77.3%
H
0.9
4.5
|
L
 -65.6%
H
0.9
6.9
|
L
 -92.2%
H
0.9
31.8
|
L
H
0.9
55
|
| Allarity Therapeutics Inc |
|
23.2
|
1.5
|
L
 1.4%
H
1.4
1.5
|
L
 8.7%
H
1.2
1.6
|
L
 27.1%
H
1.1
1.6
|
L
 80.7%
H
0.8
1.6
|
L
 40.2%
H
0.8
2.1
|
L
 -99.5%
H
0.1
366.4
|
L
H
0.1
509600
|
L
H
0.1
509600
|
| Alnylam Pharma Inc |
|
39,507.7
|
295.9
|
L
 -2.3%
H
293.8
303.5
|
L
 -1.8%
H
287
317.6
|
L
 -10.4%
H
287
343.4
|
L
 -9.8%
H
287
345.9
|
L
 9.7%
H
246
495.6
|
L
 39.5%
H
142.0
495.6
|
L
 124.0%
H
117.6
495.6
|
L
 432.7%
H
31.4
495.6
|
| Rein Therapeutics Inc |
|
91.3
|
1.2
|
L
H
1.1
1.2
|
L
 -8.6%
H
1
1.4
|
L
 -15.8%
H
1
2.1
|
L
 2.6%
H
1
2.1
|
L
 -32.4%
H
1
2.4
|
L
 -14.0%
H
1
7.4
|
L
 -94.7%
H
1
28
|
L
H
1
309.6
|
| Altimmune Inc |
|
590.8
|
3.0
|
L
 -6.8%
H
3
3.2
|
L
 15.6%
H
2.6
3.3
|
L
 -8.7%
H
2.6
3.6
|
L
 -37.6%
H
2.6
5.0
|
L
 -39.6%
H
2.6
7.7
|
L
 -38.5%
H
2.1
14.8
|
L
 -76.5%
H
2.1
23.5
|
L
 -99.6%
H
1.5
1050
|
| Alvotech |
|
998.6
|
3.2
|
L
 -10.4%
H
3.2
3.4
|
L
 -3.0%
H
3.2
3.6
|
L
 -15.6%
H
3.2
3.8
|
L
 -37.5%
H
3.0
5.3
|
L
 -59.9%
H
3.0
11.9
|
L
 -67.2%
H
3.0
18
|
L
H
3.0
18
|
L
H
3.0
18
|
| Kalaris Therapeutics Inc |
|
118.4
|
5.2
|
L
 1.8%
H
5.0
5.2
|
L
 -6.5%
H
5.0
5.7
|
L
 -17.9%
H
5.0
7.1
|
L
 -38.3%
H
5.0
11.2
|
L
 7.5%
H
2.1
11.9
|
L
 16.8%
H
0.4
12.9
|
L
 -77.0%
H
0.4
26.4
|
L
H
0.4
49.0
|
| Alzamend Neuro Inc |
|
4.0
|
1.1
|
L
 -3.6%
H
1.1
1.1
|
L
H
1.0
1.2
|
L
 11.6%
H
0.8
1.2
|
L
 -46.5%
H
0.8
2.4
|
L
 -81.5%
H
0.8
8.2
|
L
 -99.8%
H
0.8
1071.9
|
L
H
0.8
45292.5
|
L
H
0.8
45292.5
|
| Amgen |
|
177,708.6
|
329.1
|
L
 -0.6%
H
327.2
331.3
|
L
 -2.6%
H
320.5
349.5
|
L
 -3.9%
H
320.5
359.4
|
L
 -14.4%
H
320.5
391.3
|
L
 21.7%
H
261.4
391.3
|
L
 39.1%
H
211.7
391.3
|
L
 31.0%
H
198.6
391.3
|
L
 114.8%
H
133.6
391.3
|
| Amylyx Pharma Inc |
|
1,688.5
|
15.2
|
L
 -5.4%
H
14.7
16.0
|
L
 -2.6%
H
14.7
16.9
|
L
 -3.9%
H
14.7
18.6
|
L
 8.7%
H
12.7
18.6
|
L
 226.9%
H
4.2
18.6
|
L
 -47.7%
H
1.6
30.5
|
L
H
1.6
41.9
|
L
H
1.6
41.9
|
| Amphastar Pharma Inc |
|
1,070.2
|
24.0
|
L
 0.5%
H
23.9
24.3
|
L
 11.1%
H
21.6
24.3
|
L
 16.8%
H
20.1
24.3
|
L
 -17.9%
H
17.0
29.2
|
L
 0.7%
H
17.0
31.3
|
L
 -34.1%
H
17.0
67.7
|
L
 33.1%
H
17.0
67.7
|
L
 105.0%
H
11.7
67.7
|
| AnaptysBio Inc |
|
1,948.6
|
67.0
|
L
 -0.6%
H
62.1
68.7
|
L
 7.4%
H
61.2
72.4
|
L
 7.3%
H
44
73.3
|
L
 34.7%
H
44
73.3
|
L
 232.8%
H
17.1
73.3
|
L
 205.8%
H
12.2
73.3
|
L
 161.7%
H
12.2
73.3
|
L
H
10
134
|
| ANI Pharma Inc |
|
1,909.0
|
83.9
|
L
 -0.2%
H
82.8
84.8
|
L
 7.6%
H
77.9
86.2
|
L
 8.7%
H
75.9
86.2
|
L
 2.5%
H
70.2
86.2
|
L
 19.4%
H
56.7
99.5
|
L
 114.4%
H
38.9
99.5
|
L
 139.7%
H
22.3
99.5
|
L
 80.5%
H
22.3
99.5
|
| Anixa Biosciences Inc |
|
99.2
|
3.0
|
L
 -3.3%
H
2.9
3.1
|
L
 2.8%
H
2.9
3.2
|
L
 14.3%
H
2.6
3.2
|
L
H
2.4
3.2
|
L
 12.6%
H
2.4
5.5
|
L
 -24.3%
H
2.1
5.5
|
L
 -30.7%
H
2.1
6.5
|
L
 2.4%
H
0.6
8.1
|
| Annexon Inc |
|
897.0
|
5.5
|
L
 -3.2%
H
5.3
5.7
|
L
 -6.3%
H
5.3
6
|
L
 -4.8%
H
5.3
6.6
|
L
 -3.7%
H
4.8
6.6
|
L
 236.6%
H
1.6
7.2
|
L
 4.9%
H
1.3
8.4
|
L
 -72.2%
H
1.3
24.9
|
L
H
1.3
38.0
|
| AN2 Therapeutics Inc |
|
165.6
|
4.6
|
L
 -1.1%
H
4.5
4.8
|
L
 -1.7%
H
4.4
5.2
|
L
 36.5%
H
2.9
5.2
|
L
 322.0%
H
1
6.9
|
L
 300%
H
1
6.9
|
L
 -19.3%
H
0.9
22.2
|
L
H
0.9
23.6
|
L
H
0.9
23.6
|
| Applied Dna Sciences Inc |
|
2.8
|
0.5
|
L
H
0.5
0.5
|
L
 -2.0%
H
0.5
0.5
|
L
 -20.6%
H
0.5
0.8
|
L
 -46.8%
H
0.5
1.0
|
L
 -96.2%
H
0.5
13.2
|
L
 -100.0%
H
0.5
27900
|
L
 -100.0%
H
0.5
121500
|
L
 -100.0%
H
0.5
2167200
|
| Apollomics Inc (Class A) |
|
34.9
|
15.9
|
L
 4.3%
H
15.0
16.4
|
L
 21.6%
H
13
17
|
L
 13.6%
H
12.6
17
|
L
 -17.4%
H
12.6
21.5
|
L
 161.1%
H
3.7
42.1
|
L
 -96.4%
H
0.1
645
|
L
H
0.1
4900
|
L
H
0.1
4900
|
| Apellis Pharma Inc |
|
5,250.2
|
41.0
|
L
 -0.3%
H
41.0
41.1
|
L
 0.2%
H
40.9
41.1
|
L
 0.9%
H
40.6
41.1
|
L
 74.6%
H
16.8
41.1
|
L
 114.5%
H
16.1
41.1
|
L
 -56.0%
H
16.1
94.8
|
L
 -11.8%
H
16.1
94.8
|
L
H
11.5
94.8
|
| Aptorum Grp Ltd (Class A) |
|
6.8
|
0.8
|
L
 -1.2%
H
0.8
0.9
|
L
 -5.6%
H
0.8
1.0
|
L
 -4.6%
H
0.8
1.0
|
L
 3.7%
H
0.7
1.3
|
L
 -2.3%
H
0.7
4.5
|
L
 -84.3%
H
0.5
17.5
|
L
 -96.6%
H
0.5
35.4
|
L
H
0.5
332.8
|
| Aprea Therapeutics Inc |
|
10.9
|
0.9
|
L
 6.0%
H
0.9
1.0
|
L
 7.3%
H
0.8
1.0
|
L
 25.7%
H
0.7
1.1
|
L
 27.5%
H
0.6
1.1
|
L
 -49.1%
H
0.6
2.2
|
L
 -77.4%
H
0.6
8.9
|
L
 -99.0%
H
0.6
156
|
L
H
0.6
1062.2
|
| Aptevo Therapeutics Inc |
|
5.7
|
4.9
|
L
 -1.6%
H
4.7
5.0
|
L
 1.0%
H
4.3
5.6
|
L
 14.6%
H
3.8
5.7
|
L
 -27.5%
H
3.8
7.7
|
L
 -96.7%
H
3.8
258.1
|
L
 -100.0%
H
3.8
1078387.2
|
L
 -100.0%
H
3.8
18613900.8
|
L
H
3.8
68020444.8
|
| AquaBounty Tech Inc |
|
4.9
|
1.0
|
L
 -1.0%
H
0.9
1.0
|
L
 2.2%
H
0.9
1.0
|
L
 4.4%
H
0.9
1.2
|
L
 15.9%
H
0.8
1.2
|
L
 10.5%
H
0.6
3.0
|
L
 -91.3%
H
0.5
11
|
L
 -99.1%
H
0.5
130.6
|
L
H
0.5
610
|
| Aquestive Therapeutics Inc |
|
525.7
|
4.2
|
L
H
4.2
4.3
|
L
 4.4%
H
4.1
4.3
|
L
 3.4%
H
4.0
4.4
|
L
 2.9%
H
3.6
4.5
|
L
 57.3%
H
2.1
7.6
|
L
 107.4%
H
1.3
7.6
|
L
 20.5%
H
0.6
7.6
|
L
H
0.6
20.7
|
| Arcturus Therapeutics Holdings Inc |
|
253.0
|
8.9
|
L
 -2.5%
H
8.7
9.2
|
L
 6.0%
H
8.2
9.2
|
L
 8.3%
H
8.1
9.2
|
L
 17.6%
H
6.4
9.2
|
L
 -20.8%
H
5.9
24.2
|
L
 -67.2%
H
5.9
45
|
L
 -70.5%
H
5.9
65
|
L
 -69.4%
H
4.1
129.7
|
| Ardelyx Inc |
|
1,724.3
|
7.0
|
L
 -1.7%
H
6.9
7.2
|
L
 16.1%
H
6
7.4
|
L
 16.9%
H
5.7
7.4
|
L
 -4.6%
H
5.1
7.4
|
L
 76.7%
H
3.2
8.4
|
L
 51.4%
H
3.2
10.1
|
L
 5.4%
H
0.5
10.1
|
L
 -4.0%
H
0.5
16.3
|
| Arcutis Biotherapeutics Inc |
|
2,584.0
|
20.7
|
L
 -14.5%
H
20.2
23.8
|
L
 -7.6%
H
20.2
24.3
|
L
 -12.7%
H
20.2
25.5
|
L
 -24.4%
H
20.2
28.8
|
L
 44.3%
H
12.4
31.8
|
L
 41.9%
H
1.8
31.8
|
L
 -36.7%
H
1.8
35.2
|
L
H
1.8
40.9
|
| Artelo Biosciences Inc |
|
2.5
|
2.7
|
L
 -3.6%
H
2.6
2.8
|
L
 -21.4%
H
2.6
3.6
|
L
 -59.5%
H
2.6
7.5
|
L
 -39.2%
H
2.6
19.9
|
L
 -85.1%
H
2.6
85.8
|
L
 -91.1%
H
2.6
85.8
|
L
 -99.2%
H
2.6
359.1
|
L
H
2.6
46656
|
| Arvinas Inc |
|
657.4
|
10.2
|
L
 -0.7%
H
9.9
10.4
|
L
 3.8%
H
9.7
11.4
|
L
 -9.2%
H
9.7
12.1
|
L
 -24.4%
H
9.7
14.5
|
L
 46.6%
H
5.9
14.5
|
L
 -59.7%
H
5.9
53.1
|
L
 -83.9%
H
5.9
108.5
|
L
H
5.9
108.5
|
| Arrowhead Pharma Inc |
|
10,915.5
|
78.0
|
L
 -1.5%
H
75.5
79.1
|
L
 10.5%
H
69.2
79.5
|
L
 27.5%
H
59.3
79.5
|
L
 20.8%
H
54.0
79.5
|
L
 496.0%
H
12.4
79.5
|
L
 88.4%
H
9.6
79.5
|
L
 18.7%
H
9.6
93.7
|
L
 1294.5%
H
1.2
93.7
|
| Assembly Biosciences Inc |
|
491.6
|
30.9
|
L
 -1.4%
H
30.7
31.9
|
L
 17.5%
H
26.2
31.9
|
L
 5.9%
H
26.0
31.9
|
L
 18.0%
H
25.5
31.9
|
L
 144.7%
H
11.6
39.7
|
L
 150.2%
H
7.7
39.7
|
L
 -34.2%
H
7.7
56.3
|
L
 -47.5%
H
7.7
808.3
|
| ASP Isotopes Inc |
|
671.1
|
5.3
|
L
 -3.8%
H
5.2
5.5
|
L
 7.9%
H
5.0
5.6
|
L
 26.6%
H
4.1
5.8
|
L
 -8.4%
H
3.9
6.5
|
L
 -2.9%
H
3.9
14.5
|
L
 869.1%
H
0.3
14.5
|
L
H
0.3
14.5
|
L
H
0.3
14.5
|
| Assertio Holdings Inc |
|
144.1
|
22.4
|
L
 0.8%
H
22.2
22.5
|
L
 23.9%
H
18.1
22.5
|
L
 16.2%
H
18.0
22.5
|
L
 75.6%
H
11.1
22.5
|
L
 144.5%
H
8.6
22.5
|
L
 -75.8%
H
7.7
120.2
|
L
 -25.2%
H
7.7
120.2
|
L
 -97.6%
H
7.7
1621.2
|
| ATAI Life Sciences N.V. |
|
1,471.3
|
4.0
|
L
 -3.8%
H
3.9
4.2
|
L
 -2.7%
H
3.9
4.3
|
L
 4.2%
H
3.6
5.5
|
L
 6.4%
H
3.3
5.5
|
L
 190.6%
H
1.3
6.8
|
L
 99.5%
H
1.0
6.8
|
L
H
1.0
22.9
|
L
H
1.0
22.9
|
| LeonaBio Inc |
|
92.6
|
9.9
|
L
 4.7%
H
9.5
9.9
|
L
 12.4%
H
8.2
9.9
|
L
 -10.3%
H
7.8
11.9
|
L
 115.3%
H
4.2
14.2
|
L
 286.7%
H
2.3
14.2
|
L
 -66.7%
H
2.2
43.0
|
L
 -94.5%
H
2.2
236.4
|
L
H
2.2
347.9
|
| ETHZilla Corp |
|
70.0
|
4.8
|
L
 -0.4%
H
4.6
5
|
L
 -7.7%
H
4.6
5.9
|
L
 121.3%
H
1.8
5.9
|
L
 38.2%
H
1.8
5.9
|
L
 -59.5%
H
1.8
174.6
|
L
 -97.7%
H
1.8
279.3
|
L
 -100.0%
H
1.8
44650
|
L
H
1.8
49571
|
| Atossa Therapeutics Inc |
|
48.8
|
5.7
|
L
 -2.2%
H
5.6
5.8
|
L
 7.4%
H
5.2
6.2
|
L
 10.1%
H
4.7
6.3
|
L
 6.2%
H
3.8
6.3
|
L
 -54.5%
H
3.8
19.4
|
L
 -45.2%
H
3.8
34.7
|
L
 -84.0%
H
3.8
147
|
L
 -99.2%
H
3.8
1023.3
|
| Atara Biotherapeutics Inc |
|
84.5
|
9.9
|
L
 92.8%
H
6.8
12.5
|
L
 115.9%
H
4.6
12.5
|
L
 103.9%
H
4.4
12.5
|
L
 103.5%
H
3.9
12.5
|
L
 29.5%
H
3.9
19.1
|
L
 -86.4%
H
0.4
75.4
|
L
 -96.9%
H
0.4
501
|
L
 -97.4%
H
0.4
1361.3
|
| Aurinia Pharma Inc |
|
1,967.3
|
15.1
|
L
 -6.8%
H
14.4
16.3
|
L
 -0.9%
H
14.4
16.3
|
L
 -5.4%
H
14.4
16.9
|
L
 4.9%
H
13.5
16.9
|
L
 86.5%
H
7.3
16.9
|
L
 31.0%
H
4.7
16.9
|
L
 22.7%
H
4.1
34.0
|
L
 508.0%
H
1.7
34.0
|
| Aura Biosciences Inc |
|
904.5
|
8.2
|
L
 -1.1%
H
8.1
8.5
|
L
 21.8%
H
6.7
9.5
|
L
 22.8%
H
6.4
9.5
|
L
 46.4%
H
4.9
9.5
|
L
 49.9%
H
4.3
9.5
|
L
 -15.6%
H
4.3
13.5
|
L
H
4.3
26.2
|
L
H
4.3
26.2
|
| Atea Pharma Inc |
|
443.4
|
5.5
|
L
 -2.0%
H
5.4
5.6
|
L
 2.0%
H
5.4
5.8
|
L
 -5.6%
H
5.2
6.3
|
L
 33.5%
H
4.0
6.5
|
L
 97.9%
H
2.5
6.5
|
L
 65.4%
H
2.5
6.5
|
L
 -74.8%
H
2.5
46.9
|
L
H
2.5
94.2
|
| Tectonic Therapeutic Inc |
|
506.5
|
26.9
|
L
 -7.4%
H
26.3
28.8
|
L
 -0.7%
H
26.3
30.5
|
L
 -10.4%
H
26.3
31.5
|
L
 10.3%
H
16.8
36.0
|
L
 42.0%
H
14.4
36.0
|
L
 219.9%
H
1.4
61.1
|
L
 -74.4%
H
1.4
132
|
L
H
1.4
644.4
|
| Jade Biosciences Inc |
|
1,195.3
|
24.2
|
L
 -3.6%
H
23.4
25.2
|
L
 8.5%
H
22.1
26.1
|
L
 49.8%
H
15.5
28
|
L
 58.1%
H
12.9
28
|
L
 140.0%
H
6.6
28
|
L
 -96.9%
H
6.6
1134.5
|
L
H
6.6
1134.5
|
L
H
6.6
1134.5
|
| Avalo Therapeutics Inc |
|
611.0
|
22.9
|
L
 4.9%
H
21.3
24.3
|
L
 73.3%
H
12.6
24.3
|
L
 40.6%
H
12.5
24.3
|
L
 61.2%
H
12.5
24.3
|
L
 378.5%
H
3.4
24.3
|
L
 779.6%
H
0.0
34.5
|
L
 -30.9%
H
0.0
44.4
|
L
 -49.8%
H
0.0
91.8
|
| Anavex Life Sciences Corp |
|
289.1
|
3.1
|
L
 -6.6%
H
3.1
3.4
|
L
 -4.3%
H
3.1
3.5
|
L
 5.4%
H
2.9
3.8
|
L
 -23.9%
H
2.6
5.2
|
L
 -62.1%
H
2.6
14.0
|
L
 -63.0%
H
2.6
14.4
|
L
 -73.0%
H
2.6
31.5
|
L
 -35.1%
H
1.3
31.5
|
| Axsome Therapeutics Inc |
|
11,332.5
|
220.2
|
L
 -1.1%
H
216.4
221
|
L
 19.7%
H
183.9
234.3
|
L
 29.7%
H
165.2
234.3
|
L
 20.6%
H
152.3
234.3
|
L
 96.3%
H
96.1
234.3
|
L
 198.6%
H
55.0
234.3
|
L
 290.7%
H
19.4
234.3
|
L
 1836.9%
H
1.9
234.3
|
| Aytu BioPharma Inc |
|
26.5
|
2.5
|
L
 -3.5%
H
2.5
2.6
|
L
 -2.0%
H
2.5
2.6
|
L
 -7.1%
H
2.5
2.7
|
L
 3.4%
H
2.1
2.8
|
L
 97.6%
H
1.2
3.1
|
L
 61.4%
H
1.0
3.5
|
L
 -97.9%
H
1.0
123.6
|
L
 -100.0%
H
1.0
518400
|
| Aziyo Biologics Inc (Class A) |
|
-
|
1
|
L
 -2.0%
H
1.0
1.1
|
L
H
1.0
1.1
|
L
 -13.8%
H
1.0
1.2
|
L
 1.0%
H
0.9
1.4
|
L
 -41.9%
H
0.5
2.6
|
L
 -58.3%
H
0.5
2.8
|
L
 -90.8%
H
0.5
12.9
|
L
H
0.5
18.2
|
| Adagene Inc (ADR) |
|
236.5
|
3.6
|
L
 -0.8%
H
3.6
3.7
|
L
 0.9%
H
3.3
3.9
|
L
 -17.1%
H
3.2
4.8
|
L
 36.1%
H
2.5
4.8
|
L
 125.2%
H
1.3
4.8
|
L
 167.2%
H
1.1
4.8
|
L
 -71.7%
H
0.9
21.0
|
L
H
0.9
31.8
|
| Addex Therapeutics Ltd (ADR) |
|
8.6
|
7.0
|
L
 2.3%
H
6.0
7.4
|
L
 0.1%
H
6.0
7.4
|
L
 16.1%
H
5.4
7.6
|
L
 -11.3%
H
5.4
8.0
|
L
 -10.4%
H
5.4
12.1
|
L
 -51.8%
H
5
27.9
|
L
 -96.3%
H
5
229.6
|
L
H
5
750.4
|
| Akari Therapeutics PLC (ADR) |
|
7.5
|
6.6
|
L
 13.1%
H
5.9
6.6
|
L
 25.6%
H
5.2
6.6
|
L
 85.9%
H
3.3
6.6
|
L
 -30%
H
3.3
11.2
|
L
 -88.0%
H
3.3
58.4
|
L
 -95.4%
H
3.3
219.8
|
L
 -99.6%
H
3.3
1592
|
L
 -99.9%
H
3.3
17759.8
|
| Amarin Corp (ADR) |
|
311.2
|
14.8
|
L
 -0.4%
H
14.5
14.9
|
L
 3.9%
H
13.0
15
|
L
 1.4%
H
13.0
15.2
|
L
 0.6%
H
13.0
17
|
L
 45.6%
H
9.4
20.9
|
L
 967.6%
H
0.4
20.9
|
L
 226.9%
H
0.4
20.9
|
L
 876.3%
H
0.4
26.1
|
| Argen X SE (ADR) |
|
48,961.1
|
787.3
|
L
 -2.5%
H
777.1
840.7
|
L
 1.5%
H
775.0
840.7
|
L
 5.2%
H
734
852.3
|
L
 -3.0%
H
661.9
852.8
|
L
 28.0%
H
510.1
934.6
|
L
 94.8%
H
327.7
934.6
|
L
 204.8%
H
248.2
934.6
|
L
H
17.3
934.6
|
| Ascendis Pharma A/S (ADR) |
|
15,111.3
|
246.1
|
L
 4.3%
H
222
247.3
|
L
 11.7%
H
220.7
247.3
|
L
 8.6%
H
216.2
250.7
|
L
 10.8%
H
211
250.7
|
L
 51.2%
H
150.9
250.7
|
L
 160.6%
H
83.8
250.7
|
L
 85.2%
H
61.6
250.7
|
L
 1430.7%
H
11.9
250.7
|
| Alterity Therapeutics Ltd (ADR) |
|
84.6
|
4.7
|
L
 3.3%
H
4.5
4.7
|
L
 2.4%
H
4.5
4.9
|
L
 29.7%
H
3.5
5.3
|
L
 32.3%
H
3.1
5.3
|
L
 12.5%
H
2.7
7
|
L
 53.6%
H
1
7
|
L
 -62.9%
H
1
27.5
|
L
 -87.5%
H
1
66.9
|
| Autolus Therapeutics PLC (ADR) |
|
428.5
|
1.6
|
L
 -5.3%
H
1.6
1.7
|
L
 14.2%
H
1.4
1.8
|
L
 15.8%
H
1.3
1.8
|
L
 13.4%
H
1.2
1.9
|
L
 36.4%
H
1.2
2.7
|
L
 -14.8%
H
1.1
7.5
|
L
 -68.4%
H
1.1
8.2
|
L
H
1.1
53.2
|
| Astrazeneca plc |
|
565,915.5
|
182.5
|
L
 -1.3%
H
181.0
184.4
|
L
 -1.5%
H
180
190
|
L
 -10.0%
H
180
207.3
|
L
 -5.4%
H
180
212.7
|
L
 -3.1%
H
180
212.7
|
L
 -3.1%
H
180
212.7
|
L
 -3.1%
H
180
212.7
|
L
 -3.1%
H
180
212.7
|
| BridgeBio Pharma Inc |
|
13,076.1
|
67.5
|
L
 -0.9%
H
67.0
69.3
|
L
 -4.9%
H
67.0
72.5
|
L
 -6.7%
H
67.0
84.8
|
L
 -0.9%
H
62.8
84.9
|
L
 82.6%
H
31.8
84.9
|
L
 393.1%
H
12.8
84.9
|
L
 36.0%
H
5.0
84.9
|
L
H
5.0
84.9
|
| BioAtla Inc |
|
7.2
|
4.4
|
L
 -3.3%
H
4.2
4.6
|
L
 7.7%
H
3.9
4.8
|
L
 -23.0%
H
3.9
6.1
|
L
 -58.8%
H
3.9
13.3
|
L
 -81.7%
H
3.9
71.5
|
L
 -97.6%
H
3.9
203.4
|
L
 -99.8%
H
3.9
2591.5
|
L
H
3.9
3831.5
|
| BioCardia Inc |
|
11.9
|
1.1
|
L
 -1.8%
H
1.1
1.2
|
L
 -0.9%
H
1.1
1.2
|
L
 -7.6%
H
1.1
1.3
|
L
 -12.8%
H
1.1
1.4
|
L
 -55.1%
H
1
2.9
|
L
 -96.4%
H
1
43.8
|
L
 -97.8%
H
1
76.5
|
L
 -99.0%
H
1
2073.6
|
| Biocryst Pharma Inc |
|
2,261.5
|
8.9
|
L
 0.8%
H
8.6
8.9
|
L
 -1%
H
7.8
9.4
|
L
 -6.0%
H
7.8
10.0
|
L
 39.5%
H
6.3
10.3
|
L
 -13.3%
H
6
11.3
|
L
 4.0%
H
4.0
11.3
|
L
 -31.1%
H
4.0
20.0
|
L
 213.4%
H
1.4
20.0
|
| BriaCell Therapeutics Corp |
|
29.7
|
4.1
|
L
 -1.2%
H
4.0
4.3
|
L
 2.0%
H
4.0
4.3
|
L
 -5.1%
H
3.7
4.7
|
L
 -1.9%
H
3.6
4.7
|
L
 -98.8%
H
3.6
372
|
L
 -100.0%
H
3.6
11275.5
|
L
 -99.9%
H
3.6
18526.5
|
L
 -100.0%
H
3.6
83250
|
| Black Diamond Therapeutics Inc |
|
155.9
|
2.7
|
L
 -3.6%
H
2.4
2.8
|
L
 5.8%
H
2.4
3.0
|
L
 8.8%
H
2.4
3.4
|
L
 20.4%
H
1.9
3.4
|
L
 86.3%
H
1.5
4.9
|
L
 38.1%
H
1.2
7.7
|
L
 -89.4%
H
1.2
28.4
|
L
H
1.2
46.3
|
| Beam Therapeutics Inc |
|
3,233.4
|
31.5
|
L
 -2.7%
H
30.4
32.5
|
L
 7.1%
H
28.5
32.5
|
L
 29.9%
H
23.4
32.5
|
L
 18.7%
H
21.6
34.2
|
L
 96.8%
H
15.4
36.4
|
L
 -6.5%
H
13.5
49.5
|
L
 -55.1%
H
13.5
138.5
|
L
H
13
138.5
|
| Biofrontera Inc |
|
13.7
|
1.1
|
L
H
1.1
1.2
|
L
 3.6%
H
1.0
1.2
|
L
 15.2%
H
1.0
1.2
|
L
 39.0%
H
0.7
1.2
|
L
 60.6%
H
0.5
1.2
|
L
 -90.5%
H
0.5
13.4
|
L
H
0.5
292.6
|
L
H
0.5
292.6
|
| Biogen |
|
28,254.8
|
191.4
|
L
 0.4%
H
188.9
192.1
|
L
 -1.5%
H
185.4
196.0
|
L
 11.1%
H
170.4
196.0
|
L
 -4.9%
H
168.6
201
|
L
 63.8%
H
115.3
202.4
|
L
 -39.8%
H
110.0
319.8
|
L
 -29.7%
H
110.0
468.6
|
L
 -21.2%
H
110.0
468.6
|
| BioVie Inc |
|
11.6
|
1.5
|
L
 -7.2%
H
1.5
1.7
|
L
 -2.5%
H
1.5
1.8
|
L
 4.8%
H
1.4
1.8
|
L
 36.3%
H
1.1
1.8
|
L
 -86.7%
H
1.1
12.9
|
L
 -99.8%
H
1.1
869
|
L
 -99.9%
H
1.1
1910
|
L
 -99.9%
H
1.1
5625
|
| Biomea Fusion Inc |
|
117.8
|
1.6
|
L
 1.9%
H
1.6
1.7
|
L
 12.4%
H
1.3
1.7
|
L
 8.0%
H
1.3
2.2
|
L
 33.6%
H
1.1
2.2
|
L
 -2.4%
H
0.9
3.1
|
L
 -95.0%
H
0.9
43.7
|
L
 -90.5%
H
0.9
43.7
|
L
H
0.9
43.7
|
| Biomarin pharma Inc - Registered Shares |
|
10,460.6
|
54.1
|
L
 -0.9%
H
53.6
55.3
|
L
 -0.2%
H
52.7
57.4
|
L
 -3.7%
H
52.5
57.8
|
L
 -6.9%
H
52.5
66.3
|
L
 -9.3%
H
50.8
66.3
|
L
 -44.0%
H
50.8
99.6
|
L
 -31.2%
H
50.8
117.8
|
L
 -33.0%
H
50.8
131.9
|
| Bionano Genomics Inc |
|
14.8
|
1.3
|
L
 4.7%
H
1.3
1.4
|
L
 14.7%
H
1.2
1.4
|
L
 15.7%
H
1.1
1.4
|
L
 15.7%
H
1.1
1.5
|
L
 -64.1%
H
1.1
5.5
|
L
 -81.7%
H
0.1
11.6
|
L
 -97.5%
H
0.1
91.2
|
L
H
0.1
156.9
|
| Benitec Biopharma Inc |
|
415.9
|
12.1
|
L
 -3.4%
H
11.9
12.6
|
L
 -0.1%
H
11.4
12.7
|
L
 10.5%
H
10.4
14.3
|
L
 0.2%
H
9.9
14.3
|
L
 -12.7%
H
9.9
17.2
|
L
 212.1%
H
1.9
17.2
|
L
 -82.9%
H
1.9
99.6
|
L
 -97.2%
H
1.9
1371.3
|
| Bolt Biotherapeutics Inc |
|
8.8
|
4.6
|
L
H
4.5
4.8
|
L
 -3.6%
H
4.5
5.2
|
L
 -6.9%
H
4.5
5.7
|
L
 -20.5%
H
3.9
5.7
|
L
 -34.1%
H
3.9
9.2
|
L
 -85.7%
H
3.9
40.6
|
L
 -99.0%
H
3.9
490.1
|
L
H
3.9
861.4
|
| Bon Natural Life Ltd |
|
9.9
|
1.2
|
L
 3.4%
H
1.2
1.2
|
L
 -5.4%
H
1.2
1.3
|
L
 -8.3%
H
1.2
1.4
|
L
 -25.2%
H
1.1
1.7
|
L
 -14.1%
H
1.1
3.4
|
L
 -99.2%
H
1.1
200
|
L
 -100.0%
H
1.1
4400
|
L
 -100.0%
H
1.1
22532.5
|
| BioXcel Therapeutics Inc |
|
33.6
|
1.2
|
L
 -4.6%
H
1.2
1.3
|
L
 19.2%
H
1.1
1.4
|
L
 8.8%
H
1.0
1.4
|
L
 -17.3%
H
1.0
1.8
|
L
 -21.5%
H
1.0
8.1
|
L
 -94.6%
H
0.2
29.6
|
L
 -95.9%
H
0.2
39
|
L
H
0.2
71.5
|
| Blue Water Biotech Inc |
|
7.1
|
0.4
|
L
 -11.1%
H
0.4
0.5
|
L
 -45.2%
H
0.4
0.7
|
L
 -73.9%
H
0.4
2.8
|
L
 -65.8%
H
0.4
6.7
|
L
 400%
H
0.1
6.7
|
L
 -61.5%
H
0.1
6.7
|
L
H
0.1
90.9
|
L
H
0.1
90.9
|
| BeyondSpring Inc |
|
58.4
|
1.4
|
L
 -8.4%
H
1.4
1.6
|
L
 -3.4%
H
1.4
1.7
|
L
 -17.0%
H
1.4
1.8
|
L
 -5.3%
H
1.2
1.9
|
L
 -33.3%
H
1.2
3.4
|
L
 44.9%
H
0.7
4
|
L
 -85.7%
H
0.5
33
|
L
H
0.5
48.5
|
| Bicycle Therapeutics PLC (ADR) |
|
341.4
|
4.9
|
L
 -5.1%
H
4.8
5.1
|
L
 3.4%
H
4.5
5.2
|
L
H
4.5
5.4
|
L
 -13.6%
H
4.2
6.0
|
L
 -33.9%
H
4.2
9.4
|
L
 -77.5%
H
4.2
28.9
|
L
 -84.6%
H
4.2
62.1
|
L
H
4.2
62.1
|
| Biodexa Pharma PLC (ADR) |
|
3.2
|
4.9
|
L
 10.0%
H
4.3
5.1
|
L
 50%
H
3.0
5.1
|
L
 25.6%
H
2.9
5.1
|
L
 -21.6%
H
2.9
7.5
|
L
 -92.7%
H
2.9
96.5
|
L
 -100.0%
H
2.9
650053.2
|
L
 -100.0%
H
2.9
180500000
|
L
 -100.0%
H
2.9
10000000000
|
| BeiGene Ltd (ADR) |
|
33,768.8
|
317
|
L
 1.2%
H
308.4
318
|
L
 9.0%
H
291.0
318
|
L
 4.8%
H
289.5
328.4
|
L
 -10.4%
H
271.5
372.7
|
L
 38.8%
H
228.9
385.2
|
L
 26.9%
H
127.0
385.2
|
L
 1.0%
H
118.2
426.6
|
L
 1108.1%
H
24.5
426.6
|
| Bioline Rx Ltd (ADR) |
|
13.5
|
3.1
|
L
 -7.5%
H
3.1
3.3
|
L
 1.0%
H
2.6
3.5
|
L
 37.8%
H
2.2
3.5
|
L
 4.0%
H
2.2
3.5
|
L
 -5.5%
H
2.2
7.8
|
L
 -93.5%
H
0.1
101.2
|
L
 -98.0%
H
0.1
149.2
|
L
 -99.4%
H
0.1
1103.9
|
| Belite Bio Inc (ADR) |
|
6,234.6
|
156
|
L
 -0.1%
H
147.8
156.6
|
L
 1.0%
H
147.8
160.2
|
L
 -8.9%
H
147.8
183.7
|
L
 -17.0%
H
146.6
192.3
|
L
 155.3%
H
56.1
200
|
L
 453.2%
H
11
200
|
L
H
6
200
|
L
H
6
200
|
| Neuphoria Therapeutics Inc |
|
28.8
|
5.3
|
L
 -0.7%
H
5.3
5.4
|
L
 2.9%
H
5.2
5.5
|
L
 23.6%
H
4.3
5.5
|
L
 33.2%
H
3.8
5.5
|
L
 7.2%
H
3.6
21.4
|
L
 133.2%
H
0.2
21.4
|
L
H
0.2
22
|
L
H
0.2
22
|
| BioNTech SE (ADR) |
|
23,523.3
|
93.0
|
L
 -2.4%
H
92.1
97.7
|
L
 -8.4%
H
90.8
104.8
|
L
 1.9%
H
87.6
113.3
|
L
 -12.8%
H
79.5
113.3
|
L
 -1.8%
H
79.5
124
|
L
 -14.2%
H
76.5
131.5
|
L
 -44.6%
H
76.5
464
|
L
H
12.5
464
|
| Biondvax Pharma Ltd (ADR) |
|
-
|
0.5
|
L
 -5.3%
H
0.5
0.6
|
L
 -23.9%
H
0.5
0.8
|
L
 -11.5%
H
0.5
1.1
|
L
 -34.9%
H
0.5
1.1
|
L
 -81.4%
H
0.5
6.2
|
L
 -72.2%
H
0.5
6.2
|
L
 -98.1%
H
0.5
99
|
L
 -98.5%
H
0.5
620
|
| Cabaletta Bio Inc |
|
652.2
|
4
|
L
 7.2%
H
3.7
4.1
|
L
 43.9%
H
2.7
4.2
|
L
 32.9%
H
2.7
4.2
|
L
 59.4%
H
2.4
4.2
|
L
 247.8%
H
1.1
4.2
|
L
 -68.2%
H
1.0
26.4
|
L
 -56.5%
H
0.6
26.4
|
L
H
0.6
26.4
|
| CalciMedica Inc |
|
10.1
|
0.6
|
L
 3.2%
H
0.6
0.7
|
L
 14.3%
H
0.5
0.7
|
L
 3.2%
H
0.5
0.8
|
L
 6.7%
H
0.5
0.9
|
L
 -67.8%
H
0.5
7.2
|
L
 -81.1%
H
0.5
8.6
|
L
 -98.9%
H
0.5
98.8
|
L
H
0.5
530.3
|
| Capricor Therapeutics Inc |
|
1,963.1
|
33.9
|
L
 -1.3%
H
33.0
34.4
|
L
 4.6%
H
30.8
34.6
|
L
 7.1%
H
29.6
36.8
|
L
 37.3%
H
22.1
36.8
|
L
 364.9%
H
4.3
40.4
|
L
 765.8%
H
2.7
40.4
|
L
 895.3%
H
2.6
40.4
|
L
 -6.4%
H
0.9
54
|
| Tvardi Therapeutics Inc |
|
39.5
|
4.2
|
L
 15.0%
H
3.6
4.3
|
L
 37.6%
H
3.0
4.3
|
L
 41.3%
H
2.8
4.3
|
L
 13.2%
H
2.8
4.3
|
L
 -84.0%
H
2.8
43.7
|
L
 -97.3%
H
2.8
168.1
|
L
 -99.1%
H
2.8
681.5
|
L
 -97.9%
H
2.8
1067.3
|
| Crescent Biopharma Inc |
|
-
|
18
|
L
 -0.3%
H
17.5
19.0
|
L
 -14.0%
H
14.9
23.2
|
L
 -7.1%
H
14.9
27.4
|
L
 89.3%
H
8.7
27.4
|
L
 58.6%
H
7.6
27.4
|
L
 469.6%
H
3.1
27.4
|
L
 62.7%
H
0.9
27.4
|
L
 -63.0%
H
0.9
123.8
|
| C4 Therapeutics Inc |
|
328.3
|
3.0
|
L
 1.7%
H
2.8
3.1
|
L
 16.4%
H
2.6
3.2
|
L
 4.9%
H
2.5
3.2
|
L
 63.7%
H
1.7
3.8
|
L
 111.4%
H
1.2
3.8
|
L
 -9.4%
H
1.1
11.9
|
L
 -91.0%
H
1.1
51.2
|
L
H
1.1
51.2
|
| Niagen Bioscience Inc |
|
333.7
|
4.2
|
L
 -15.7%
H
4.0
4.4
|
L
 -12.0%
H
4.0
5.1
|
L
 -6.3%
H
4.0
5.1
|
L
 -19.4%
H
4.0
5.8
|
L
 -52%
H
4.0
14.7
|
L
 208.1%
H
1.3
14.7
|
L
 -51.2%
H
1.2
14.7
|
L
 -9.7%
H
1.2
23.7
|
| Cullinan Oncology Inc |
|
904.6
|
14.7
|
L
 -1.8%
H
14.1
15.1
|
L
 14.6%
H
12.7
15.9
|
L
 -1.3%
H
12.4
15.9
|
L
 20.4%
H
11.4
16.7
|
L
 87.5%
H
5.7
16.7
|
L
 53.7%
H
5.7
30.2
|
L
 -49.2%
H
5.7
37.7
|
L
H
5.7
59.9
|
| Compugen Ltd |
|
270.4
|
2.9
|
L
 3.6%
H
2.8
2.9
|
L
 10%
H
2.6
2.9
|
L
 31.2%
H
2.2
3.2
|
L
 71.3%
H
1.6
3.2
|
L
 127.0%
H
1.2
3.2
|
L
 354.0%
H
0.5
3.2
|
L
 -61.6%
H
0.5
9.2
|
L
 -55.7%
H
0.5
19.9
|
| Cognition Therapeutics Inc |
|
103.7
|
1.2
|
L
 -5.7%
H
1.1
1.3
|
L
 -1.7%
H
1.1
1.3
|
L
 38.1%
H
0.7
1.4
|
L
 9.4%
H
0.6
1.4
|
L
 176.2%
H
0.2
3.8
|
L
 -25.6%
H
0.2
3.8
|
L
H
0.2
13.8
|
L
H
0.2
13.8
|
| Coherus Biosciences Inc |
|
263.8
|
1.8
|
L
 0.6%
H
1.7
1.8
|
L
 1.2%
H
1.7
1.9
|
L
 5.4%
H
1.6
2.0
|
L
 -17.8%
H
1.5
2.2
|
L
 89.3%
H
0.7
2.6
|
L
 -76.2%
H
0.7
8.2
|
L
 -87.9%
H
0.7
19.3
|
L
 -90.8%
H
0.7
32.0
|
| Cingulate Inc |
|
64.1
|
5.2
|
L
 -1.9%
H
5.1
5.5
|
L
 11.0%
H
4.8
5.5
|
L
 -15.7%
H
4.2
6.6
|
L
 -32.1%
H
4.2
11.9
|
L
 29.1%
H
3.2
11.9
|
L
 384.3%
H
0.2
20.8
|
L
H
0.2
20.8
|
L
H
0.2
20.8
|
| Clene Inc |
|
87.0
|
7.4
|
L
 3.2%
H
6.8
7.5
|
L
 27.4%
H
5.7
8.7
|
L
 28.3%
H
5.2
8.7
|
L
 72.3%
H
4.0
8.7
|
L
 159.3%
H
2.3
13.5
|
L
 -60.7%
H
2.3
21.8
|
L
 -95.4%
H
2.3
356.4
|
L
H
0.5
356.4
|
| Cellectar Biosciences Inc |
|
14.0
|
3.3
|
L
 -6.5%
H
3.2
3.5
|
L
 28.9%
H
2.5
4.7
|
L
 21.8%
H
2.5
4.7
|
L
 8.6%
H
2.4
4.7
|
L
 -54.4%
H
2.4
20.6
|
L
 -92.5%
H
2.4
133.5
|
L
 -99.2%
H
2.4
552
|
L
 -99.9%
H
2.4
14790
|
| Clearmind Medicine Inc |
|
5.7
|
0.6
|
L
H
0.5
0.6
|
L
 -20%
H
0.5
0.7
|
L
 -52.1%
H
0.5
1.5
|
L
 -58.5%
H
0.5
1.5
|
L
 -98.5%
H
0.5
52.4
|
L
 -99.9%
H
0.5
948
|
L
 -100.0%
H
0.5
788400
|
L
H
0.5
788400
|
| Compass Therapeutics Inc |
|
337.4
|
1.8
|
L
 -3.2%
H
1.8
1.9
|
L
 8.4%
H
1.7
2.0
|
L
 -67.0%
H
1.6
6.8
|
L
 -72.2%
H
1.6
6.8
|
L
 7.1%
H
1.6
6.9
|
L
 -45.3%
H
0.8
6.9
|
L
 -65.5%
H
0.8
6.9
|
L
H
0.8
11
|
| Cns Pharma Inc |
|
5.8
|
7.1
|
L
 2.9%
H
6.7
7.7
|
L
 214.2%
H
2.2
10.5
|
L
 206.0%
H
1.9
10.5
|
L
 57.4%
H
1.9
10.5
|
L
 -47.2%
H
1.9
34.8
|
L
 -100.0%
H
1.9
4470000
|
L
 -100.0%
H
1.9
120600000
|
L
H
1.9
256050000
|
| Context Therapeutics Inc |
|
214.1
|
2.3
|
L
 -3.3%
H
2.3
2.4
|
L
 -0.4%
H
2.2
2.5
|
L
 -14.0%
H
2.2
2.8
|
L
 2.2%
H
2.1
3.6
|
L
 187.7%
H
0.5
3.6
|
L
 323.6%
H
0.5
3.6
|
L
H
0.5
10.9
|
L
H
0.5
10.9
|
| Cocrystal Pharma Inc |
|
19.2
|
1.4
|
L
 -1.4%
H
1.4
1.4
|
L
H
1.3
1.5
|
L
 -7.3%
H
1.2
1.6
|
L
 43.3%
H
0.9
2.0
|
L
 -6.1%
H
0.9
2.7
|
L
 -45.7%
H
0.9
3.3
|
L
 -91.7%
H
0.9
17.9
|
L
 -99.4%
H
0.9
237.6
|
| Co-Diagnostics Inc |
|
7.0
|
1.9
|
L
 17.7%
H
1.6
2
|
L
 26.1%
H
1.5
2
|
L
 25.3%
H
1.4
2
|
L
 -18.2%
H
1.4
4.0
|
L
 -81.6%
H
1.4
46.5
|
L
 -95.3%
H
1.4
66.9
|
L
 -99.2%
H
1.4
354.6
|
L
H
1.4
929.7
|
| Z Squared Inc |
|
667.6
|
13.0
|
L
 -7.2%
H
12.9
14
|
L
 -17.3%
H
12.9
16.7
|
L
 11.0%
H
9
18.8
|
L
 15.2%
H
9
18.8
|
L
 56.0%
H
6.8
21.4
|
L
 -54.0%
H
2.3
43.8
|
L
 31.1%
H
2.3
242.6
|
L
H
2.3
242.6
|
| Cogent Biosciences Inc |
|
5,642.8
|
34.8
|
L
 -3.0%
H
34.5
35.7
|
L
 -3.0%
H
34.5
37.5
|
L
 -1.8%
H
34.3
38.0
|
L
 -6.2%
H
32.7
40.5
|
L
 640.2%
H
4.6
43.7
|
L
 210.1%
H
3.7
43.7
|
L
 324.3%
H
3.7
43.7
|
L
H
1.2
70.6
|
| Collegium pharma Inc |
|
1,274.6
|
39.3
|
L
 7.7%
H
35.8
39.6
|
L
 16.5%
H
33.4
39.6
|
L
 20.7%
H
31.9
39.6
|
L
 -17.4%
H
31.5
47.5
|
L
 45.5%
H
26.7
50.8
|
L
 71.7%
H
20.8
50.8
|
L
 79.3%
H
14.0
50.8
|
L
 160.5%
H
7.4
50.8
|
| Corcept Therapeutics Inc |
|
5,480.3
|
51.1
|
L
 -2.1%
H
49.8
52.6
|
L
 9.6%
H
45.7
53.0
|
L
 25.0%
H
40.4
53.0
|
L
 25.0%
H
28.7
53.0
|
L
 -27.8%
H
28.7
91
|
L
 112.1%
H
20.8
117.3
|
L
 135.1%
H
15.8
117.3
|
L
 968.0%
H
4.6
117.3
|
| Cosmos Health Inc |
|
18.3
|
0.4
|
L
H
0.3
0.4
|
L
 -2.8%
H
0.3
0.4
|
L
 12.9%
H
0.3
0.5
|
L
 -22.2%
H
0.3
0.5
|
L
 -20.5%
H
0.3
1.3
|
L
 -88.6%
H
0.3
4
|
L
 -99.8%
H
0.3
194.3
|
L
 -99.8%
H
0.3
312.5
|
| Cumberland Pharma Inc |
|
64.2
|
4.3
|
L
 -1.8%
H
4.1
4.3
|
L
 1.9%
H
4.1
4.8
|
L
 38.4%
H
3.0
6.0
|
L
 9.7%
H
2.7
6.0
|
L
 -2.7%
H
1.9
6.3
|
L
 148.0%
H
1.0
7.3
|
L
 58.9%
H
1.0
7.5
|
L
 -8.7%
H
1.0
8.0
|
| Catalyst Pharma Inc |
|
3,812.3
|
31.2
|
L
 2.1%
H
31.1
31.3
|
L
 10.3%
H
27.7
31.3
|
L
 24.7%
H
24.7
32.6
|
L
 27.5%
H
22.2
32.6
|
L
 35.1%
H
19.1
32.6
|
L
 81.1%
H
11.1
32.6
|
L
 567.2%
H
4.4
32.6
|
L
 5008.2%
H
0.6
32.6
|
| Corbus Pharma Holdings Inc |
|
192.8
|
10.9
|
L
 -0.5%
H
10.3
11.3
|
L
 10.7%
H
9.5
11.4
|
L
 7.2%
H
9.5
11.4
|
L
 38.8%
H
7.2
11.4
|
L
 73.9%
H
6.1
20.6
|
L
 3.4%
H
3.0
61.9
|
L
 -76.5%
H
2.1
68.7
|
L
 -84.0%
H
2.1
323.4
|
| Caribou Biosciences Inc |
|
184.7
|
1.9
|
L
 -3.6%
H
1.8
2.0
|
L
 -2.1%
H
1.8
2.0
|
L
 -3.6%
H
1.8
2.4
|
L
 19.8%
H
1.5
2.4
|
L
 150.7%
H
0.7
3.5
|
L
 -57.7%
H
0.7
8.6
|
L
H
0.7
32.6
|
L
H
0.7
32.6
|
| Cardiol Therapeutics Inc (Class A) |
|
145.2
|
1.3
|
L
 -1.5%
H
1.3
1.4
|
L
 -0.8%
H
1.3
1.4
|
L
 -6.5%
H
1.3
1.7
|
L
 30%
H
0.9
1.7
|
L
 22.6%
H
0.9
1.7
|
L
 113.1%
H
0.6
3.1
|
L
 -59.9%
H
0.5
5.0
|
L
H
0.5
8.5
|
| Curis Inc |
|
23.2
|
0.6
|
L
 -6.5%
H
0.6
0.6
|
L
 3.6%
H
0.6
0.6
|
L
 9.4%
H
0.5
0.8
|
L
 -43.7%
H
0.5
1.2
|
L
 -73.5%
H
0.5
3.1
|
L
 -96.4%
H
0.5
19.6
|
L
 -99.7%
H
0.5
348
|
L
 -99.7%
H
0.5
372
|
| CorMedix Inc |
|
621.3
|
7.9
|
L
 -1.6%
H
7.9
8.1
|
L
 5.9%
H
7.5
8.1
|
L
 11.9%
H
7.0
8.1
|
L
 3.0%
H
6.1
8.1
|
L
 -29.0%
H
6.1
17.4
|
L
 60%
H
2.6
17.4
|
L
 -1.4%
H
2.6
17.4
|
L
 -52%
H
0.9
18.8
|
| Crinetics Pharma Inc |
|
4,585.6
|
43.5
|
L
 4.3%
H
40.1
43.6
|
L
 13.1%
H
37.6
43.6
|
L
 15.4%
H
36.6
43.6
|
L
 -4.0%
H
33.1
48.6
|
L
 42.5%
H
25.8
58.0
|
L
 94.6%
H
15.8
62.5
|
L
 161.2%
H
15.2
62.5
|
L
H
10.6
62.5
|
| Cronos Grp Inc |
|
967.0
|
2.6
|
L
 -1.9%
H
2.6
2.7
|
L
 -0.4%
H
2.6
2.7
|
L
 -0.4%
H
2.5
3.3
|
L
 -2.7%
H
2.4
3.3
|
L
 38.9%
H
1.8
3.4
|
L
 27.9%
H
1.6
3.4
|
L
 -66.3%
H
1.6
9.4
|
L
H
0.2
25.1
|
| CRISPR Therapeutics AG |
|
5,055.8
|
52.4
|
L
 -4.8%
H
51.7
55.5
|
L
 3.4%
H
49.4
55.5
|
L
 6.7%
H
47.9
59.4
|
L
 7.6%
H
44.1
61.8
|
L
 58.1%
H
33.5
78.5
|
L
 -6.0%
H
30.0
91.1
|
L
 -51.4%
H
30.0
169.8
|
L
H
11.6
220.2
|
| Corvus Pharma Inc |
|
1,226.9
|
14.6
|
L
 -5.6%
H
14.6
15.6
|
L
 1.2%
H
14.4
16.3
|
L
 -0.8%
H
14.1
19.7
|
L
 -28.7%
H
13.0
21.6
|
L
 335.5%
H
3.2
27.0
|
L
 1115.8%
H
1.1
27.0
|
L
 396.3%
H
0.6
27.0
|
L
 20.7%
H
0.6
27.0
|
| Champions Oncology Inc |
|
83.2
|
6.0
|
L
 0.2%
H
5.9
6
|
L
 2.4%
H
5.7
6.3
|
L
 1.7%
H
5.7
6.3
|
L
 -8.6%
H
5.5
6.9
|
L
 2.6%
H
5.5
9.6
|
L
 15.9%
H
3.6
12.0
|
L
 -40.3%
H
3.6
12.0
|
L
 47.9%
H
1.1
17.9
|
| CytomX Therapeutics Inc |
|
870.8
|
4
|
L
 -3.2%
H
3.9
4.1
|
L
 -1.2%
H
3.9
4.4
|
L
 -9.1%
H
3.9
5.1
|
L
 -29.5%
H
3.9
8.2
|
L
 312.4%
H
0.9
8.2
|
L
 135.3%
H
0.4
8.2
|
L
 -50.9%
H
0.4
9.0
|
L
 -67.0%
H
0.4
35
|
| Cue Biopharma Inc |
|
116.3
|
35.7
|
L
 5.2%
H
28.6
35.8
|
L
 174.9%
H
13.2
41.4
|
L
 572.9%
H
5.2
41.4
|
L
 272.2%
H
5.0
41.4
|
L
 58.8%
H
5.0
41.4
|
L
 -75.6%
H
5.0
153.6
|
L
 -89.1%
H
5.0
552.6
|
L
H
5.0
950.7
|
| Cadrenal Therapeutics Inc |
|
18.5
|
6.0
|
L
 -2.4%
H
5.9
6.5
|
L
 7.7%
H
5.4
7.3
|
L
 29.5%
H
4.2
7.3
|
L
 5.6%
H
4.2
9.0
|
L
 -61.6%
H
4.2
16.5
|
L
 336.2%
H
0.4
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
| Cyclacel Pharma Inc |
|
5.5
|
1.0
|
L
 -1%
H
1.0
1.0
|
L
 6.5%
H
0.9
1.2
|
L
 -2.9%
H
0.9
1.3
|
L
 -10.8%
H
0.7
1.3
|
L
 -98.8%
H
0.7
83.3
|
L
 -99.9%
H
0.7
3168
|
L
 -100.0%
H
0.7
28620
|
L
 -100.0%
H
0.7
784800
|
| Cyclerion Therapeutics Inc |
|
13.6
|
3.2
|
L
 -2.8%
H
3.1
3.2
|
L
 -5.1%
H
3.0
3.4
|
L
 -24.1%
H
2.8
4.1
|
L
 186.4%
H
1.0
8.5
|
L
 4.7%
H
1.0
8.5
|
L
 -44.3%
H
1.0
8.5
|
L
 -93.7%
H
1.0
97.2
|
L
H
1.0
457
|
| Cytokinetics Inc |
|
9,158.0
|
74.3
|
L
 -0.7%
H
72.8
76.3
|
L
 24.7%
H
59.7
80.2
|
L
 14.4%
H
58.6
80.2
|
L
 19.2%
H
58.4
80.2
|
L
 118.7%
H
29.3
80.2
|
L
 88.4%
H
26.0
110
|
L
 217.9%
H
17.7
110
|
L
 824.0%
H
5.8
110
|
| Cellectis (ADR) |
|
388.3
|
3.9
|
L
 -2.3%
H
3.7
4
|
L
 3.5%
H
3.7
4.0
|
L
 12.2%
H
3.3
4.6
|
L
 8.1%
H
3.0
4.6
|
L
 144.3%
H
1.3
5.5
|
L
 103.2%
H
1.0
5.5
|
L
 -75.1%
H
1.0
17.1
|
L
 -87.5%
H
1.0
38.9
|
| Chemomab Therapeutics Ltd (ADR) |
|
12.5
|
1.7
|
L
 -2.8%
H
1.7
1.8
|
L
 19.2%
H
1.5
1.8
|
L
 4.8%
H
1.5
1.8
|
L
 13.7%
H
1.4
2.2
|
L
 -64.3%
H
1.4
5.9
|
L
 -71.4%
H
1.4
10.2
|
L
 -97.8%
H
1.4
111.7
|
L
H
1.4
736
|
| Compass Pathways PLC (ADR) |
|
1,266.9
|
9.4
|
L
 -3.8%
H
9.1
9.8
|
L
 12.1%
H
8.2
9.8
|
L
 63.3%
H
5.4
10.2
|
L
 51.7%
H
4.9
10.2
|
L
 158.0%
H
2.3
10.2
|
L
 16.8%
H
2.3
12.8
|
L
 -72.9%
H
2.3
49.5
|
L
H
2.3
61.7
|
| Centessa Pharma PLC (ADR) |
|
6,082.1
|
39.6
|
L
 0.0%
H
39.5
39.7
|
L
 0.4%
H
39.4
39.8
|
L
 -0.2%
H
39.2
39.8
|
L
 68.6%
H
22.5
40.3
|
L
 229.8%
H
11.0
40.3
|
L
 744.6%
H
4.0
40.3
|
L
H
2.9
40.3
|
L
H
2.9
40.3
|
| Connect Biopharma Holdings Ltd (ADR) |
|
129.8
|
2.3
|
L
 -6.1%
H
2.3
2.5
|
L
 -7.9%
H
2.3
2.6
|
L
 -18.5%
H
2.3
3.2
|
L
 -4.1%
H
2.3
3.8
|
L
 194.9%
H
0.7
3.8
|
L
 104.4%
H
0.5
3.8
|
L
 -85.5%
H
0.5
29.3
|
L
H
0.5
29.3
|
| Dare Bioscience Inc |
|
42.4
|
2.9
|
L
 -7.9%
H
2.7
3.1
|
L
 38.6%
H
2.1
3.8
|
L
 60.8%
H
1.7
3.8
|
L
 72.2%
H
1.3
3.8
|
L
 0.3%
H
1.3
9.2
|
L
 -75.8%
H
0.3
12.7
|
L
 -81.6%
H
0.3
30.1
|
L
 -99.0%
H
0.3
429.6
|
| Journey Medical Corp |
|
136.7
|
5
|
L
 -4.0%
H
5.0
5.2
|
L
H
4.9
5.4
|
L
 2.9%
H
4.8
5.6
|
L
 -40.1%
H
4.3
9.1
|
L
 -23.1%
H
4.3
9.6
|
L
 222.6%
H
1.0
9.6
|
L
H
1.0
10.2
|
L
H
1.0
10.2
|
| Diffusion Pharma Inc |
|
-
|
3.8
|
L
 -0.8%
H
3.7
3.9
|
L
 4.1%
H
3.6
4.0
|
L
 -4.5%
H
3.6
4.3
|
L
 -28.4%
H
3.5
5.6
|
L
 -56.7%
H
3.5
13.1
|
L
 -33.6%
H
3.5
14.4
|
L
 -92.6%
H
3.5
64.1
|
L
 -100.0%
H
3.5
17437.5
|
| DiaMedica Therapeutics Inc |
|
351.9
|
6.5
|
L
 0.2%
H
5.9
6.5
|
L
 9.6%
H
5.8
6.6
|
L
 -1.4%
H
5.7
7.0
|
L
 -19.8%
H
5.7
9.0
|
L
 69.2%
H
3.5
10.4
|
L
 293.4%
H
1.6
10.4
|
L
 -23.8%
H
1.1
10.4
|
L
 65.3%
H
1.1
13.8
|
| Denali Therapeutics Inc |
|
3,127.5
|
19.7
|
L
 -3.4%
H
19.2
20.4
|
L
 6.0%
H
18.1
20.5
|
L
 1.7%
H
18.1
21.8
|
L
 -6.5%
H
17.9
23.5
|
L
 41.1%
H
12.6
23.8
|
L
 -25.7%
H
10.6
33.3
|
L
 -63.5%
H
10.6
79.7
|
L
H
10.6
93.9
|
| Dominari Holdings Inc |
|
74.4
|
3.3
|
L
 -2.7%
H
3.2
3.3
|
L
 18.4%
H
2.8
3.5
|
L
 15.4%
H
2.7
3.5
|
L
 -11.8%
H
2.7
3.7
|
L
 -37.3%
H
2.7
8.4
|
L
 4.8%
H
0.8
13.6
|
L
 -78.1%
H
0.8
20.6
|
L
 -97.4%
H
0.8
308.4
|
| DarioHealth Corp |
|
59.3
|
8.1
|
L
 1.8%
H
8.0
8.3
|
L
 8.3%
H
7.1
8.3
|
L
 6.4%
H
6.2
8.3
|
L
 -18.4%
H
6.2
12.2
|
L
 -42%
H
5.9
17.7
|
L
 -89.4%
H
5.9
91.6
|
L
 -97.8%
H
5.9
476
|
L
 -99.6%
H
5.9
2360.0
|
| Dermata Therapeutics Inc |
|
5.2
|
1.3
|
L
 2.4%
H
1.3
1.3
|
L
 3.2%
H
1.2
1.4
|
L
 -1.5%
H
1.2
1.4
|
L
 -29.0%
H
1.1
2.3
|
L
 42.9%
H
0.6
7.1
|
L
 -24.9%
H
0.2
7.1
|
L
H
0.2
111.2
|
L
H
0.2
111.2
|
| Bright Minds Biosciences Inc |
|
869.3
|
88.8
|
L
 -0.1%
H
87.0
90.1
|
L
 -0.3%
H
81.3
90.1
|
L
 18.5%
H
71.2
92.4
|
L
 16.9%
H
66.2
92.4
|
L
 206.1%
H
23.2
123.8
|
L
 2941.8%
H
0.9
123.8
|
L
 286.2%
H
0.9
123.8
|
L
H
0.9
123.8
|
| Design Therapeutics Inc |
|
880.6
|
14.1
|
L
 -3.1%
H
14.0
14.7
|
L
 -10.7%
H
13.0
15.8
|
L
 12.5%
H
11.9
17.3
|
L
 37.3%
H
9.7
17.3
|
L
 288.4%
H
3.1
17.3
|
L
 86.0%
H
1.9
17.3
|
L
 -47.0%
H
1.9
29.2
|
L
H
1.9
50.5
|
| Precision Biosciences Inc |
|
184.3
|
7.5
|
L
 -0.5%
H
7.2
7.6
|
L
 8.4%
H
6.5
8.1
|
L
 24.5%
H
5.7
8.1
|
L
 96.8%
H
3.6
8.1
|
L
 46.7%
H
3.5
8.8
|
L
 780%
H
0.3
19.4
|
L
 -11.2%
H
0.3
19.4
|
L
H
0.3
23.7
|
| Dyne Therapeutics Inc |
|
2,898.0
|
17.5
|
L
 -6.9%
H
17.4
19.0
|
L
 0.8%
H
17.0
19.0
|
L
 -4.4%
H
17.0
21.4
|
L
 4.4%
H
14
21.4
|
L
 75.1%
H
8.1
25
|
L
 25.6%
H
6.4
47.5
|
L
 -3.2%
H
4.3
47.5
|
L
H
4.3
47.5
|
| DBV Tech (ADR) |
|
1,183.1
|
20.0
|
L
 -0.6%
H
19.6
20.4
|
L
 -1.5%
H
18.9
21.4
|
L
 -1.8%
H
18.9
23.0
|
L
 -6.0%
H
18.6
24.7
|
L
 112.9%
H
7.5
26.2
|
L
 21.2%
H
0.5
26.2
|
L
 -66.7%
H
0.5
65.8
|
L
 -93.4%
H
0.5
505.7
|
| Editas Medicine Inc |
|
296.6
|
3.0
|
L
 -4.7%
H
3.0
3.3
|
L
 7.5%
H
2.8
3.3
|
L
 11.4%
H
2.6
3.7
|
L
 66.5%
H
1.7
3.7
|
L
 127.8%
H
1.3
4.5
|
L
 -69.0%
H
0.9
11.9
|
L
 -91.2%
H
0.9
73.0
|
L
 -89.9%
H
0.9
100.0
|
| Edesa Biotech Inc |
|
154.9
|
17.4
|
L
 16.3%
H
15.0
17.7
|
L
 9.6%
H
13.5
20.3
|
L
 199.5%
H
5.1
20.3
|
L
 1456.3%
H
0.7
20.3
|
L
 651.3%
H
0.7
20.3
|
L
 134.9%
H
0.7
20.3
|
L
 -58.4%
H
0.7
84
|
L
 -98.1%
H
0.7
1669.9
|
| Eledon Pharma Inc |
|
297.9
|
3.9
|
L
 1.6%
H
3.7
3.9
|
L
 15.6%
H
3.4
3.9
|
L
 24.9%
H
3.0
4.2
|
L
 76.3%
H
2.0
4.2
|
L
 34.5%
H
1.4
4.6
|
L
 44.0%
H
1.1
5.4
|
L
 -58.4%
H
1.1
10.2
|
L
 -99.6%
H
1.1
1239.9
|
| Elicio Therapeutics Inc |
|
187.2
|
10.0
|
L
 -4.2%
H
9.9
11
|
L
 -3%
H
9.9
11.2
|
L
 -6.2%
H
9.9
13.9
|
L
 20.3%
H
8.1
14.9
|
L
 95.1%
H
4.9
14.9
|
L
 31.7%
H
3.0
24.4
|
L
 -93.0%
H
3.0
162.6
|
L
H
3.0
263
|
| Enliven Therapeutics Inc |
|
2,453.5
|
40.3
|
L
 -2.2%
H
39.5
41.3
|
L
 -5.0%
H
39.5
43.6
|
L
 3.5%
H
38.8
48.5
|
L
 37.0%
H
25.3
48.5
|
L
 104.6%
H
14.8
48.5
|
L
 105.1%
H
9.8
48.5
|
L
 41.7%
H
3.9
48.5
|
L
H
3.9
250.8
|
| Climb Bio Inc |
|
568.9
|
11.9
|
L
 -2.5%
H
11.7
12.5
|
L
 35.7%
H
7.9
12.5
|
L
 76.7%
H
6.2
12.5
|
L
 118.9%
H
5.1
12.5
|
L
 892.5%
H
1.1
12.5
|
L
 251.3%
H
1.1
12.5
|
L
H
1.1
29.7
|
L
H
1.1
29.7
|
| Enlivex Therapeutics Ltd |
|
192.8
|
0.8
|
L
 -3.6%
H
0.8
0.9
|
L
H
0.8
0.9
|
L
 -8.1%
H
0.7
1.0
|
L
 -31.0%
H
0.7
1.3
|
L
 -27.3%
H
0.7
2.1
|
L
 -70.8%
H
0.7
4.6
|
L
 -91.9%
H
0.7
14.0
|
L
 -99.0%
H
0.7
89.6
|
| Enochian Biosciences Inc |
|
-
|
0.3
|
L
 6.5%
H
0.3
0.4
|
L
H
0.3
0.4
|
L
 17.9%
H
0.3
0.5
|
L
 -50%
H
0.2
1.1
|
L
 3.1%
H
0.1
1.7
|
L
 -73.6%
H
0.1
2.3
|
L
 -91.3%
H
0.1
13.8
|
L
 -83.1%
H
0.1
13.8
|
| Ensysce Biosciences Inc |
|
3.4
|
0.4
|
L
 -5.1%
H
0.4
0.4
|
L
 2.8%
H
0.3
0.4
|
L
 -33.9%
H
0.3
0.6
|
L
 -19.6%
H
0.3
0.8
|
L
 -83.0%
H
0.3
2.8
|
L
 -89.1%
H
0.1
9.9
|
L
 -100.0%
H
0.1
4108.8
|
L
H
0.1
5757.6
|
| Enanta Pharma Inc |
|
437.9
|
15.1
|
L
 -1.0%
H
14.8
15.9
|
L
 8.8%
H
13.6
15.9
|
L
 13.9%
H
12.8
15.9
|
L
 11.7%
H
11.8
15.9
|
L
 198.8%
H
5.0
17.2
|
L
 -58.1%
H
4.1
36.0
|
L
 -70.4%
H
4.1
102
|
L
 -39.6%
H
4.1
127.8
|
| Entera Bio Ltd |
|
74.6
|
1.4
|
L
 9.6%
H
1.2
1.4
|
L
 22.3%
H
1.1
1.4
|
L
 15.1%
H
1.1
1.4
|
L
 31.7%
H
0.9
1.7
|
L
 -36.9%
H
0.9
3.2
|
L
 67.1%
H
0.5
3.4
|
L
 -56.8%
H
0.5
8.7
|
L
H
0.5
10.2
|
| Enveric Biosciences Inc |
|
6.3
|
3.2
|
L
 -0.3%
H
3.1
3.4
|
L
 -38.6%
H
3.1
4.6
|
L
 59.3%
H
1.7
7.9
|
L
 33.8%
H
1.7
7.9
|
L
 -78.2%
H
1.7
17.8
|
L
 -99.1%
H
1.7
1256.4
|
L
 -100.0%
H
1.7
33660
|
L
 -100.0%
H
1.7
12150000
|
| Evolus Inc |
|
420.8
|
6.4
|
L
 1.1%
H
6.3
6.6
|
L
 23.4%
H
5.1
6.7
|
L
 53.6%
H
4.0
6.7
|
L
 42%
H
3.9
6.7
|
L
 -45.0%
H
3.9
12.2
|
L
 -24.8%
H
3.9
17.8
|
L
 -26.3%
H
3.9
17.8
|
L
H
2.9
39.5
|
| Equillium Inc |
|
135.3
|
2.1
|
L
 -1.4%
H
2.1
2.2
|
L
 2.9%
H
2.0
2.2
|
L
 6.5%
H
1.7
2.5
|
L
 40.8%
H
1.5
2.7
|
L
 478.4%
H
0.3
2.7
|
L
 303.8%
H
0.3
3.3
|
L
 -64.1%
H
0.3
7.8
|
L
H
0.3
27.1
|
| Erasca Inc |
|
3,234.0
|
10.4
|
L
 -4.6%
H
10
10.9
|
L
 14.2%
H
8.9
11.2
|
L
 -39.3%
H
8.7
24.3
|
L
 -15.4%
H
8.7
24.3
|
L
 732%
H
1.1
24.3
|
L
 256.2%
H
1.0
24.3
|
L
H
1.0
24.5
|
L
H
1.0
24.5
|
| Esperion Therapeutics Inc |
|
808.3
|
3.1
|
L
 -0.3%
H
3.1
3.2
|
L
 64.4%
H
1.9
3.2
|
L
 23.1%
H
1.8
3.2
|
L
 -7.7%
H
1.8
3.7
|
L
 220.4%
H
0.7
4.2
|
L
 124.3%
H
0.7
4.2
|
L
 -84.9%
H
0.7
26.8
|
L
 -78.9%
H
0.7
82.7
|
| Eton Pharma Inc |
|
848.7
|
31.0
|
L
 2.9%
H
29.8
31.4
|
L
 31.6%
H
23.3
32.3
|
L
 24.1%
H
22.5
32.3
|
L
 110.2%
H
14.5
32.3
|
L
 86.5%
H
13.1
32.3
|
L
 761.7%
H
2.4
32.3
|
L
 283.4%
H
2.0
32.3
|
L
H
2.0
32.3
|
| Edgewise Therapeutics Inc |
|
3,826.0
|
35.6
|
L
 -3.8%
H
35.0
38.2
|
L
 16.9%
H
30.1
40.0
|
L
 8.4%
H
30.1
40.0
|
L
 22.3%
H
26.8
40.0
|
L
 147.4%
H
12.2
40.0
|
L
 266.8%
H
5.1
40.0
|
L
 21.4%
H
5.1
40.0
|
L
H
5.1
40.5
|
| Exelixis Inc |
|
12,352.9
|
46.2
|
L
 -5.1%
H
45.7
48.7
|
L
 3.4%
H
43.5
48.9
|
L
 5.1%
H
43.5
48.9
|
L
 5.3%
H
39.7
48.9
|
L
 25.4%
H
33.8
49.6
|
L
 137.2%
H
18.5
49.6
|
L
 99.0%
H
14.9
49.6
|
L
 864.7%
H
4.7
49.6
|
| Hyperion DeFi Inc |
|
40.7
|
3.6
|
L
 -1.9%
H
3.5
3.8
|
L
 -9.9%
H
3.3
4.8
|
L
 8.2%
H
3.0
5.0
|
L
 -13.8%
H
2.8
5.0
|
L
 246.6%
H
1.0
17.2
|
L
 -99.0%
H
0.0
390.4
|
L
 -99.1%
H
0.0
530.4
|
L
H
0.0
859.2
|
| EyePoint Pharma Inc |
|
1,123.7
|
13.4
|
L
 0.5%
H
13.2
14.1
|
L
 4.3%
H
12.9
14.2
|
L
 2.3%
H
12.5
15.3
|
L
 0.8%
H
11.8
18.9
|
L
 114.6%
H
5.3
19.1
|
L
 105.0%
H
3.9
31.0
|
L
 40.1%
H
2.2
31.0
|
L
 -53.3%
H
2.2
42.5
|
| Evaxion Biotech A/S (ADR) |
|
33.9
|
4.1
|
L
 -7.7%
H
3.9
4.4
|
L
 -4.5%
H
3.9
4.8
|
L
 9.4%
H
3.3
4.8
|
L
 21.1%
H
3.0
4.8
|
L
 176.9%
H
1.4
12.2
|
L
 -69.2%
H
0.8
18.5
|
L
 -93.8%
H
0.8
250.4
|
L
H
0.8
250.4
|
| Evotec SE (ADR) |
|
1,083.3
|
3.1
|
L
 -5.9%
H
3.1
3.2
|
L
 3.7%
H
3.0
3.3
|
L
 16.4%
H
2.5
3.4
|
L
 -13.6%
H
2.3
3.7
|
L
 -24.7%
H
2.3
4.8
|
L
 -67.7%
H
2.3
13.5
|
L
 -85.3%
H
2.3
26.6
|
L
 53.3%
H
2.0
26.6
|
| Fate Therapeutics Inc |
|
282.6
|
2.4
|
L
 6.1%
H
2.1
2.5
|
L
 96.0%
H
1.2
2.5
|
L
 104.2%
H
1.1
2.5
|
L
 113.2%
H
1.0
2.5
|
L
 153.1%
H
0.9
2.5
|
L
 -57.2%
H
0.7
8.8
|
L
 -96.8%
H
0.7
97.4
|
L
 42.1%
H
0.7
121.2
|
| Fortress Biotech Inc |
|
79.7
|
2.4
|
L
 -5.9%
H
2.4
2.5
|
L
 8.1%
H
2.2
2.6
|
L
 -4.4%
H
2.2
2.6
|
L
 -26.6%
H
2.2
4.2
|
L
 37.9%
H
1.6
4.5
|
L
 -78.1%
H
1.2
11.6
|
L
 -95.8%
H
1.2
67.4
|
L
 -94.6%
H
1.2
91.5
|
| Forte Biosciences Inc |
|
535.9
|
26.2
|
L
 -1.3%
H
25.7
27.1
|
L
 -6.6%
H
25.7
30.4
|
L
 -1.0%
H
25.1
35.8
|
L
 -5.2%
H
22.0
35.8
|
L
 314.1%
H
6.1
35.8
|
L
 -0.3%
H
4.1
35.8
|
L
 -96.7%
H
4.1
1089.3
|
L
H
0.0
1349.8
|
| 4D Molecular Therapeutics Inc |
|
519.1
|
9.9
|
L
 -4.7%
H
9.8
10.4
|
L
 12.7%
H
8.6
10.4
|
L
 -0.1%
H
8.6
10.9
|
L
 10.5%
H
8.0
10.9
|
L
 222.4%
H
3
12.3
|
L
 -41.4%
H
2.2
36.3
|
L
 -70.4%
H
2.2
36.3
|
L
H
2.2
55.1
|
| Fennec Pharma Inc |
|
239.5
|
6.9
|
L
 -3.9%
H
6.8
7.2
|
L
 10.2%
H
6.2
7.3
|
L
 7.5%
H
5.7
7.3
|
L
 -12.0%
H
5.7
9.2
|
L
 14.8%
H
5.7
9.9
|
L
 -15.8%
H
4.0
11.9
|
L
 12.9%
H
3.8
11.9
|
L
 192.4%
H
1.6
15.0
|
| Kyntra Bio Inc |
|
28.7
|
7.1
|
L
 -0.3%
H
7.1
7.2
|
L
 0.7%
H
7.1
7.3
|
L
 1.7%
H
6.8
7.5
|
L
 -13.6%
H
6.3
9.0
|
L
 -2.5%
H
4.9
12.6
|
L
 -98.4%
H
4.5
486.8
|
L
 -98.6%
H
4.5
753.1
|
L
 -98.2%
H
4.5
1713.8
|
| Foghorn Therapeutics Inc |
|
246.6
|
4.2
|
L
 -10.3%
H
4.1
4.7
|
L
 -11.8%
H
4.1
4.9
|
L
 -13.9%
H
4.1
5.6
|
L
 -26.1%
H
4.1
6.0
|
L
 5.5%
H
3.3
7.0
|
L
 -30.6%
H
2.7
10.2
|
L
 -58.8%
H
2.7
24.3
|
L
H
2.7
28.3
|
| Q32 Bio Inc |
|
76.7
|
5.4
|
L
 -0.6%
H
5.2
5.8
|
L
 -1.1%
H
5.0
5.8
|
L
 -3.6%
H
4.8
7.2
|
L
 28.3%
H
3.4
8.0
|
L
 253.3%
H
1.3
8.0
|
L
 -69.8%
H
1.3
53.8
|
L
 -95.2%
H
1.3
160.2
|
L
H
1.3
572.4
|
| ZeroStack Corp |
|
55.4
|
5.6
|
L
 6.9%
H
4.9
5.8
|
L
 -10.3%
H
4.9
6.5
|
L
 12.1%
H
4.8
7.6
|
L
 -40.3%
H
4.8
10.4
|
L
 -75.0%
H
4.8
47
|
L
 -96.4%
H
4.8
213.7
|
L
H
4.8
16731
|
L
H
4.8
16731
|
| Frequency Therapeutics Inc |
|
-
|
12.9
|
L
 -3.4%
H
12.7
13.7
|
L
 2.2%
H
12.3
13.8
|
L
 -6.5%
H
12.3
14.5
|
L
 2.6%
H
9.9
15.6
|
L
 -14.7%
H
5.2
55.9
|
L
 -35.1%
H
5.2
55.9
|
L
 -97.5%
H
5.2
545
|
L
H
5.2
2918.5
|
| Fulcrum Therapeutics Inc |
|
458.4
|
6.9
|
L
 -3.2%
H
6.9
7.1
|
L
 -3.8%
H
6.9
7.6
|
L
 -12.1%
H
6.9
8.4
|
L
 -29.4%
H
6.5
12.0
|
L
 28.6%
H
4.8
15.7
|
L
 142.3%
H
2.3
15.7
|
L
 -35.0%
H
2.3
33.1
|
L
H
2.3
33.1
|
| First Wave BioPharma Inc |
|
4.4
|
2.9
|
L
 11.3%
H
2.5
3.0
|
L
 33.2%
H
2.1
3.0
|
L
 30.7%
H
2
3.0
|
L
 -2.1%
H
1.9
3.3
|
L
 578.6%
H
0.4
5.8
|
L
 -94.9%
H
0.4
62.4
|
L
 -100.0%
H
0.4
40741.3
|
L
H
0.4
235200
|
| Galectin Therapeutics Inc |
|
138.9
|
2.1
|
L
 -6.2%
H
2.0
2.2
|
L
 -6.2%
H
2.0
2.4
|
L
 -17.6%
H
2.0
2.6
|
L
 -24.6%
H
2.0
3.5
|
L
 55.2%
H
1.2
7.1
|
L
 22.7%
H
0.7
7.1
|
L
 -42.7%
H
0.7
7.1
|
L
 68.8%
H
0.5
9.5
|
| Gain Therapeutics Inc |
|
79.8
|
1.9
|
L
 -2.1%
H
1.8
1.9
|
L
 6.3%
H
1.8
2.0
|
L
 0.5%
H
1.7
2.2
|
L
 6.9%
H
1.7
3.1
|
L
 -1.1%
H
1.4
4.3
|
L
 -66%
H
0.9
5.6
|
L
 -83%
H
0.9
11.1
|
L
H
0.9
17.9
|
| CytoMed Therapeutics Ltd |
|
8.5
|
0.7
|
L
 -21.7%
H
0.7
0.9
|
L
 -27.3%
H
0.7
1
|
L
 -32.1%
H
0.7
1.0
|
L
 -38.5%
H
0.7
1.1
|
L
 -68.6%
H
0.7
3.7
|
L
 -81.0%
H
0.7
9.3
|
L
H
0.7
9.3
|
L
H
0.7
9.3
|
| Geron Corp |
|
935.7
|
1.5
|
L
 -7.6%
H
1.4
1.6
|
L
 -3.3%
H
1.4
1.7
|
L
 -16.6%
H
1.4
1.8
|
L
 -4.6%
H
1.4
2.0
|
L
 10.6%
H
1.0
2.0
|
L
 -47.1%
H
1.0
5.3
|
L
 9.0%
H
1.0
5.3
|
L
 -45.3%
H
0.8
7.0
|
| GH Research PLC |
|
1,440.4
|
21.0
|
L
 -6.4%
H
20.6
22.6
|
L
 9.7%
H
19.2
22.9
|
L
 38.8%
H
14.3
24.7
|
L
 38.6%
H
12.8
24.7
|
L
 108.0%
H
9.5
24.7
|
L
 132.2%
H
5.1
24.7
|
L
H
5.1
30.4
|
L
H
5.1
30.4
|
| Gilead Sciences |
|
166,395.8
|
134.1
|
L
 -1.6%
H
133.8
136.5
|
L
 4.1%
H
128.0
136.8
|
L
 -4.3%
H
127.6
143.0
|
L
 -12.1%
H
127.6
157.3
|
L
 37.0%
H
95.3
157.3
|
L
 68.1%
H
62.1
157.3
|
L
 101.5%
H
57.2
157.3
|
L
 58.3%
H
56.6
157.3
|
| Galmed Pharma Ltd |
|
4.2
|
0.6
|
L
H
0.6
0.7
|
L
 12.5%
H
0.5
0.7
|
L
 21.2%
H
0.5
1.3
|
L
 -4.6%
H
0.4
1.3
|
L
 -56.3%
H
0.4
2.3
|
L
 -99.1%
H
0.2
72
|
L
 -99.9%
H
0.2
734.4
|
L
 -99.9%
H
0.2
4870.8
|
| Greenwich LifeSciences Inc |
|
327.2
|
23.6
|
L
 2.4%
H
22.7
23.7
|
L
 9.4%
H
21.4
24.9
|
L
 7.2%
H
21
30.3
|
L
 -18.6%
H
20.5
30.3
|
L
 151.8%
H
7.8
34.1
|
L
 109.6%
H
7.6
34.1
|
L
 -30.3%
H
6.8
49.0
|
L
H
3.3
158.1
|
| Galecto Inc |
|
1,507.0
|
25.0
|
L
 1.2%
H
24.2
26.0
|
L
 4.4%
H
24.1
27.0
|
L
 1.7%
H
22.9
28.8
|
L
 -1.1%
H
16.5
34.0
|
L
 738.6%
H
2.5
38.3
|
L
 1067.8%
H
0.5
38.3
|
L
 355.2%
H
0.5
38.3
|
L
H
0.5
38.3
|
| Monte Rosa Therapeutics Inc |
|
1,585.1
|
19.8
|
L
 -2.8%
H
19.2
20.3
|
L
 5.8%
H
18.6
20.7
|
L
 17.0%
H
16.3
21.6
|
L
 1.3%
H
14.2
21.6
|
L
 378.5%
H
3.5
25.8
|
L
 282.4%
H
2.4
25.8
|
L
H
2.4
45.6
|
L
H
2.4
45.6
|
| GlycoMimetics Inc |
|
1,161.6
|
18
|
L
 -0.3%
H
17.5
19.0
|
L
 -14.0%
H
14.9
23.2
|
L
 -7.1%
H
14.9
27.4
|
L
 89.3%
H
8.7
27.4
|
L
 -25.3%
H
8.7
28
|
L
 -88.2%
H
8.7
353
|
L
 -92.2%
H
8.7
416
|
L
 -97.2%
H
8.7
2605
|
| Genelux Corp |
|
126.9
|
2.8
|
L
 -1.4%
H
2.7
2.9
|
L
 13.2%
H
2.5
3.0
|
L
 3.7%
H
2.3
3.0
|
L
 18.4%
H
2.3
3.0
|
L
 21.5%
H
2.3
8.5
|
L
 -88.9%
H
1.6
41.0
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
| Genprex Inc |
|
9.0
|
0.9
|
L
 -3.4%
H
0.9
0.9
|
L
 -1.2%
H
0.9
1.0
|
L
 -40.7%
H
0.9
1.5
|
L
 -60.9%
H
0.9
2.6
|
L
 196.6%
H
0.1
13.0
|
L
 6.2%
H
0.1
13.0
|
L
 -74.9%
H
0.1
13.0
|
L
H
0.1
19.5
|
| Gossamer Bio Inc |
|
79.8
|
0.3
|
L
 -2.9%
H
0.3
0.4
|
L
 -2.9%
H
0.3
0.4
|
L
 -2.9%
H
0.3
0.5
|
L
 -85.0%
H
0.3
2.5
|
L
 -68.8%
H
0.3
3.9
|
L
 -75%
H
0.3
3.9
|
L
 -95.9%
H
0.3
15.2
|
L
H
0.3
27.2
|
| Geovax Labs Inc |
|
5.1
|
1.8
|
L
 6.7%
H
1.7
2.0
|
L
 67.6%
H
1
2
|
L
 40.8%
H
1.0
2
|
L
 -34.1%
H
1.0
2.8
|
L
 -92.4%
H
1.0
34.8
|
L
 -99.3%
H
1.0
288.4
|
L
 -99.9%
H
1.0
2812.5
|
L
 -100.0%
H
1.0
379518072.3
|
| Graphite Bio Inc |
|
566.1
|
9.7
|
L
 0.4%
H
9.4
9.8
|
L
 7.4%
H
8.7
9.8
|
L
 1.1%
H
8.7
10.4
|
L
 -31.7%
H
8.3
15.0
|
L
 -63.7%
H
8.3
50.4
|
L
 -94.1%
H
8.3
413
|
L
H
8.3
1666
|
L
H
8.3
1666
|
| GT Biopharma Inc |
|
13.9
|
0.4
|
L
 -2.5%
H
0.4
0.4
|
L
 44.4%
H
0.3
0.4
|
L
 -11.4%
H
0.3
0.4
|
L
 -27.8%
H
0.3
0.6
|
L
 -83.6%
H
0.3
3.9
|
L
 30%
H
0.2
10.7
|
L
 -97.6%
H
0.2
19.7
|
L
 -100.0%
H
0.2
2295
|
| Galapagos NV (ADR) |
|
1,827.3
|
27.7
|
L
 -3.8%
H
27.2
28.5
|
L
 -0.5%
H
27.2
29.0
|
L
 -5.7%
H
27.2
29.4
|
L
 -16.9%
H
27.2
36.2
|
L
 5.6%
H
24.7
37.8
|
L
 -35.3%
H
22.4
45.2
|
L
 -63.6%
H
22.4
81.1
|
L
 -39.5%
H
22.4
274.0
|
| Genmab (ADR) |
|
16,612.4
|
27.1
|
L
 -3.0%
H
26.8
28.3
|
L
 3.6%
H
26.2
28.3
|
L
 -2.5%
H
25.7
29.4
|
L
 -12.4%
H
25.0
31.4
|
L
 32.5%
H
18.9
35.4
|
L
 -33.0%
H
17.2
42.7
|
L
 -27.3%
H
17.2
49.1
|
L
 84.7%
H
12.1
49.1
|
| Genenta Science SpA (ADR) |
|
15.1
|
0.6
|
L
 -7.3%
H
0.6
0.7
|
L
 -8.6%
H
0.6
0.8
|
L
 -5.9%
H
0.6
0.8
|
L
 -12.3%
H
0.6
1.1
|
L
 -84.9%
H
0.6
10
|
L
 -88.5%
H
0.6
10
|
L
H
0.6
13.1
|
L
H
0.6
13.1
|
| Grifols SA (ADR) - Level III |
|
5,485.4
|
8.1
|
L
 -4.2%
H
8.0
8.5
|
L
 1.9%
H
8.0
8.5
|
L
 -2.1%
H
7.9
8.8
|
L
 -13.2%
H
7.4
9.8
|
L
 11.6%
H
7.1
11.1
|
L
 8.3%
H
5.3
12.2
|
L
 -55.1%
H
5.3
19.1
|
L
 -45.9%
H
5.3
25.7
|
| Halozyme Therapeutics Inc |
|
7,723.3
|
65.2
|
L
 -1.8%
H
64.5
66.6
|
L
 3.4%
H
62.4
67.4
|
L
 3.3%
H
62.3
70.3
|
L
 -19.8%
H
61.3
82.2
|
L
 9.8%
H
47.5
82.2
|
L
 110.3%
H
29.9
82.2
|
L
 36.7%
H
29.9
82.2
|
L
 586.2%
H
7.7
82.2
|
| HCW Biologics Inc |
|
2.2
|
0.3
|
L
 -8.6%
H
0.3
0.4
|
L
 -22.0%
H
0.3
0.5
|
L
 10.3%
H
0.3
0.5
|
L
 -69.2%
H
0.3
1.2
|
L
 -95.2%
H
0.3
17.8
|
L
 -99.5%
H
0.2
100.8
|
L
H
0.2
311
|
L
H
0.2
311
|
| Hillstream BioPharma Inc |
|
35.0
|
3.0
|
L
 -6.9%
H
2.9
3.2
|
L
 -4.5%
H
2.9
3.3
|
L
 -8.3%
H
2.9
3.8
|
L
 -28.0%
H
2.9
5.3
|
L
 124.1%
H
1.1
9.1
|
L
 -72.0%
H
1.1
132.8
|
L
H
1.1
132.8
|
L
H
1.1
132.8
|
| Hoth Therapeutics Inc |
|
13.2
|
0.7
|
L
 -6.8%
H
0.7
0.7
|
L
 -4.2%
H
0.7
0.8
|
L
 19.0%
H
0.5
0.8
|
L
 -14.8%
H
0.5
1.3
|
L
 -25%
H
0.5
2.1
|
L
 -58.9%
H
0.5
4.3
|
L
 -98.2%
H
0.5
55
|
L
H
0.5
347
|
| Werewolf Therapeutics Inc |
|
30.1
|
0.6
|
L
 -4.6%
H
0.6
0.7
|
L
 -8.8%
H
0.6
0.8
|
L
 -40.4%
H
0.6
1.1
|
L
 1.6%
H
0.5
1.1
|
L
 -33.3%
H
0.5
2.4
|
L
 -79.2%
H
0.5
8.2
|
L
 -95.5%
H
0.5
21.7
|
L
H
0.5
24.0
|
| Harmony Biosciences Holdings Inc |
|
1,818.2
|
31.4
|
L
 -4.2%
H
28.9
31.5
|
L
 1.2%
H
28.9
33
|
L
 13.4%
H
27.3
35.0
|
L
 -15.7%
H
25.9
38.2
|
L
 -2.0%
H
25.5
40.9
|
L
 -12.4%
H
18.6
41.6
|
L
 14.6%
H
18.6
62.1
|
L
H
18.6
62.1
|
| Harrow Health Inc |
|
1,455.5
|
39.1
|
L
 -3.0%
H
38.8
40.6
|
L
 -3.0%
H
38.8
41.7
|
L
 11.2%
H
34.1
42.1
|
L
 -17.5%
H
33.0
54.5
|
L
 61.9%
H
21.2
54.9
|
L
 44.1%
H
7.6
59.2
|
L
 374.5%
H
5.4
59.2
|
L
 955.4%
H
1.4
59.2
|
| Heron Therapeutics Inc |
|
233.9
|
1.2
|
L
 -5.3%
H
1.2
1.3
|
L
 4.2%
H
1.2
1.3
|
L
 53.1%
H
0.8
1.3
|
L
 -1.6%
H
0.7
1.3
|
L
 -48.8%
H
0.7
2.5
|
L
 -49.8%
H
0.5
3.9
|
L
 -92.6%
H
0.5
18.8
|
L
 -92.6%
H
0.5
42.9
|
| Quantum BioPharma Ltd (Class B) (Sub Voting) |
|
29.2
|
5.0
|
L
 -5.1%
H
4.9
5.4
|
L
 -11.3%
H
4.9
6.2
|
L
 39.9%
H
2.8
6.2
|
L
 19.3%
H
2.1
6.5
|
L
 -45.4%
H
2.1
38.3
|
L
 -94.1%
H
2.1
109.2
|
L
 -95.2%
H
2.1
146.3
|
L
H
2.1
11431.9
|
| Humacyte Inc |
|
239.8
|
1.1
|
L
 10.2%
H
1.0
1.1
|
L
 31.7%
H
0.8
1.1
|
L
 66.2%
H
0.6
1.1
|
L
 14.9%
H
0.6
1.3
|
L
 -12.2%
H
0.6
2.9
|
L
 -76.6%
H
0.6
10.0
|
L
 -89.2%
H
0.6
17.5
|
L
H
0.6
17.5
|
| HUTCHMED (China) Ltd (ADR) |
|
2,288.7
|
13.3
|
L
 -0.9%
H
13.3
13.6
|
L
 -0.4%
H
12.8
13.6
|
L
 -13.9%
H
12.8
15.8
|
L
 -12.3%
H
12.8
15.8
|
L
 -10.4%
H
12.8
19.5
|
L
 -16.4%
H
10.7
21.9
|
L
 -50.9%
H
7.4
43.9
|
L
 -3.6%
H
7.4
43.9
|
| ImmunityBio Inc |
|
8,127.4
|
7.8
|
L
 -7.4%
H
7.4
8.1
|
L
 11.5%
H
6.9
8.4
|
L
 9.6%
H
6.7
8.6
|
L
 28.3%
H
5.8
12.4
|
L
 286.1%
H
1.8
12.4
|
L
 40.1%
H
1.3
12.4
|
L
 -51.5%
H
1.2
18.1
|
L
H
1.2
40.8
|
| Immucell Corp |
|
76.6
|
8.5
|
L
 -2.2%
H
8.4
8.8
|
L
 0.4%
H
8.4
9.1
|
L
 28.1%
H
6.4
9.1
|
L
 35.7%
H
6
9.1
|
L
 67.1%
H
4.5
9.1
|
L
 72.9%
H
3.3
9.1
|
L
 -14.2%
H
3.3
11.0
|
L
 30.5%
H
3.3
13.2
|
| Ideaya Biosciences Inc |
|
2,504.9
|
28.2
|
L
 -1.7%
H
28.0
28.5
|
L
 0.7%
H
27.8
29.4
|
L
 -12.7%
H
27.8
38.1
|
L
 -12.2%
H
27.8
38.1
|
L
 59.1%
H
16.8
39.3
|
L
 48.1%
H
13.5
47.7
|
L
 48.6%
H
8.1
47.7
|
L
H
3.0
47.7
|
| InflaRx N.V. |
|
191.6
|
2.7
|
L
 6%
H
2.3
3.0
|
L
 33.8%
H
1.9
3.0
|
L
 181.9%
H
0.9
3.0
|
L
 194.4%
H
0.8
3.0
|
L
 64.6%
H
0.7
3.0
|
L
 -39.5%
H
0.7
5.2
|
L
 -21.8%
H
0.7
7.3
|
L
H
0.7
53.1
|
| ImageneBio Inc |
|
66.7
|
5.9
|
L
 -2.8%
H
5.6
6.1
|
L
 -0.3%
H
5.5
6.2
|
L
 29.9%
H
4.5
6.6
|
L
 -14.5%
H
3.9
7.6
|
L
 -56.0%
H
3.9
18
|
L
 -93.3%
H
3.9
91.0
|
L
 -97.9%
H
3.9
292.6
|
L
H
3.9
451.3
|
| Inhibikase Therapeutics Inc |
|
262.7
|
2.0
|
L
 -1%
H
1.9
2.0
|
L
 7.0%
H
1.8
2.0
|
L
 11.2%
H
1.6
2.0
|
L
 17.1%
H
1.6
2.3
|
L
 2.6%
H
1.3
2.3
|
L
 -48.7%
H
0.8
4.4
|
L
 -93.5%
H
0.8
38.5
|
L
H
0.8
70.8
|
| Illumina Inc |
|
20,986.8
|
138.7
|
L
 -2.7%
H
137.1
142.4
|
L
 15.2%
H
121.4
143.0
|
L
 8.6%
H
118.3
143.0
|
L
 15.9%
H
112.7
143.0
|
L
 86.1%
H
73.9
155.5
|
L
 -30.5%
H
68.7
213.9
|
L
 -63.2%
H
68.7
526
|
L
 -1.4%
H
68.7
555.8
|
| IM Cannabis Corp |
|
1.6
|
0.3
|
L
H
0.3
0.3
|
L
H
0.2
0.3
|
L
 -21.2%
H
0.2
0.6
|
L
 -77.4%
H
0.2
1.2
|
L
 -85.2%
H
0.2
7.1
|
L
 -94.0%
H
0.2
8.6
|
L
 -99.9%
H
0.2
381
|
L
H
0.2
697.8
|
| Immix Biopharma Inc |
|
505.7
|
9.5
|
L
 -7.6%
H
9.5
10.3
|
L
 10.5%
H
8.6
10.4
|
L
 11.1%
H
8.3
10.5
|
L
 41.5%
H
6.0
11.6
|
L
 389.2%
H
1.9
11.6
|
L
 256.0%
H
1.3
11.6
|
L
H
0.7
11.6
|
L
H
0.7
11.6
|
| Immunome Inc |
|
2,513.0
|
22.2
|
L
 -4.6%
H
21.8
23.3
|
L
 -3.3%
H
21.8
24.0
|
L
 3.3%
H
20.8
24.9
|
L
 -10.8%
H
19.2
25.2
|
L
 191.2%
H
7.2
27.7
|
L
 310.9%
H
4.5
31.0
|
L
 -1.4%
H
2.1
31.0
|
L
H
2.1
63.8
|
| Imunon Inc |
|
10.9
|
2.7
|
L
 0.7%
H
2.7
2.8
|
L
 1.9%
H
2.7
3.0
|
L
 -13.1%
H
2.7
3.2
|
L
 -16.5%
H
2.5
3.6
|
L
 -78.1%
H
2.5
47.4
|
L
 -86.8%
H
2.5
54.8
|
L
 -98.8%
H
2.5
348.8
|
L
 -99.9%
H
2.5
5040
|
| Immuneering Corp (Class A) |
|
337.7
|
5.2
|
L
 0.6%
H
5.1
5.3
|
L
 -0.6%
H
5.1
5.5
|
L
 -3.3%
H
5.1
6.2
|
L
 5.9%
H
4.7
6.2
|
L
 338.7%
H
1.1
10.1
|
L
 -34.6%
H
1
11.9
|
L
H
1
34.0
|
L
H
1
34.0
|
| Immatics N.V |
|
1,493.8
|
11.1
|
L
 -3.2%
H
11.0
11.6
|
L
 -0.5%
H
10.6
11.7
|
L
 8.1%
H
9.9
11.7
|
L
 15.7%
H
9.1
11.7
|
L
 142.7%
H
3.9
12.4
|
L
 10.3%
H
3.3
13.8
|
L
 -3.4%
H
3.3
16.3
|
L
H
3.3
18.4
|
| Immunic Inc |
|
160.1
|
11.8
|
L
 6.6%
H
10.5
11.8
|
L
 17.2%
H
9.1
11.8
|
L
 0.4%
H
8.5
13.4
|
L
 89.5%
H
5.9
15.1
|
L
 9.8%
H
5.1
15.1
|
L
 -29.2%
H
5.1
31.1
|
L
 -90.1%
H
5.1
151.2
|
L
 -99.6%
H
5.1
3900
|
| Immunovant Inc |
|
5,540.1
|
27.2
|
L
 -5.1%
H
26.8
28.8
|
L
 1%
H
26.5
28.8
|
L
 9.4%
H
23.9
30.1
|
L
 0.6%
H
22.8
30.1
|
L
 96.7%
H
13.4
30.1
|
L
 41.8%
H
12.7
45.6
|
L
 65.1%
H
3.1
45.6
|
L
H
3.1
53.8
|
| IN8bio Inc |
|
15.8
|
1.6
|
L
 1.3%
H
1.6
1.6
|
L
 6.0%
H
1.4
1.7
|
L
 13.5%
H
1.3
1.7
|
L
 -19.6%
H
1.3
2.1
|
L
 841.2%
H
0.1
4.2
|
L
 -31.3%
H
0.1
4.2
|
L
H
0.1
10.3
|
L
H
0.1
10.3
|
| Inhibrx Inc |
|
5,899.5
|
124.5
|
L
 -12.2%
H
120.5
141.8
|
L
 -0.2%
H
120.5
142.1
|
L
 95.4%
H
60.3
155.3
|
L
 48.4%
H
57.3
155.3
|
L
 901.0%
H
10.8
155.3
|
L
 361.4%
H
10.8
155.3
|
L
 640.3%
H
7.7
155.3
|
L
H
7.7
155.3
|
| Incyte |
|
19,532.7
|
97.8
|
L
 -2.1%
H
97.1
99.7
|
L
 -1.3%
H
94.8
100.9
|
L
 3.1%
H
92.8
102.9
|
L
 -9.8%
H
89.3
109.5
|
L
 64.0%
H
57.8
112.3
|
L
 46.9%
H
50.3
112.3
|
L
 18.8%
H
50.3
112.3
|
L
 38.3%
H
50.3
153.2
|
| Indaptus Therapeutics Inc |
|
4.6
|
2.0
|
L
 -1.0%
H
1.8
2.2
|
L
 -30.5%
H
1.8
3.1
|
L
 16%
H
1.5
3.8
|
L
 12.8%
H
1.5
3.8
|
L
 372.1%
H
0.3
13.4
|
L
 -17.8%
H
0.3
13.4
|
L
 -85.9%
H
0.3
28.8
|
L
 -99.3%
H
0.3
8800
|
| Indivior PLC |
|
4,680.9
|
39.6
|
L
 -2.5%
H
39.4
41
|
L
 16.0%
H
34.9
41
|
L
 30.2%
H
29.9
41
|
L
 15.3%
H
27.7
41
|
L
 238.5%
H
10.6
41
|
L
 97.7%
H
7.3
41
|
L
 1776.8%
H
2.0
41
|
L
 1785.7%
H
0.4
41
|
| MiNK Therapeutics Inc |
|
55.7
|
11.2
|
L
 -0.2%
H
11.0
11.2
|
L
 -5.3%
H
11.0
12.4
|
L
 -2.2%
H
10.4
14.9
|
L
 2.0%
H
8.5
16.9
|
L
 51.6%
H
6.3
76
|
L
 -29.2%
H
0.9
76
|
L
H
0.9
221.6
|
L
H
0.9
221.6
|
| InMed Pharma Inc |
|
2.3
|
0.7
|
L
 -4.1%
H
0.7
0.8
|
L
H
0.7
0.8
|
L
H
0.6
0.8
|
L
 -25.5%
H
0.6
1.1
|
L
 -76.0%
H
0.6
8.0
|
L
 -97.2%
H
0.6
41.6
|
L
 -100.0%
H
0.6
1800
|
L
 -99.9%
H
0.6
32175
|
| INmune Bio Inc |
|
38.0
|
1.4
|
L
 -5.9%
H
1.4
1.5
|
L
 7.5%
H
1.3
1.6
|
L
 16.3%
H
1.2
1.6
|
L
 -5.3%
H
1.1
1.7
|
L
 -79.9%
H
1.1
11.6
|
L
 -82.3%
H
1.1
14.7
|
L
 -86.3%
H
1.1
30.4
|
L
H
1.1
30.4
|
| Inovio Pharma Inc |
|
111.8
|
1.4
|
L
 10.5%
H
1.3
1.4
|
L
 22.3%
H
1.1
1.4
|
L
 21.2%
H
1.0
1.4
|
L
 -17.5%
H
1.0
2.0
|
L
 -19.9%
H
1.0
3.0
|
L
 67.1%
H
0.3
14.8
|
L
 -79.0%
H
0.3
14.8
|
L
 -84.7%
H
0.3
33.8
|
| Insmed Inc |
|
22,664.5
|
105
|
L
 -23.4%
H
103.5
125.4
|
L
 -22.2%
H
103.5
142.9
|
L
 -35.9%
H
103.5
164.0
|
L
 -29.9%
H
103.5
167.4
|
L
 54.7%
H
63.8
212.8
|
L
 441.2%
H
18.1
212.8
|
L
 223.1%
H
16.0
212.8
|
L
 845.1%
H
9.0
212.8
|
| Innoviva Inc |
|
1,688.4
|
22.8
|
L
 1.2%
H
22.2
24.0
|
L
 -1.1%
H
22.2
24.0
|
L
 -1.0%
H
22.2
24.5
|
L
 4.6%
H
21.3
25.1
|
L
 21.9%
H
16.5
25.1
|
L
 94.0%
H
11.6
25.1
|
L
 97.9%
H
10.6
25.1
|
L
 92.9%
H
7.6
25.1
|
| Ionis Pharma Inc |
|
12,563.3
|
76.0
|
L
 -1.1%
H
74.9
76.6
|
L
 1.6%
H
72.9
77.8
|
L
 2.3%
H
71.2
77.8
|
L
 -12.1%
H
68.9
86.5
|
L
 138.6%
H
31.7
86.7
|
L
 110%
H
24.0
86.7
|
L
 103.6%
H
24.0
86.7
|
L
 123.5%
H
19.6
86.7
|
| Iovance Biotherapeutics Inc |
|
1,585.1
|
3.6
|
L
 -13.2%
H
3.5
4.1
|
L
 7.3%
H
3.3
4.2
|
L
 7.6%
H
3.2
4.3
|
L
 40.3%
H
2.5
5.6
|
L
 14.5%
H
1.6
5.6
|
L
 -48.2%
H
1.6
18.3
|
L
 -87.6%
H
1.6
30.8
|
L
 -31.9%
H
1.6
54.2
|
| Century Therapeutics Inc |
|
416.6
|
2.3
|
L
 -1.3%
H
2.2
2.4
|
L
 5%
H
2.2
2.4
|
L
 5.5%
H
2.1
2.6
|
L
 35.9%
H
1.7
3.0
|
L
 335.9%
H
0.4
3.0
|
L
 -25.5%
H
0.3
5.5
|
L
H
0.3
32.9
|
L
H
0.3
32.9
|
| Disc Medicine Inc |
|
2,599.3
|
67.5
|
L
 -1.6%
H
66.1
68.7
|
L
 2.4%
H
65.0
69.5
|
L
 2.6%
H
64.4
72.4
|
L
 -15.3%
H
40
79.8
|
L
 58.6%
H
40
99.5
|
L
 120.5%
H
25.6
99.5
|
L
 -43.7%
H
11.6
129.5
|
L
H
11.6
190.9
|
| Ironwood Pharma Inc (Class A) |
|
686.4
|
4.2
|
L
 -13.7%
H
4.0
4.8
|
L
 0.5%
H
4.0
4.9
|
L
 18.1%
H
3.3
4.9
|
L
 -8.6%
H
3.0
4.9
|
L
 348.4%
H
0.5
5.8
|
L
 -60.9%
H
0.5
15.7
|
L
 -60.2%
H
0.5
15.7
|
L
 -50.3%
H
0.5
17.7
|
| Invivyd Inc |
|
404.4
|
1.4
|
L
 -2.1%
H
1.4
1.5
|
L
 5.2%
H
1.4
1.6
|
L
 10%
H
1.2
1.8
|
L
 -10.1%
H
1.2
2.0
|
L
 169.8%
H
0.5
3.1
|
L
 20.2%
H
0.4
5.2
|
L
H
0.4
78.8
|
L
H
0.4
78.8
|
| I-Mab (ADR) |
|
255.9
|
2.2
|
L
 -1.3%
H
2.1
2.3
|
L
 -5.5%
H
2.1
2.6
|
L
 -8.3%
H
2.1
2.8
|
L
 -40%
H
2.1
3.9
|
L
 149.4%
H
0.8
6.8
|
L
 -26.7%
H
0.6
6.8
|
L
 -96.2%
H
0.6
85.4
|
L
H
0.6
85.4
|
| Immunocore Holdings PLC (ADR) |
|
1,557.5
|
30.6
|
L
 -0.4%
H
30.2
31.5
|
L
 9.7%
H
27.6
31.5
|
L
 -4.1%
H
27.6
32.8
|
L
 -4.3%
H
27.6
34.9
|
L
 9.1%
H
27.4
40.7
|
L
 -48.8%
H
23.2
77.0
|
L
 -22.8%
H
18.4
77.0
|
L
H
18.4
77.0
|
| Immutep Ltd (ADR) |
|
63.4
|
0.4
|
L
 -2.3%
H
0.4
0.4
|
L
 -10.4%
H
0.4
0.5
|
L
 19.4%
H
0.3
1.1
|
L
 -83.6%
H
0.3
3.0
|
L
 -78.8%
H
0.3
3.5
|
L
 -73.8%
H
0.3
3.9
|
L
 -86.6%
H
0.3
5.4
|
L
 -86.6%
H
0.3
8.0
|
| Immuron Ltd (ADR) |
|
6.8
|
0.8
|
L
 1.2%
H
0.8
0.9
|
L
 2.5%
H
0.8
0.9
|
L
 1.2%
H
0.8
1
|
L
 2.5%
H
0.7
1
|
L
 -57.4%
H
0.7
2.4
|
L
 -55.6%
H
0.7
6.0
|
L
 -83.8%
H
0.7
6.0
|
L
H
0.7
29.0
|
| Innate Pharma (ADR) |
|
128.5
|
1.4
|
L
 -9.3%
H
1.4
1.5
|
L
 -7.4%
H
1.4
1.6
|
L
 -1.4%
H
1.3
1.8
|
L
 -19.9%
H
1.2
1.9
|
L
 -39.1%
H
1.2
2.6
|
L
 -54.3%
H
1.2
3.6
|
L
 -65.3%
H
1.2
12.0
|
L
H
1.2
12.0
|
| Inventiva (ADR) |
|
1,110.9
|
5.4
|
L
 -0.9%
H
5.3
5.5
|
L
 8.3%
H
5.0
5.6
|
L
 -5.6%
H
4.9
5.8
|
L
 -9.0%
H
4.9
7.1
|
L
 55.1%
H
2.9
8.0
|
L
 87.1%
H
1.5
8.0
|
L
 -62.9%
H
1.5
16.9
|
L
H
1.5
19.1
|
| Jaguar Health Inc |
|
1.1
|
3.0
|
L
 5.7%
H
2.7
3.2
|
L
 -62.2%
H
2.5
8
|
L
 -79.2%
H
2.5
15.8
|
L
 -87.3%
H
2.5
34.8
|
L
 -99.2%
H
2.5
396.0
|
L
 -100.0%
H
2.5
64050
|
L
 -100.0%
H
2.5
26932500
|
L
 -100.0%
H
2.5
880621875
|
| Janux Therapeutics Inc |
|
886.4
|
14.5
|
L
 -0.6%
H
14.3
14.7
|
L
 3.1%
H
14.0
14.8
|
L
 -2.7%
H
14.0
16.6
|
L
 11.3%
H
12.7
16.6
|
L
 -43.1%
H
12.1
35.3
|
L
 -1.4%
H
5.7
71.7
|
L
H
5.7
71.7
|
L
H
5.7
71.7
|
| Jazz Pharma PLC |
|
15,002.1
|
227.0
|
L
 -0.7%
H
221.8
229
|
L
 13.5%
H
201.0
230.4
|
L
 21.5%
H
185.5
230.4
|
L
 37.1%
H
161.4
230.4
|
L
 104.2%
H
97.5
230.4
|
L
 62.8%
H
95.5
230.4
|
L
 31.3%
H
95.5
230.4
|
L
 57.2%
H
86.9
230.4
|
| Jasper Therapeutics Inc |
|
25.5
|
0.9
|
L
 -4.2%
H
0.9
1.0
|
L
 2.3%
H
0.9
1.0
|
L
 33.8%
H
0.6
1.1
|
L
 -32.6%
H
0.6
1.5
|
L
 -80.8%
H
0.6
7.2
|
L
 -39.3%
H
0.4
31.0
|
L
H
0.4
31.0
|
L
H
0.4
31.0
|
| Kala Pharma Inc |
|
74.4
|
0.1
|
L
 -33.3%
H
0.1
0.1
|
L
 -27.3%
H
0.1
0.1
|
L
 -52.9%
H
0.1
0.2
|
L
 -81.8%
H
0.1
0.5
|
L
 -97.7%
H
0.1
20.6
|
L
 -99.5%
H
0.1
20.6
|
L
 -100.0%
H
0.1
338.5
|
L
H
0.1
1337.5
|
| KalVista Pharma Inc |
|
1,420.6
|
26.7
|
L
H
26.7
26.7
|
L
 0.2%
H
26.6
26.8
|
L
 32.3%
H
18.7
26.8
|
L
 79.3%
H
14.2
26.8
|
L
 113.9%
H
9.8
26.8
|
L
 177.8%
H
7.2
26.8
|
L
 7.8%
H
4.1
30.7
|
L
 156.2%
H
4.1
45
|
| Kamada Ltd |
|
476.5
|
8.3
|
L
 -0.2%
H
8.2
8.5
|
L
 1.9%
H
8.1
8.5
|
L
 -0.2%
H
8.1
8.6
|
L
 0.6%
H
8.0
9.4
|
L
 24.2%
H
6.5
9.4
|
L
 65.5%
H
4.1
9.4
|
L
 35.9%
H
3.7
9.4
|
L
 102.0%
H
3.6
13.3
|
| Kiniksa Pharma Ltd (Class A) |
|
4,380.1
|
56.9
|
L
 -2.2%
H
55.8
57.6
|
L
 7.4%
H
52.6
58.3
|
L
 14.9%
H
41.5
58.3
|
L
 32.1%
H
41.1
58.3
|
L
 111.3%
H
24.9
58.3
|
L
 315.9%
H
12.9
58.3
|
L
 289.4%
H
7.4
58.3
|
L
H
5.0
58.3
|
| Kodiak Sciences Inc |
|
2,715.0
|
43.7
|
L
 -4.8%
H
42.4
45.6
|
L
 0.0%
H
41.9
46.6
|
L
 12%
H
38.4
47.8
|
L
 89.6%
H
21
47.8
|
L
 1049.5%
H
2.8
47.8
|
L
 827.4%
H
1.4
47.8
|
L
 -57.1%
H
1.4
132.0
|
L
H
1.4
171.2
|
| Kiora Pharma Inc |
|
10.9
|
2.5
|
L
 -2.4%
H
2.4
2.6
|
L
 4.3%
H
2.3
2.6
|
L
 21.3%
H
2.2
2.9
|
L
 14.0%
H
1.8
2.9
|
L
 -25.8%
H
1.8
4.2
|
L
 -11.2%
H
0.4
5.6
|
L
 -98.5%
H
0.4
257.2
|
L
 -99.9%
H
0.4
2400
|
| Karyopharm Therapeutics Inc |
|
199.6
|
8.9
|
L
 -1.9%
H
8.7
9
|
L
 5.4%
H
8.2
9.6
|
L
 40.0%
H
6.0
9.7
|
L
 41.4%
H
5
11.0
|
L
 41.2%
H
3.7
11.0
|
L
 -78.2%
H
0.6
41.9
|
L
 -92.8%
H
0.6
221.0
|
L
 -92.5%
H
0.6
444.2
|
| Keros Therapeutics Inc |
|
230.3
|
11.6
|
L
 -1.2%
H
11.3
11.7
|
L
 4.9%
H
10.9
12.1
|
L
 -1.9%
H
10.8
12.6
|
L
 -33.8%
H
10.4
17.6
|
L
 -15.4%
H
10.4
22.6
|
L
 -73.6%
H
9.1
73
|
L
 -78.6%
H
9.1
73
|
L
H
9.1
88.8
|
| Krystal Biotech Inc |
|
8,746.6
|
296.7
|
L
 2.7%
H
279.7
297.5
|
L
 14.1%
H
252.0
303
|
L
 13.3%
H
252.0
303
|
L
 8.8%
H
242
303
|
L
 112.7%
H
122.8
303
|
L
 252.2%
H
83.4
303
|
L
 321.4%
H
38.9
303
|
L
H
8.0
303
|
| TuHURA Biosciences Inc |
|
152.8
|
2.4
|
L
 -5.5%
H
2.3
2.5
|
L
 14.3%
H
2.1
2.6
|
L
 65.5%
H
1.3
3.4
|
L
 281.0%
H
0.6
3.4
|
L
 -35.7%
H
0.4
4.2
|
L
 -98.0%
H
0.2
196
|
L
 -99.9%
H
0.2
4987.5
|
L
 -100.0%
H
0.2
190225
|
| Pasithea Therapeutics Corp |
|
20.9
|
0.8
|
L
 -1.2%
H
0.8
0.9
|
L
 21.7%
H
0.7
1.0
|
L
 6.3%
H
0.7
1.0
|
L
 16.7%
H
0.5
1.0
|
L
 -44.4%
H
0.3
2.1
|
L
 154.5%
H
0.3
9.3
|
L
H
0.3
9.3
|
L
H
0.3
9.3
|
| Kura Oncology Inc |
|
827.3
|
9.3
|
L
 -2.5%
H
9.1
9.6
|
L
 6.5%
H
8.7
9.6
|
L
 9.8%
H
8.3
10.0
|
L
 19.0%
H
7.5
10.0
|
L
 61.0%
H
5.5
12.5
|
L
 -18.2%
H
5.4
24.2
|
L
 -62.7%
H
5.4
26.4
|
L
 237.7%
H
2.5
43
|
| Kymera Therapeutics Inc |
|
6,961.5
|
84.6
|
L
 -1.9%
H
83.4
86.7
|
L
 3.8%
H
77.6
86.7
|
L
 -0.8%
H
77.6
90.1
|
L
 6.3%
H
73.3
95.9
|
L
 196.2%
H
28.1
103
|
L
 191.7%
H
9.6
103
|
L
 106.5%
H
9.6
103
|
L
H
9.6
103
|
| Kezar Life Sciences Inc |
|
54.4
|
7.4
|
L
 -0.3%
H
7.4
7.5
|
L
 0.8%
H
7.2
7.5
|
L
 -0.5%
H
7.2
7.5
|
L
 20.3%
H
6.1
7.6
|
L
 76.9%
H
3.5
7.6
|
L
 -72.1%
H
0.7
31.3
|
L
 -86.6%
H
0.7
185.5
|
L
H
0.7
363.3
|
| Kazia Therapeutics Ltd (ADR) |
|
153.2
|
13.4
|
L
 -3.1%
H
13.1
13.9
|
L
 8.0%
H
12.5
14.4
|
L
 82.7%
H
7.2
14.4
|
L
 131.6%
H
4.9
14.4
|
L
 316.5%
H
3.1
17.4
|
L
 -78.0%
H
2.9
79
|
L
 -97.4%
H
2.9
614
|
L
 -96.7%
H
2.9
792.5
|
| Lexaria Bioscience Corp |
|
15.9
|
0.6
|
L
 -4.5%
H
0.6
0.7
|
L
 -7.3%
H
0.6
0.7
|
L
 -39.6%
H
0.6
1.1
|
L
 -11.1%
H
0.6
1.1
|
L
 -40.7%
H
0.5
1.6
|
L
 -51.1%
H
0.5
6.9
|
L
 -89.6%
H
0.5
12.5
|
L
 -80.5%
H
0.5
76.2
|
| Lifecore Biomedical Inc |
|
178.8
|
4.8
|
L
 -3.8%
H
4.7
5
|
L
 -3.4%
H
4.6
5.4
|
L
 17.2%
H
4.0
5.5
|
L
 -37.0%
H
3.6
8.2
|
L
 -31.4%
H
3.6
9.0
|
L
 8.4%
H
3.6
11.5
|
L
 -61.6%
H
1.5
12.9
|
L
 -57.4%
H
1.5
15.6
|
| Lifevantage Corp |
|
64.3
|
5.0
|
L
 -16.3%
H
4.9
5.2
|
L
 -0.6%
H
4.9
6.2
|
L
 20.1%
H
3.9
6.2
|
L
 -0.2%
H
3.9
6.2
|
L
 -58.1%
H
3.9
15
|
L
 34.9%
H
3.7
27.4
|
L
 -33.9%
H
3.0
27.4
|
L
 -48.8%
H
2.9
27.4
|
| Ligand Pharma Inc (Class B) |
|
2,551.2
|
210.3
|
L
 -9.6%
H
200.0
225.6
|
L
 -6.5%
H
200.0
236.3
|
L
 3.3%
H
198.6
247.4
|
L
 10.4%
H
178.7
247.4
|
L
 103.6%
H
98.9
247.4
|
L
 165.1%
H
49.3
247.4
|
L
 157.7%
H
46.8
247.4
|
L
 173.5%
H
36.9
247.4
|
| Longeveron Inc (Class A) |
|
24.9
|
0.9
|
L
 -2.3%
H
0.9
0.9
|
L
 -2.3%
H
0.8
0.9
|
L
 -22.7%
H
0.8
1.2
|
L
 66.7%
H
0.5
1.2
|
L
 -41.8%
H
0.5
1.8
|
L
 -97.2%
H
0.5
44
|
L
 -98.4%
H
0.5
450
|
L
H
0.5
450
|
| Atyr Pharma Inc |
|
90.2
|
0.9
|
L
 -11.5%
H
0.9
1.0
|
L
 21.1%
H
0.8
1.1
|
L
 12.2%
H
0.8
1.1
|
L
 2.2%
H
0.7
1.1
|
L
 -71.5%
H
0.6
7.3
|
L
 -57.2%
H
0.6
7.3
|
L
 -75.1%
H
0.6
13.1
|
L
 -97.9%
H
0.6
90.9
|
| Lixte biotech Holdings Inc |
|
57.3
|
4.9
|
L
 12.1%
H
4.0
5
|
L
 40.9%
H
3.3
5
|
L
 71.2%
H
2.5
5
|
L
 67.1%
H
2.4
5
|
L
 317.8%
H
0.6
6.3
|
L
 -13.1%
H
0.6
9.5
|
L
 -82.5%
H
0.6
49.5
|
L
 -31.0%
H
0.6
110.4
|
| Lipocine Inc |
|
19.2
|
2.4
|
L
 -1.7%
H
2.3
2.4
|
L
 4.4%
H
2.3
2.5
|
L
 23.2%
H
1.9
2.6
|
L
 -71.9%
H
1.8
10.5
|
L
 -28.0%
H
1.8
12.4
|
L
 -42.1%
H
1.8
12.4
|
L
 -89.7%
H
1.8
32.1
|
L
 -98.4%
H
1.8
163.0
|
| Leap Therapeutics Inc |
|
103.5
|
1.1
|
L
 -6.2%
H
1.0
1.2
|
L
 24.7%
H
0.8
1.3
|
L
 37.7%
H
0.7
1.3
|
L
 53.6%
H
0.5
1.3
|
L
 211.8%
H
0.2
3.7
|
L
 -72.8%
H
0.2
10.2
|
L
 -93.4%
H
0.2
41.7
|
L
H
0.2
102.5
|
| Liquidia Corp |
|
3,758.4
|
42.3
|
L
 0.3%
H
41.0
43.0
|
L
 10.8%
H
37.5
43.0
|
L
 12.3%
H
35.8
43.0
|
L
 -1.8%
H
29.1
43.7
|
L
 172.1%
H
11.9
46.7
|
L
 471.4%
H
5.7
46.7
|
L
 1558.0%
H
2.3
46.7
|
L
H
2.3
46.7
|
| Larimar Therapeutics Inc |
|
415.5
|
4
|
L
 -3.6%
H
3.9
4.1
|
L
 -7.8%
H
3.9
4.4
|
L
 -20.8%
H
3.9
5.4
|
L
 18.7%
H
2.7
6.4
|
L
 90.5%
H
1.7
6.4
|
L
 -15.4%
H
1.6
13.7
|
L
 -70.7%
H
1.5
15.5
|
L
 -94.6%
H
1.5
148.3
|
| Lisata Therapeutics Inc |
|
29.4
|
3.2
|
L
 -0.9%
H
3.1
3.4
|
L
 0.3%
H
3.1
3.4
|
L
 -35.4%
H
2.8
5.0
|
L
 -28.9%
H
2.8
5.1
|
L
 40.4%
H
1.8
5.1
|
L
 0.3%
H
1.8
5.1
|
L
 -85.7%
H
1.8
25.2
|
L
 -96.9%
H
1.8
174.8
|
| Lantern Pharma Inc |
|
23.1
|
2.0
|
L
 -4.7%
H
2.0
2.2
|
L
 3.0%
H
2.0
2.3
|
L
 25.9%
H
1.5
2.8
|
L
 -22.7%
H
1.1
3.1
|
L
 -46.5%
H
1.1
5.7
|
L
 -59.3%
H
1.1
12.0
|
L
 -85.7%
H
1.1
16.5
|
L
H
1.1
24.8
|
| Lexicon Pharma Inc |
|
746.1
|
1.7
|
L
 5%
H
1.5
1.7
|
L
 8.4%
H
1.5
1.7
|
L
 5.7%
H
1.5
2.0
|
L
 36.6%
H
1.2
2.0
|
L
 154.6%
H
0.5
2.0
|
L
 -51.9%
H
0.3
3.7
|
L
 -62.3%
H
0.3
6.3
|
L
 -86.3%
H
0.3
19.6
|
| Lyell Immunopharma Inc |
|
468.1
|
20.1
|
L
 -3.8%
H
19.5
21.2
|
L
 -2.6%
H
19.5
21.5
|
L
 -7.5%
H
19.5
25.3
|
L
 -11.7%
H
17.3
27.8
|
L
 141.1%
H
7.7
45
|
L
 -59.6%
H
7.7
79.4
|
L
H
7.7
396.8
|
L
H
7.7
396.8
|
| Legend Biotech Corp (ADR) |
|
5,284.2
|
28.6
|
L
 -1.4%
H
28.0
29.2
|
L
 25.5%
H
22.4
30.4
|
L
 52.9%
H
17.6
30.4
|
L
 67.1%
H
16.7
30.4
|
L
 -8.9%
H
16.2
45.3
|
L
 -57.4%
H
16.2
77.3
|
L
 2.6%
H
16.2
77.3
|
L
H
16.2
77.3
|
| Mustang Bio Inc |
|
5.5
|
0.7
|
L
 -2.7%
H
0.7
0.8
|
L
 -2.7%
H
0.7
0.8
|
L
 -4.0%
H
0.7
0.8
|
L
 -7.6%
H
0.7
1.0
|
L
 -36.0%
H
0.5
7
|
L
 -99.7%
H
0.1
408.5
|
L
 -100.0%
H
0.1
3045
|
L
H
0.1
10012.5
|
| Microbot Medical Inc |
|
143.0
|
2.1
|
L
 -2.7%
H
2.1
2.2
|
L
 4.4%
H
2.0
2.2
|
L
 -9.8%
H
2.0
2.7
|
L
 21.0%
H
1.7
2.9
|
L
 -12.7%
H
1.6
4.7
|
L
 91.9%
H
0.8
4.7
|
L
 -69.4%
H
0.8
9.6
|
L
 -99.5%
H
0.8
526.5
|
| Moleculin Biotech Inc |
|
13.3
|
2.5
|
L
 0.4%
H
2.5
2.6
|
L
 -0.8%
H
2.4
2.6
|
L
 7.3%
H
2.3
2.8
|
L
 -42.2%
H
1.8
5.3
|
L
 -90.2%
H
1.8
28.6
|
L
 -99.2%
H
1.8
3318.8
|
L
 -99.8%
H
1.8
3318.8
|
L
H
1.8
21555
|
| Seres Therapeutics Inc |
|
74.0
|
7.7
|
L
 -3.5%
H
7.4
8
|
L
 9.5%
H
6.9
8.3
|
L
 -12.4%
H
6.6
9.2
|
L
 -44.7%
H
6.6
14.7
|
L
 -9.7%
H
6.5
30.0
|
L
 30.6%
H
0.4
30.0
|
L
 -64.9%
H
0.4
30.0
|
L
 -67.9%
H
0.4
38.5
|
| Madrigal Pharma Inc |
|
15,528.3
|
534.9
|
L
 -0.9%
H
512.3
542
|
L
 3.1%
H
497.2
559
|
L
 0.2%
H
497.2
559
|
L
 12.0%
H
416.2
572.2
|
L
 81.2%
H
265
615
|
L
 74.6%
H
119.8
615
|
L
 322.1%
H
52.3
615
|
L
 3720.4%
H
6.6
615
|
| MediWound Ltd |
|
222.0
|
17.3
|
L
 -0.6%
H
17
17.6
|
L
 6.3%
H
16.3
17.6
|
L
 4.5%
H
16.1
18.1
|
L
 -2.9%
H
14.9
18.3
|
L
 -2.9%
H
14.9
22.5
|
L
 57.7%
H
7.1
24
|
L
 -36.7%
H
7.1
43.5
|
L
 -68.3%
H
7.1
60.1
|
| MEI Pharma Inc |
|
41.5
|
1.1
|
L
 -4.2%
H
1.1
1.2
|
L
 -0.9%
H
1.1
1.2
|
L
H
1.1
1.2
|
L
 7.6%
H
1.0
1.3
|
L
 -46.2%
H
1.0
9
|
L
 -82.3%
H
1.0
9
|
L
 -98.3%
H
1.0
71.2
|
L
 -95.7%
H
1.0
102.8
|
| Macrogenics Inc |
|
186.9
|
2.9
|
L
 -2.3%
H
2.9
3.1
|
L
H
2.9
3.4
|
L
 -7.6%
H
2.9
3.9
|
L
 62.4%
H
1.6
3.9
|
L
 100%
H
1.2
3.9
|
L
 -58.6%
H
1.0
21.9
|
L
 -90.8%
H
1.0
32.8
|
L
 -83.8%
H
1.0
36.5
|
| Mangoceuticals Inc |
|
5.8
|
0.3
|
L
 -2.9%
H
0.3
0.4
|
L
 3.0%
H
0.3
0.4
|
L
 -10.5%
H
0.3
0.5
|
L
 -10.5%
H
0.2
0.7
|
L
 -80.9%
H
0.2
2.8
|
L
 -72.8%
H
0.1
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
| Magenta Therapeutics Inc |
|
-
|
85.5
|
L
 -5.5%
H
83.6
91.2
|
L
 2.4%
H
83.1
91.8
|
L
 0.0%
H
82
96.5
|
L
 68.4%
H
45.6
96.5
|
L
 334.1%
H
16.6
96.5
|
L
 652.4%
H
9.8
96.5
|
L
 -49.3%
H
5.1
211.5
|
L
H
5.1
336
|
| MeiraGTx Holdings PLC |
|
896.1
|
9.7
|
L
 -2.2%
H
9.5
10.0
|
L
 8.2%
H
9.0
10.1
|
L
 1.7%
H
8.8
11.9
|
L
 30.3%
H
6.6
11.9
|
L
 64.9%
H
4.6
11.9
|
L
 57.4%
H
3.5
11.9
|
L
 -28.1%
H
3.5
24.9
|
L
H
3.5
30.2
|
| Mirum Pharma Inc |
|
6,276.4
|
102.9
|
L
 -6.5%
H
98.6
112
|
L
 9.3%
H
88.3
112
|
L
 7.0%
H
88.3
112
|
L
 2.5%
H
84.3
112
|
L
 151.1%
H
40
112
|
L
 292.4%
H
23.1
112
|
L
 481.5%
H
12.8
112
|
L
H
6.5
112
|
| Milestone Pharma Inc |
|
226.1
|
1.9
|
L
 -4.1%
H
1.9
2.0
|
L
 3.9%
H
1.8
2.0
|
L
 24.3%
H
1.5
2.3
|
L
 7.4%
H
1
2.3
|
L
 47.7%
H
1
3.1
|
L
 -47.4%
H
0.6
4.5
|
L
 -66.0%
H
0.6
9.9
|
L
H
0.6
28.0
|
| MoonLake Immunotherapeutics (Class A) |
|
1,253.1
|
17.2
|
L
 -2.8%
H
16.9
17.6
|
L
 6.8%
H
16.1
18
|
L
 1.3%
H
16.0
19.7
|
L
 10.9%
H
15.2
19.7
|
L
 -56.2%
H
6.0
62.8
|
L
 -36.1%
H
6.0
65.0
|
L
 68.8%
H
4.3
65.0
|
L
H
4.3
65.0
|
| Mineralys Therapeutics Inc |
|
2,420.0
|
29.4
|
L
 -2.6%
H
28.0
30.7
|
L
 14.8%
H
25.8
30.9
|
L
 4.0%
H
25.2
31.5
|
L
 -1.4%
H
22.4
32.2
|
L
 103.0%
H
12.6
47.7
|
L
 87.3%
H
5.9
47.7
|
L
H
5.9
47.7
|
L
H
5.9
47.7
|
| Mannkind Corp |
|
1,096.2
|
3.6
|
L
 -0.3%
H
3.3
3.9
|
L
 29.1%
H
2.7
4.3
|
L
 38.7%
H
2.4
4.3
|
L
 -38.6%
H
2.2
6.1
|
L
 -25.7%
H
2.2
6.5
|
L
 -10.4%
H
2.2
7.6
|
L
 -13.0%
H
2.2
7.6
|
L
 -46.6%
H
0.7
7.6
|
| Mind Medicine Inc |
|
2,530.3
|
23.2
|
L
 -0.9%
H
22.7
23.5
|
L
 13.2%
H
20.4
23.5
|
L
 13.6%
H
19.8
26.3
|
L
 37.3%
H
15.6
26.3
|
L
 267.7%
H
6.0
26.3
|
L
 580.4%
H
2.4
26.3
|
L
 -54.6%
H
2.1
60.6
|
L
H
0.0
154.8
|
| Medicinova Inc |
|
70.4
|
1.4
|
L
 -1.4%
H
1.4
1.5
|
L
 4.4%
H
1.4
1.5
|
L
 1.4%
H
1.4
1.5
|
L
 -10.6%
H
1.3
1.8
|
L
 -3.4%
H
1.2
2.0
|
L
 -33.8%
H
1.1
2.7
|
L
 -64.3%
H
1.1
5.1
|
L
 -79.3%
H
1.1
14.5
|
| Monopar Therapeutics Inc |
|
418.2
|
62.4
|
L
 -2.2%
H
58.5
66.2
|
L
 24.6%
H
50.3
66.2
|
L
 16.3%
H
50.1
66.2
|
L
 8.1%
H
50.1
66.2
|
L
 61.0%
H
28.4
105
|
L
 1158.7%
H
1.4
105
|
L
 140.6%
H
1.4
105
|
L
H
1.4
240
|
| Marker Therapeutics Inc |
|
24.0
|
1.4
|
L
 -1.4%
H
1.4
1.5
|
L
 -0.7%
H
1.4
1.6
|
L
 2.1%
H
1.3
1.8
|
L
 -12.7%
H
1.2
1.8
|
L
 26.3%
H
0.8
4.1
|
L
H
0.8
9.7
|
L
 -93.8%
H
0.7
36.5
|
L
 -98.1%
H
0.7
135.5
|
| Moderna |
|
19,260.0
|
48.5
|
L
 -0.5%
H
47.8
52
|
L
 6.2%
H
43.7
52
|
L
 -0.5%
H
43.7
56.2
|
L
 18.4%
H
36.7
59.6
|
L
 98.7%
H
22.3
59.6
|
L
 -64.6%
H
22.3
170.5
|
L
 -69.8%
H
22.3
497.5
|
L
H
11.5
497.5
|
| Maravai LifeSciences Holdings Inc (Class A) |
|
581.1
|
3.9
|
L
H
3.7
4.1
|
L
 13.2%
H
3.5
4.1
|
L
 33.6%
H
2.8
4.1
|
L
 25.5%
H
2.8
4.1
|
L
 93.1%
H
2.0
4.1
|
L
 -72.8%
H
1.7
16.6
|
L
 -88.9%
H
1.7
63.6
|
L
H
1.7
63.6
|
| Mannatech Inc |
|
9.0
|
4.7
|
L
 -4.3%
H
4.3
4.7
|
L
 4.7%
H
4.3
5.0
|
L
 -15.1%
H
4.3
8.5
|
L
 -36.8%
H
4.3
8.5
|
L
 -53.8%
H
4.3
12.5
|
L
 -64.1%
H
4.3
16.5
|
L
 -75.4%
H
4.3
49.1
|
L
 -75.5%
H
4.3
49.1
|
| MaxCyte Inc |
|
93.2
|
0.9
|
L
 2.4%
H
0.8
0.9
|
L
 6.1%
H
0.8
0.9
|
L
 22.5%
H
0.7
0.9
|
L
 7.4%
H
0.6
0.9
|
L
 -67.3%
H
0.6
2.9
|
L
 -81.7%
H
0.6
5.5
|
L
 -85.1%
H
0.6
17.4
|
L
H
0.6
17.4
|
| TNF Pharma Inc |
|
29.5
|
3.8
|
L
 -6.2%
H
3.7
4.0
|
L
 4.2%
H
3.6
4.2
|
L
 7.1%
H
3.3
4.3
|
L
 -4.6%
H
3.1
5.0
|
L
 -81.1%
H
2.5
33.6
|
L
 -99.9%
H
2.5
7050
|
L
 -100.0%
H
2.5
29850
|
L
 -99.9%
H
2.5
29850
|
| Mainz Biomed N.V. |
|
4.6
|
0.4
|
L
 -2.6%
H
0.3
0.4
|
L
 -19.6%
H
0.3
0.5
|
L
 -22.9%
H
0.3
0.6
|
L
 -60.6%
H
0.3
1.0
|
L
 -84.8%
H
0.3
2.6
|
L
 -99.8%
H
0.3
240
|
L
H
0.3
1200
|
L
H
0.3
1200
|
| Mesoblast Ltd (ADR) |
|
1,913.4
|
14.8
|
L
 -6.4%
H
14.7
15.6
|
L
 -4.8%
H
14.7
16.1
|
L
 -0.5%
H
13.3
16.9
|
L
 -7.2%
H
13.3
18.4
|
L
 36.0%
H
9.9
21.5
|
L
 340.5%
H
1.0
22
|
L
 109.3%
H
1.0
22
|
L
 99.5%
H
1.0
22
|
| Molecular Partners AG (ADR) |
|
153.4
|
4.1
|
L
 -4.2%
H
4.1
4.2
|
L
 -7.9%
H
4.1
4.5
|
L
 1.5%
H
3.9
4.5
|
L
 -12.8%
H
3.7
5.4
|
L
 0.5%
H
3.4
5.4
|
L
 -40.2%
H
3.3
12.7
|
L
 -81.2%
H
3.3
32.0
|
L
 -85.0%
H
3.3
32.0
|
| Mereo Biopharma Grp PLC (ADR) |
|
38.3
|
0.2
|
L
H
0.2
0.3
|
L
 -14.3%
H
0.2
0.3
|
L
 -25%
H
0.2
0.4
|
L
 -42.9%
H
0.2
0.5
|
L
 -89.7%
H
0.2
3.1
|
L
 -80%
H
0.2
5.0
|
L
 -92.7%
H
0.2
5.0
|
L
H
0.2
8.5
|
| Natural Alternatives Intl Inc |
|
16.9
|
2.7
|
L
 0.7%
H
2.7
2.8
|
L
 2.6%
H
2.6
2.8
|
L
 2.2%
H
2.6
2.9
|
L
 -14.6%
H
2.3
3.5
|
L
 1.5%
H
2.3
5.0
|
L
 -64.9%
H
2.3
7.9
|
L
 -80.9%
H
2.3
19.9
|
L
 -75.9%
H
2.3
19.9
|
| NewAmsterdam Pharma Co NV |
|
4,006.9
|
34.9
|
L
 12.5%
H
31.1
35.4
|
L
 22.6%
H
28.0
35.4
|
L
 2.1%
H
27.9
36.7
|
L
 1.6%
H
27.9
37.8
|
L
 83.4%
H
16.8
42
|
L
 151.3%
H
5.6
42
|
L
 255.2%
H
5.6
42
|
L
H
5.6
42
|
| Nature`s Sunshine Products Inc |
|
429.8
|
24.6
|
L
 -6.4%
H
24.4
26.2
|
L
 -9.2%
H
24.4
27.4
|
L
 -0.2%
H
24.4
28
|
L
 -6.8%
H
22.7
28.1
|
L
 97.8%
H
12.9
28.1
|
L
 128.2%
H
10.1
28.1
|
L
 17.5%
H
7.9
28.1
|
L
 162.6%
H
5.5
28.1
|
| Nautilus biotech Inc |
|
366.0
|
2.9
|
L
 -2.0%
H
2.8
3.1
|
L
 15.2%
H
2.5
3.1
|
L
 -14.0%
H
2.4
3.4
|
L
 41.9%
H
2.0
4.3
|
L
 329.9%
H
0.6
4.3
|
L
 22.0%
H
0.6
4.7
|
L
 -71.5%
H
0.6
12.4
|
L
H
0.6
25.9
|
| Neurocrine Biosciences Inc |
|
15,467.6
|
149.6
|
L
 1.8%
H
146.1
150.4
|
L
 14.0%
H
129.8
150.4
|
L
 12.9%
H
125.6
150.4
|
L
 5.9%
H
122.1
150.4
|
L
 25.8%
H
115.7
160.2
|
L
 53.6%
H
84.2
160.2
|
L
 67.3%
H
71.9
160.2
|
L
 248.9%
H
37.3
160.2
|
| Minerva Neurosciences Inc |
|
268.7
|
6.1
|
L
 -1.8%
H
6.0
6.2
|
L
 -4.2%
H
5.9
6.6
|
L
 17.0%
H
5.1
7.6
|
L
 27.5%
H
4.7
8.8
|
L
 280.1%
H
1.3
12.5
|
L
 2%
H
1.2
13.5
|
L
 -66%
H
1.2
28.3
|
L
 -88.4%
H
1.2
126.7
|
| Nektar Therapeutics |
|
2,813.1
|
83.4
|
L
 -2.0%
H
81.8
85.8
|
L
 0.2%
H
81.8
88.1
|
L
 11.6%
H
73
109
|
L
 126.5%
H
35.6
109
|
L
 765.7%
H
8.0
109
|
L
 577.8%
H
6.2
109
|
L
 -70.0%
H
6.2
303.8
|
L
 -58.5%
H
6.2
1670.4
|
| Nkarta Inc |
|
224.6
|
3.2
|
L
 -5.1%
H
3.1
3.3
|
L
 17.1%
H
2.7
3.4
|
L
 33.5%
H
2.1
3.7
|
L
 55.9%
H
2.0
3.7
|
L
 69.4%
H
1.6
3.7
|
L
 -32.0%
H
1.3
16.2
|
L
 -87.8%
H
1.3
40.6
|
L
H
1.3
79.2
|
| NLS Pharmaceutics Ltd |
|
17.3
|
3.2
|
L
 -2.4%
H
3.2
3.4
|
L
 -5.3%
H
3.2
4.8
|
L
 51.4%
H
2.1
5.1
|
L
 17.0%
H
1.8
5.1
|
L
 -81.3%
H
1.8
30.8
|
L
 -99.4%
H
1.2
612
|
L
 -99.7%
H
1.2
1492
|
L
H
1.2
2940
|
| Neoleukin Therapeutics Inc |
|
-
|
31.3
|
L
 -3.3%
H
29.6
33.5
|
L
 18.1%
H
24.9
33.5
|
L
 52.7%
H
19.1
33.5
|
L
 81.4%
H
16.2
33.5
|
L
 73.8%
H
14.7
37.3
|
L
 73.9%
H
12.2
37.3
|
L
 -86.1%
H
7.5
237.3
|
L
 -79.7%
H
7.5
399.4
|
| 9 Meters Biopharma Inc |
|
-
|
8.7
|
L
 -1.3%
H
8.7
8.9
|
L
 12.5%
H
8.0
9.3
|
L
 17.2%
H
7.4
9.3
|
L
 8.3%
H
7.0
9.3
|
L
 22.5%
H
6.2
9.3
|
L
 976.5%
H
0.0
9.3
|
L
 -62.7%
H
0.0
31
|
L
H
0.0
1010
|
| MetaVia Inc |
|
6.9
|
1.3
|
L
 -5%
H
1.3
1.4
|
L
 -10.7%
H
1.3
1.5
|
L
 9.0%
H
1.2
1.7
|
L
 -26.9%
H
1.2
2.0
|
L
 -83.7%
H
1.2
19.0
|
L
 -97.4%
H
1.2
74.3
|
L
 -100.0%
H
1.2
17344.8
|
L
H
1.2
1424940
|
| Nurix Therapeutics Inc |
|
1,683.4
|
16.3
|
L
 -3.6%
H
15.9
16.9
|
L
 -2.0%
H
15.9
17.4
|
L
 3.1%
H
15.5
17.7
|
L
 -3.4%
H
14.0
17.7
|
L
 68.9%
H
8.2
22.5
|
L
 68.2%
H
4.2
29.6
|
L
 -40.5%
H
4.2
37.4
|
L
H
4.2
52.4
|
| NeuroSense Therapeutics Ltd |
|
31.8
|
0.9
|
L
 -2.2%
H
0.9
0.9
|
L
 10%
H
0.8
1.0
|
L
 15.8%
H
0.7
1.0
|
L
 -6.4%
H
0.6
1.1
|
L
 -14.6%
H
0.6
2.6
|
L
 -49.1%
H
0.4
2.6
|
L
H
0.4
8.2
|
L
H
0.4
8.2
|
| NRX Pharma Inc |
|
101.2
|
3.1
|
L
 0.3%
H
2.9
3.1
|
L
 5.2%
H
2.9
3.2
|
L
 36%
H
2.1
3.3
|
L
 60.2%
H
1.6
3.3
|
L
 59.4%
H
1.6
3.8
|
L
 -50%
H
1.1
54
|
L
 -99.0%
H
1.1
488
|
L
H
1.1
769.9
|
| Intellia Therapeutics Inc |
|
1,630.5
|
13.7
|
L
 -1.0%
H
13.4
14.1
|
L
 10.2%
H
12.6
14.3
|
L
 3.1%
H
11.8
17.0
|
L
 11.6%
H
11.2
17.0
|
L
 89.1%
H
6.8
28.3
|
L
 -68.8%
H
5.9
47.5
|
L
 -79.4%
H
5.9
202.7
|
L
 -38.0%
H
5.9
202.7
|
| Nuvalent Inc (Class A) |
|
8,087.3
|
102.4
|
L
 -1.8%
H
100.2
104.1
|
L
 3.3%
H
97.8
105.7
|
L
 -1.3%
H
97.8
109.5
|
L
 -1.2%
H
93.9
109.5
|
L
 50.2%
H
63.6
113.0
|
L
 165.9%
H
37.1
113.5
|
L
H
7.1
113.5
|
L
H
7.1
113.5
|
| Novavax Inc |
|
1,517.7
|
9.2
|
L
 -1.4%
H
9.2
10.2
|
L
 15.8%
H
7.8
10.2
|
L
 15.8%
H
7.7
10.2
|
L
 11.9%
H
7.6
12.0
|
L
 52.1%
H
5.8
12.0
|
L
 19.7%
H
3.5
23.9
|
L
 -94.6%
H
3.5
277.8
|
L
 -90.0%
H
3.5
331.7
|
| Nuvectis Pharma Inc |
|
241.6
|
10.3
|
L
 3.2%
H
9.8
10.5
|
L
 21.4%
H
8.4
10.5
|
L
 34.9%
H
7.6
10.5
|
L
 16.1%
H
7.2
10.5
|
L
 15.2%
H
5.6
11.2
|
L
 -31.4%
H
4.4
18.7
|
L
H
3.1
20.9
|
L
H
3.1
20.9
|
| Nextcure Inc |
|
36.7
|
10.2
|
L
 -5.0%
H
9.8
10.7
|
L
 13.9%
H
8.5
10.9
|
L
 -7.7%
H
8.5
13.5
|
L
 -8.3%
H
8.5
14.7
|
L
 92.8%
H
4.1
15.7
|
L
 -46.6%
H
2.8
30.8
|
L
 -89.2%
H
2.8
110.2
|
L
H
2.8
1308
|
| NuCana PLC (ADR) |
|
8.7
|
2.1
|
L
 -5.4%
H
2.1
2.3
|
L
 2.5%
H
2.0
2.3
|
L
 24.4%
H
1.7
2.3
|
L
 -5.9%
H
1.3
2.3
|
L
 -100.0%
H
1.3
16720
|
L
 -100.0%
H
1.3
950000
|
L
 -100.0%
H
1.3
3850000
|
L
H
1.3
32000000
|
| Ocugen Inc |
|
461.4
|
1.4
|
L
 -1.4%
H
1.4
1.5
|
L
 -14.3%
H
1.4
1.9
|
L
 -18.6%
H
1.4
2.0
|
L
 8.3%
H
1.3
2.7
|
L
 100%
H
0.6
2.7
|
L
 105.7%
H
0.3
2.7
|
L
 -85.0%
H
0.3
17.7
|
L
 -98.5%
H
0.2
268.2
|
| Oculis Holding AG |
|
1,802.7
|
31.1
|
L
 5.1%
H
29.4
31.3
|
L
 17.5%
H
26.4
31.3
|
L
 18.0%
H
25.9
31.3
|
L
 9.2%
H
24.0
31.3
|
L
 69.8%
H
16
31.3
|
L
 143.1%
H
9.1
31.3
|
L
H
6.3
31.3
|
L
H
6.3
31.3
|
| Ocular Therapeutix Inc |
|
2,169.3
|
9.7
|
L
 -0.3%
H
9.5
9.8
|
L
 5.1%
H
9.1
10.0
|
L
 20.0%
H
7.9
10.0
|
L
 5.7%
H
6.2
11.5
|
L
 34.8%
H
6.2
16.4
|
L
 54.9%
H
2
16.4
|
L
 -39.0%
H
2
16.9
|
L
 -4.7%
H
2
24.3
|
| Opus Genetics Inc |
|
382.7
|
5.4
|
L
 1.9%
H
5.0
5.4
|
L
 14.8%
H
4.7
5.4
|
L
 16.3%
H
4.4
5.8
|
L
 78.1%
H
3.0
5.8
|
L
 476.3%
H
0.9
5.8
|
L
 -13.3%
H
0.7
6.6
|
L
 16.3%
H
0.7
7
|
L
 -96.0%
H
0.7
340.8
|
| Insight Molecular Diagnostics Inc |
|
160.1
|
5.0
|
L
 -1.4%
H
4.7
5.2
|
L
 29.5%
H
3.7
5.4
|
L
 47.2%
H
2.6
5.4
|
L
 -32.2%
H
2.4
7.5
|
L
 71.6%
H
2.3
8.5
|
L
 -5.0%
H
1.9
8.5
|
L
 -94.4%
H
1.9
125
|
L
 -95.0%
H
1.9
159
|
| OKYO Pharma Ltd - Ordinary Shares - New |
|
85.0
|
1.6
|
L
 -3.6%
H
1.6
1.7
|
L
 6.6%
H
1.5
1.7
|
L
 3.2%
H
1.5
1.7
|
L
 -15.6%
H
1.4
2.3
|
L
 8.7%
H
1.3
3.4
|
L
 -5.8%
H
0.8
3.4
|
L
H
0.8
7
|
L
H
0.8
7
|
| Olema Pharma Inc |
|
1,321.5
|
15.1
|
L
 -0.4%
H
14.6
15.3
|
L
 7%
H
14.0
15.3
|
L
 -0.3%
H
14.0
17.5
|
L
 -40.3%
H
13.0
26.3
|
L
 228.9%
H
3.9
36.3
|
L
 127.2%
H
2.9
36.3
|
L
 -28.5%
H
2
36.3
|
L
H
2
60.3
|
| Omeros Corp |
|
1,056.5
|
14.6
|
L
 -1.3%
H
14.4
14.9
|
L
 0.6%
H
14.4
15.3
|
L
 34.6%
H
10.4
15.3
|
L
 30.4%
H
9.8
15.3
|
L
 130.9%
H
3.0
17.7
|
L
 185.9%
H
0.9
17.7
|
L
 -16.6%
H
0.9
18.9
|
L
 18.3%
H
0.9
27.1
|
| Oncolytics Biotech Inc |
|
104.5
|
0.9
|
L
 -2.2%
H
0.9
0.9
|
L
 3.5%
H
0.9
1.0
|
L
 -5.3%
H
0.8
1.2
|
L
 1.1%
H
0.8
1.2
|
L
 76.5%
H
0.3
1.5
|
L
 -43.8%
H
0.3
3.4
|
L
 -69.2%
H
0.3
3.4
|
L
 -82.4%
H
0.3
8.5
|
| Traws Pharma Inc |
|
25.8
|
1.7
|
L
H
1.6
1.7
|
L
 30.8%
H
1.3
1.8
|
L
 -1.2%
H
1
1.8
|
L
 -13.3%
H
1
2.5
|
L
 14.1%
H
1.0
3.3
|
L
 -95.1%
H
1.0
36.3
|
L
 -99.2%
H
1.0
412.5
|
L
 -100.0%
H
1.0
45956.3
|
| VivoSim Labs Inc |
|
4.1
|
1.4
|
L
H
1.4
1.5
|
L
 -2.1%
H
1.4
1.6
|
L
 -17.5%
H
1.4
1.9
|
L
 -38.2%
H
1.3
2.3
|
L
 -26.6%
H
1.3
5.3
|
L
 -93.8%
H
0.3
24.6
|
L
 -98.4%
H
0.3
135
|
L
 -99.8%
H
0.3
1197.6
|
| ORIC Pharma Inc |
|
912.0
|
8.8
|
L
 -5.3%
H
8.7
9.1
|
L
 -6.7%
H
8.7
10.1
|
L
 -1.1%
H
8.7
11.2
|
L
 -15.5%
H
7.2
14.3
|
L
 74.8%
H
4.5
14.9
|
L
 72.4%
H
3.9
16.7
|
L
 -63.1%
H
2.4
26.7
|
L
H
2.4
40.8
|
| Oramed Pharma Inc |
|
158.1
|
3.9
|
L
 -0.3%
H
3.8
3.9
|
L
 1.8%
H
3.8
4.0
|
L
 13.7%
H
3.4
4.2
|
L
 14.7%
H
3.1
4.2
|
L
 75.3%
H
2.0
4.2
|
L
 40.6%
H
1.7
5.3
|
L
 -63.2%
H
1.7
31.5
|
L
 -56.0%
H
1.7
31.5
|
| Outlook Therapeutics Inc |
|
26.6
|
0.2
|
L
 -4.4%
H
0.2
0.2
|
L
 -15.4%
H
0.2
0.3
|
L
 10%
H
0.2
0.4
|
L
 -48.8%
H
0.2
0.5
|
L
 -84.6%
H
0.2
3.0
|
L
 -100.0%
H
0.2
812
|
L
 -100.0%
H
0.2
1308
|
L
H
0.2
17568
|
| Ovid Therapeutics Inc |
|
472.4
|
2.7
|
L
 -1.8%
H
2.7
2.8
|
L
 1.5%
H
2.7
3.0
|
L
 18.7%
H
2.2
3.1
|
L
 70.6%
H
1.4
3.1
|
L
 841.4%
H
0.3
3.1
|
L
 -24.8%
H
0.2
4.1
|
L
 -21.1%
H
0.2
4.8
|
L
H
0.2
15.9
|
| Phibro Animal Health Corp (Class A) |
|
1,749.5
|
43.2
|
L
 -26.2%
H
42.9
50.9
|
L
 -17.8%
H
42.9
58.7
|
L
 -21.4%
H
42.9
60.1
|
L
 -18.7%
H
42.9
60.1
|
L
 126.7%
H
19
60.1
|
L
 194.8%
H
9.4
60.1
|
L
 67.2%
H
9.4
60.1
|
L
 109.7%
H
9.4
60.1
|
| Palisade Bio Inc |
|
333.6
|
2.0
|
L
 -0.5%
H
1.9
2.0
|
L
 3.1%
H
1.9
2.2
|
L
 3.1%
H
1.8
2.9
|
L
 21.3%
H
1.5
2.9
|
L
 136.9%
H
0.5
2.9
|
L
 -91.7%
H
0.4
36.6
|
L
 -100.0%
H
0.4
5092.5
|
L
 -100.0%
H
0.4
594000
|
| Passage Bio Inc |
|
13.1
|
4.1
|
L
 -1.0%
H
4.0
4.3
|
L
 -23.7%
H
4.0
5.5
|
L
 -53.4%
H
4.0
12.1
|
L
 -57.1%
H
4.0
12.1
|
L
 -39.6%
H
4.0
20
|
L
 -80.2%
H
4.0
35.8
|
L
 -98.8%
H
4.0
357.8
|
L
H
4.0
764.6
|
| Paranovus Entertainment Tech Ltd (Class A) |
|
1.3
|
1.3
|
L
 3.3%
H
1.2
1.3
|
L
 13.5%
H
1.1
1.3
|
L
 -33.7%
H
1.0
2.1
|
L
 -91.8%
H
1.0
28.4
|
L
 -99.9%
H
1.0
1488
|
L
 -100.0%
H
1.0
5808
|
L
 -100.0%
H
1.0
44160
|
L
H
1.0
146400
|
| Puma biotech Inc |
|
369.5
|
7.3
|
L
 -2.6%
H
7.0
7.5
|
L
 -2.9%
H
7.0
7.7
|
L
 5.4%
H
6.6
7.9
|
L
 4.6%
H
5.5
7.9
|
L
 143.6%
H
2.9
7.9
|
L
 130.5%
H
2.1
7.9
|
L
 -25%
H
1.6
12.0
|
L
 -69.1%
H
1.6
136.9
|
| Pacira BioSciences Inc |
|
930.2
|
23.6
|
L
 -0.2%
H
23.2
24.2
|
L
 -6.0%
H
23.2
27.1
|
L
 6.2%
H
22.0
27.1
|
L
 12.6%
H
20.6
27.1
|
L
 -6%
H
18.8
27.6
|
L
 -44.9%
H
11.2
43.8
|
L
 -62.6%
H
11.2
82.2
|
L
 -50.1%
H
11.2
82.2
|
| Processa Pharma Inc |
|
7.9
|
2.9
|
L
 4.4%
H
2.8
3.0
|
L
 8.3%
H
2.5
3.0
|
L
 2.5%
H
2.5
3.5
|
L
 20.6%
H
1.8
3.5
|
L
 -56.0%
H
1.8
19.6
|
L
 -99.2%
H
1.8
450
|
L
 -99.9%
H
1.8
4495.5
|
L
 -100.0%
H
1.8
17937.5
|
| Vaxcyte Inc |
|
7,433.1
|
51.5
|
L
 -9.8%
H
48.5
55.0
|
L
 -10.2%
H
48.5
59.7
|
L
 -13.9%
H
48.5
63.3
|
L
 -8.3%
H
48.5
65
|
L
 76.1%
H
28.1
65
|
L
 0.2%
H
27.7
121.1
|
L
 197.2%
H
15.5
121.1
|
L
H
15.5
121.1
|
| PDS biotech Corp |
|
63.6
|
1.1
|
L
 7.6%
H
1.1
1.2
|
L
 18.8%
H
1.0
1.2
|
L
 46.2%
H
0.7
1.4
|
L
 58.3%
H
0.5
1.4
|
L
 -4.2%
H
0.5
1.9
|
L
 -82.5%
H
0.5
10.3
|
L
 -76.9%
H
0.5
17.9
|
L
 -99.3%
H
0.5
355.4
|
| PepGen Inc |
|
123.8
|
1.8
|
L
 -2.7%
H
1.7
1.9
|
L
 15.5%
H
1.6
1.9
|
L
 -1.7%
H
1.5
1.9
|
L
 -60.0%
H
1.3
7.1
|
L
 38.8%
H
1.0
7.8
|
L
 -88.0%
H
0.9
19.3
|
L
H
0.9
20
|
L
H
0.9
20
|
| Precigen Inc |
|
1,479.5
|
4.2
|
L
 -5.7%
H
4.1
4.4
|
L
 0.7%
H
4.0
4.4
|
L
 -1.0%
H
3.8
4.4
|
L
 -3.3%
H
3.0
5.5
|
L
 196.4%
H
1.2
5.5
|
L
 240.2%
H
0.7
5.5
|
L
 -37.5%
H
0.7
8.7
|
L
 -84.2%
H
0.7
32.9
|
| Phathom Pharma Inc |
|
975.4
|
12.2
|
L
 -3.5%
H
11.8
12.7
|
L
 3.8%
H
9.7
13
|
L
 8.7%
H
9.7
13.7
|
L
 -2.8%
H
9.7
14.4
|
L
 409.6%
H
2.2
18.3
|
L
 -1.0%
H
2.2
19.7
|
L
 -63.7%
H
2.2
39.0
|
L
H
2.2
64.5
|
| Phio Pharma Corp |
|
13.2
|
1.1
|
L
 -0.9%
H
1.1
1.2
|
L
 -3.4%
H
1.1
1.2
|
L
 -9.5%
H
1.1
1.3
|
L
 23.9%
H
0.9
1.9
|
L
 -33.7%
H
0.8
4.2
|
L
 -96.8%
H
0.6
61.7
|
L
 -99.5%
H
0.6
307.8
|
L
 -100.0%
H
0.6
194238
|
| Pharvaris NV |
|
1,941.3
|
29.7
|
L
 -1.4%
H
29.0
30.5
|
L
 -0.5%
H
28.6
31.1
|
L
 4.6%
H
26
31.1
|
L
 12.3%
H
25.0
31.1
|
L
 76.4%
H
14.6
31.1
|
L
 220.9%
H
7.9
33
|
L
 21.9%
H
1.8
33
|
L
H
1.8
42.9
|
| Pliant Therapeutics Inc |
|
76.8
|
1.2
|
L
 0.8%
H
1.2
1.3
|
L
 2.5%
H
1.2
1.3
|
L
 -5.3%
H
1.2
1.4
|
L
 8.8%
H
1.1
1.4
|
L
 -13.3%
H
1.1
2.0
|
L
 -94.6%
H
1.1
24.7
|
L
 -96.1%
H
1.1
36.6
|
L
H
1.1
43.9
|
| Pluri Inc |
|
36.0
|
3.3
|
L
 1.2%
H
3.3
3.4
|
L
 -2.3%
H
3.2
3.5
|
L
 2.5%
H
3.2
3.9
|
L
 -3.8%
H
3.0
3.9
|
L
 -30.7%
H
2.8
6.1
|
L
 -55.1%
H
0.7
8.6
|
L
 -89.2%
H
0.7
36.4
|
L
 -97.4%
H
0.7
169.6
|
| PharmaCyte Biotech Inc |
|
8.6
|
0.8
|
L
 3.9%
H
0.7
0.8
|
L
 6.7%
H
0.7
0.8
|
L
 12.7%
H
0.6
0.8
|
L
 8.1%
H
0.6
0.8
|
L
 -28.6%
H
0.6
1.5
|
L
 -71.4%
H
0.6
3.2
|
L
 -96.6%
H
0.6
24
|
L
 -99.2%
H
0.6
253.4
|
| Praxis Precision Medicines Inc |
|
9,289.3
|
333.3
|
L
 -1.4%
H
317.9
353
|
L
 3.1%
H
310
353
|
L
 7.5%
H
300.6
353
|
L
 4.3%
H
271.9
356
|
L
 847.6%
H
35.2
356
|
L
 1938.4%
H
12.5
356
|
L
 -19.6%
H
11.9
432.2
|
L
H
11.9
914.3
|
| PainReform Ltd |
|
1.6
|
1.9
|
L
 -0.5%
H
1.9
2.0
|
L
 1.1%
H
1.9
2
|
L
 -24.9%
H
1.9
2.8
|
L
 -35.8%
H
1.8
3.7
|
L
 -12.4%
H
0.6
3.7
|
L
 -95.4%
H
0.2
158.5
|
L
 -98.8%
H
0.2
470.4
|
L
H
0.2
471
|
| Prelude Therapeutics Inc |
|
410.2
|
5.2
|
L
 6.4%
H
4.7
5.3
|
L
 20.6%
H
4.3
5.3
|
L
 40.0%
H
3.7
5.5
|
L
 137.3%
H
2.0
5.5
|
L
 543.8%
H
0.8
5.5
|
L
 -20.9%
H
0.6
6.9
|
L
 -87.4%
H
0.6
45.3
|
L
H
0.6
95.4
|
| Prime Medicine Inc |
|
563.5
|
3.1
|
L
 -8.5%
H
3.1
3.6
|
L
 -11.6%
H
3.1
3.7
|
L
 -6.6%
H
3.1
4.0
|
L
 -12.6%
H
3.0
4.8
|
L
 134.6%
H
1.1
6.9
|
L
 -78.2%
H
1.1
17.2
|
L
H
1.1
21.7
|
L
H
1.1
21.7
|
| ProKidney Corp Ordinary |
|
266.9
|
1.9
|
L
 -4.1%
H
1.8
2.0
|
L
 3.3%
H
1.8
2.0
|
L
 3.9%
H
1.7
2.2
|
L
 0.5%
H
1.6
2.6
|
L
 172.5%
H
0.5
7.1
|
L
 -79.2%
H
0.5
13.5
|
L
H
0.5
14.2
|
L
H
0.5
14.2
|
| ProQR Therapeutics NV |
|
166.5
|
1.6
|
L
 -8.1%
H
1.6
1.7
|
L
 2.6%
H
1.5
1.7
|
L
 -12.7%
H
1.4
2.2
|
L
 5.3%
H
1.3
2.2
|
L
 1.3%
H
1.3
3.1
|
L
 -25.1%
H
1.1
4.6
|
L
 -73.1%
H
0.5
9.1
|
L
 -66.9%
H
0.5
24
|
| Prothena Corporation plc |
|
566.3
|
10.5
|
L
 -5.9%
H
10.4
11.2
|
L
 -3.2%
H
10.4
11.3
|
L
 4.8%
H
9.8
11.6
|
L
 18.1%
H
8.2
11.6
|
L
 43.1%
H
4.3
11.7
|
L
 -86.6%
H
4.3
79.4
|
L
 -55.5%
H
4.3
79.8
|
L
 -72.5%
H
4.3
79.8
|
| Alpha Compute Corp |
|
6.1
|
0.3
|
L
 -3.7%
H
0.3
0.3
|
L
 18.2%
H
0.2
0.3
|
L
 -18.8%
H
0.2
0.4
|
L
 -51.9%
H
0.2
0.6
|
L
 -97.0%
H
0.2
13.8
|
L
 -99.6%
H
0.2
88
|
L
 -100.0%
H
0.2
899.5
|
L
 -99.9%
H
0.2
1310
|
| Plus Therapeutics Inc |
|
40.8
|
6.0
|
L
 -0.8%
H
5.8
6.5
|
L
 6.3%
H
5.5
6.7
|
L
 78.7%
H
2.9
8
|
L
 -8.5%
H
2.9
8.7
|
L
 -52.4%
H
2.9
23.4
|
L
 -94.0%
H
2.9
127.3
|
L
 -99.3%
H
2.9
1106.3
|
L
 -100.0%
H
2.9
815625
|
| PTC Therapeutics Inc |
|
5,347.0
|
64.5
|
L
 -3.1%
H
64.2
66.3
|
L
 -0.1%
H
63.2
67.3
|
L
 -6.4%
H
63.2
73.8
|
L
 -13.6%
H
61.4
75.0
|
L
 78.2%
H
37.9
87.5
|
L
 15.5%
H
17.5
87.5
|
L
 59.9%
H
17.5
87.5
|
L
 809.6%
H
4.0
87.5
|
| Protagonist Therapeutics Inc |
|
6,968.2
|
98.9
|
L
 -4.9%
H
98.5
104.7
|
L
 0.3%
H
97.1
105.0
|
L
 -3.9%
H
95.4
107
|
L
 17%
H
77
107.8
|
L
 135.3%
H
41.3
107.8
|
L
 298.4%
H
13.7
107.8
|
L
 252.8%
H
6.9
107.8
|
L
H
4.5
107.8
|
| Pulmatrix Inc |
|
4.7
|
1.3
|
L
 -4.4%
H
1.3
1.3
|
L
 4.8%
H
1.3
1.4
|
L
 -1.5%
H
1.2
1.5
|
L
 -47.6%
H
1.2
3.4
|
L
 -79.2%
H
1.2
9.4
|
L
 -56.7%
H
1.2
10.4
|
L
 -92.6%
H
1.2
23.4
|
L
 -99.7%
H
1.2
1396
|
| Polypid Ltd |
|
84.7
|
4.4
|
L
 -0.9%
H
4.3
4.5
|
L
 -2.0%
H
4.3
4.6
|
L
 4.7%
H
4.0
4.8
|
L
 -1.8%
H
4.0
4.8
|
L
 63.8%
H
2.4
5.1
|
L
 -61.1%
H
2.3
13.2
|
L
 -98.3%
H
2.3
289.2
|
L
H
2.3
583.5
|
| Pyxis Oncology Inc |
|
142.1
|
2.3
|
L
 -1.7%
H
2.2
2.3
|
L
 36.1%
H
1.6
2.4
|
L
 55.9%
H
1.4
2.4
|
L
 49.7%
H
1.3
2.4
|
L
 111.2%
H
1.0
5.6
|
L
 -21.8%
H
0.8
6.9
|
L
H
0.8
19
|
L
H
0.8
19
|
| Pharming Grp N.V. (ADR) |
|
847.5
|
12
|
L
 -26.8%
H
11.8
13.1
|
L
 -26.7%
H
11.8
17.0
|
L
 -27.3%
H
11.8
18.4
|
L
 -25.4%
H
11.8
18.4
|
L
 32.7%
H
8.6
21.3
|
L
 6.6%
H
6.7
21.3
|
L
 -4.8%
H
6.1
21.3
|
L
H
6.1
22.0
|
| Purple Biotech Ltd (ADR) |
|
3.6
|
3.9
|
L
 -6.0%
H
3.9
4.3
|
L
 -7.6%
H
3.9
4.5
|
L
 -5.6%
H
3.9
5
|
L
 -35.1%
H
3.6
6.1
|
L
 -82.5%
H
3.6
29
|
L
 -100.0%
H
3.6
7959.6
|
L
 -100.0%
H
3.6
27000
|
L
 -100.0%
H
3.6
278000
|
| PureTech Health Plc ADR |
|
413.1
|
17.0
|
L
 -0.2%
H
16.9
17.7
|
L
 -2.5%
H
16.6
19.3
|
L
 9.5%
H
15.4
19.3
|
L
 -6.2%
H
14.5
19.3
|
L
 -2.5%
H
14.5
19.9
|
L
 -38.4%
H
13.3
34
|
L
 -70.1%
H
13.3
59.9
|
L
H
13.3
65.9
|
| AIxCrypto Holdings Inc |
|
30.6
|
1.4
|
L
 -4.2%
H
1.4
1.5
|
L
 -1.4%
H
1.4
1.5
|
L
 0.7%
H
1.2
1.7
|
L
 -2.8%
H
0.9
1.7
|
L
 -60%
H
0.9
8.8
|
L
 -97.4%
H
0.1
63
|
L
 -99.9%
H
0.1
1560
|
L
 -100.0%
H
0.1
468750
|
| Qilian Intl Holding Grp ltd (Class A) |
|
58.2
|
0.3
|
L
 -3.3%
H
0.3
0.3
|
L
 -3.3%
H
0.3
0.3
|
L
 -12.1%
H
0.3
0.4
|
L
 -74.6%
H
0.3
1.5
|
L
 -97.4%
H
0.3
17.2
|
L
 -95.0%
H
0.3
17.2
|
L
 -98.7%
H
0.3
25.0
|
L
H
0.3
110
|
| Quince Therapeutics Inc |
|
21.2
|
1.3
|
L
 6.6%
H
1.2
1.3
|
L
 5.7%
H
1.2
1.3
|
L
 47.7%
H
0.9
3.8
|
L
 -6.5%
H
0.8
9.8
|
L
 -87.6%
H
0.8
45.5
|
L
 -91.7%
H
0.8
45.5
|
L
 -99.6%
H
0.8
1219.8
|
L
H
0.8
1219.8
|
| uniQure NV |
|
1,515.2
|
24.2
|
L
 5.8%
H
22.6
24.3
|
L
 44.4%
H
17.7
24.3
|
L
 38.9%
H
13.2
24.3
|
L
 -5.9%
H
8.7
27.0
|
L
 110.4%
H
8.7
71.5
|
L
 13.2%
H
3.7
71.5
|
L
 -26.5%
H
3.7
71.5
|
L
 100.1%
H
3.7
82.5
|
| Quoin Pharma Ltd (ADR) |
|
11.5
|
6.4
|
L
 -0.9%
H
6.0
6.7
|
L
 7.4%
H
5.8
6.7
|
L
 -1.1%
H
5.2
7.0
|
L
 -10.8%
H
5.2
10.8
|
L
 2.7%
H
5.2
41.8
|
L
 -99.8%
H
5.1
8400
|
L
 -100.0%
H
5.1
3003840
|
L
H
5.1
3003840
|
| Rain Oncology Inc |
|
53.1
|
1.5
|
L
 -22.3%
H
1.4
1.9
|
L
 -34.8%
H
1.4
2.3
|
L
 -46.1%
H
1.4
2.9
|
L
 -33.3%
H
1.4
3.8
|
L
 -66.9%
H
1.4
9.2
|
L
 -83.4%
H
0.8
10.5
|
L
 -91.2%
H
0.8
22.2
|
L
H
0.8
23.9
|
| Rani Therapeutics Holdings Inc |
|
92.8
|
0.9
|
L
 -3.1%
H
0.9
1.0
|
L
 6.9%
H
0.9
1
|
L
 12.1%
H
0.7
1.1
|
L
 -23.8%
H
0.7
1.4
|
L
 -13.9%
H
0.4
3.9
|
L
 -80.3%
H
0.4
8.8
|
L
 -99.6%
H
0.4
36.3
|
L
H
0.4
224.5
|
| Ultragenyx Pharmaceutical Inc |
|
2,628.7
|
26.1
|
L
 0.8%
H
25.5
26.5
|
L
 8.1%
H
24.2
27.3
|
L
 14.3%
H
22.3
27.3
|
L
 5.8%
H
18.3
27.3
|
L
 -25.5%
H
18.3
42.4
|
L
 -44.7%
H
18.3
60.4
|
L
 -77.4%
H
18.3
117.5
|
L
 -58.6%
H
18.3
179.7
|
| Rocket Pharmaceuticals Inc |
|
400.7
|
3.7
|
L
 -4.9%
H
3.7
3.9
|
L
 5.5%
H
3.4
3.9
|
L
 6.1%
H
3.3
4.1
|
L
 16.1%
H
3.1
5.5
|
L
 -41.8%
H
2.2
7.4
|
L
 -82.5%
H
2.2
32.5
|
L
 -91.5%
H
2.2
49.7
|
L
 -91.2%
H
2.2
67.5
|
| Regeneron Pharma |
|
74,341.4
|
709.1
|
L
 -1.7%
H
707.4
725.3
|
L
 3.3%
H
688.9
726.2
|
L
 -7.1%
H
668.8
775.6
|
L
 -9.7%
H
668.8
815
|
L
 27.0%
H
476.5
821.1
|
L
 -7.0%
H
476.5
1211.2
|
L
 42.2%
H
476.5
1211.2
|
L
 91.7%
H
271.4
1211.2
|
| Replimune Grp Inc |
|
275.8
|
3.3
|
L
 -2.9%
H
3.2
3.5
|
L
 40.3%
H
2.4
3.6
|
L
 -60.9%
H
1.5
8.8
|
L
 -56.9%
H
1.5
9.1
|
L
 -55.5%
H
1.5
13.2
|
L
 -80.9%
H
1.5
24.8
|
L
 -90.6%
H
1.5
40.2
|
L
H
1.5
54.9
|
| Revelation Biosciences Inc |
|
3.8
|
1.0
|
L
H
1
1.1
|
L
 -11.3%
H
1
1.2
|
L
 -12.1%
H
1.0
1.3
|
L
 -38.2%
H
1.0
1.6
|
L
 -97.1%
H
1.0
40.1
|
L
 -100.0%
H
1.0
7488
|
L
 -100.0%
H
1.0
2276064
|
L
H
1.0
2276064
|
| Regencell Bioscience Holdings Ltd |
|
15,561.6
|
31.5
|
L
 14.1%
H
27.4
32
|
L
 8.7%
H
27.0
32
|
L
 2.1%
H
26.5
33.5
|
L
 15.6%
H
20
40
|
L
 688.7%
H
3.9
83.6
|
L
 4527.9%
H
0.1
83.6
|
L
H
0.1
83.6
|
L
H
0.1
83.6
|
| Repligen Corp |
|
7,164.3
|
126.4
|
L
 0.5%
H
123.8
127.7
|
L
 11.8%
H
113.0
131.5
|
L
 8.1%
H
109.5
141.5
|
L
 -11.1%
H
109.5
146.4
|
L
 -3.0%
H
109.5
175.8
|
L
 -21.1%
H
103.0
211.1
|
L
 -31.7%
H
103.0
327.3
|
L
 381.6%
H
21.1
327.3
|
| Regenxbio Inc |
|
537.9
|
10.4
|
L
 2.0%
H
9.9
10.4
|
L
 24.1%
H
8.6
10.4
|
L
 18.4%
H
8.2
10.4
|
L
 0.9%
H
7.6
10.8
|
L
 31.6%
H
6.9
16.2
|
L
 -44.8%
H
5.0
28.8
|
L
 -70.0%
H
5.0
46.5
|
L
 3.9%
H
5.0
85.1
|
| Rigel Pharma |
|
516.6
|
26.2
|
L
 -1.6%
H
25.9
26.7
|
L
 -10.2%
H
25.8
30.4
|
L
 -4.1%
H
25.8
33.2
|
L
 -23.2%
H
25.0
37.0
|
L
 43.7%
H
16.9
52.2
|
L
 2123.7%
H
0.7
52.2
|
L
 704.9%
H
0.6
52.2
|
L
 1035.9%
H
0.6
52.2
|
| Relay Therapeutics Inc |
|
2,249.9
|
12.5
|
L
 -3.2%
H
12.3
12.9
|
L
 -0.5%
H
11.8
13.4
|
L
 0.5%
H
11.8
17.3
|
L
 40.3%
H
8.4
17.3
|
L
 297.1%
H
2.7
17.3
|
L
 11.0%
H
1.8
17.3
|
L
 -57.1%
H
1.8
38.6
|
L
H
1.8
64.4
|
| Relmada Therapeutics Inc |
|
779.3
|
7.4
|
L
 -5.5%
H
7.3
7.8
|
L
 0.8%
H
7.2
8
|
L
 7.7%
H
6.6
8
|
L
 91.5%
H
3.5
8
|
L
 1963.9%
H
0.3
8
|
L
 130.7%
H
0.2
8
|
L
 -80.0%
H
0.2
39.7
|
L
 -26.3%
H
0.2
54
|
| TransCode Therapeutics Inc |
|
7.0
|
7.7
|
L
 1.7%
H
7.5
8.3
|
L
 -8.9%
H
7.5
9.3
|
L
 -14.6%
H
7.5
10.3
|
L
 -14.1%
H
7.5
11.1
|
L
 -24.6%
H
6.1
21.0
|
L
 -100.0%
H
6.1
286070.4
|
L
H
6.1
5174400
|
L
H
6.1
5174400
|
| RenovoRx Inc |
|
39.6
|
0.9
|
L
 -1.1%
H
0.9
0.9
|
L
 6.0%
H
0.8
1.0
|
L
 -5.4%
H
0.8
1.1
|
L
 -11.1%
H
0.8
1.3
|
L
 -14.6%
H
0.7
1.5
|
L
 -67.5%
H
0.6
3.3
|
L
H
0.6
16.7
|
L
H
0.6
16.7
|
| Roivant Sciences Ltd |
|
20,240.0
|
28.3
|
L
 -1.9%
H
27.9
28.9
|
L
 2.8%
H
27.5
29
|
L
 1.4%
H
27.1
30.2
|
L
 9.5%
H
25.7
30.3
|
L
 155.7%
H
10.6
30.3
|
L
 228.1%
H
8.2
30.3
|
L
 185.4%
H
2.5
30.3
|
L
H
2.5
30.3
|
| Royalty Pharma PLC (Class A) |
|
22,307.8
|
50.2
|
L
 -1.0%
H
49.3
50.9
|
L
 1.4%
H
49.1
51.7
|
L
 6.1%
H
46.5
51.7
|
L
 12.4%
H
42.5
51.7
|
L
 56.3%
H
32.2
51.7
|
L
 43.0%
H
24.1
51.7
|
L
 22.3%
H
24.1
51.7
|
L
H
24.1
56.5
|
| Revolution Medicines Inc |
|
30,296.6
|
142.5
|
L
 -5.7%
H
142.1
149.8
|
L
 1.4%
H
138.8
151.4
|
L
 49.4%
H
94
155.7
|
L
 46.2%
H
91.5
155.7
|
L
 280.6%
H
34
155.7
|
L
 485.5%
H
15.5
155.7
|
L
 391.4%
H
14.1
155.7
|
L
H
14.1
155.7
|
| Reviva Pharma Holdings Inc |
|
11.0
|
0.9
|
L
 -2.3%
H
0.8
0.9
|
L
 -1.2%
H
0.8
0.9
|
L
 21.1%
H
0.7
1
|
L
 -85.0%
H
0.6
6.1
|
L
 -94.6%
H
0.6
23.2
|
L
 -99.5%
H
0.6
184.4
|
L
 -99.2%
H
0.6
185
|
L
H
0.6
302
|
| Recursion Pharma Inc (Class A) |
|
1,730.8
|
3.3
|
L
 -4.7%
H
3.3
3.5
|
L
 -0.9%
H
3.1
3.6
|
L
 3.8%
H
3.0
3.9
|
L
 -17.8%
H
2.8
4.1
|
L
 -21.4%
H
2.8
7.2
|
L
 -36.6%
H
2.8
16.7
|
L
 -88.3%
H
2.8
42.8
|
L
H
2.8
42.8
|
| Rhythm Pharma Inc |
|
6,541.2
|
96.2
|
L
 -0.4%
H
94.0
97.5
|
L
 17.2%
H
79.4
99
|
L
 10.7%
H
79.4
99
|
L
 -7.1%
H
74.5
106.3
|
L
 53.5%
H
55.3
122.2
|
L
 476.6%
H
15.5
122.2
|
L
 347.6%
H
3.0
122.2
|
L
H
3.0
122.2
|
| Rezolute Inc |
|
295.7
|
3.1
|
L
 -1.6%
H
3
3.2
|
L
 -1.0%
H
3
3.5
|
L
 -5.2%
H
3.0
3.9
|
L
 -1.0%
H
2.3
4.1
|
L
 -17.8%
H
1.1
11.5
|
L
 34.3%
H
0.7
11.5
|
L
 -55.3%
H
0.7
17.4
|
L
 -93.6%
H
0.7
100
|
| Redhill Biopharma (ADR) |
|
5.2
|
1.0
|
L
 -1.0%
H
1.0
1.0
|
L
 -2.9%
H
0.9
1.1
|
L
 21.7%
H
0.8
1.1
|
L
 -5.6%
H
0.7
1.1
|
L
 -47.7%
H
0.7
3.3
|
L
 -98.1%
H
0.7
82
|
L
 -100.0%
H
0.7
11180
|
L
 -100.0%
H
0.7
16540
|
| SAB Biotherapeutics Inc |
|
287.4
|
4.1
|
L
 7.6%
H
3.8
4.5
|
L
 17.5%
H
3.5
4.5
|
L
 6.2%
H
3.4
4.5
|
L
 -1.9%
H
3.4
5.2
|
L
 144.9%
H
1.6
6.6
|
L
 370.1%
H
0.4
6.6
|
L
 -58.7%
H
0.4
12.9
|
L
H
0.4
12.9
|
| Sana biotech Inc |
|
945.0
|
3.5
|
L
 -3.9%
H
3.4
3.6
|
L
 7.7%
H
3.2
3.7
|
L
 8.7%
H
3.0
4.1
|
L
 -10.9%
H
2.7
4.5
|
L
 104.7%
H
1.6
6.6
|
L
 -38.6%
H
1.3
12
|
L
 -79.0%
H
1.3
26.6
|
L
H
1.3
44.6
|
| Filana Therapeutics Inc |
|
65.7
|
1.4
|
L
 -5.6%
H
1.3
1.4
|
L
 -5.6%
H
1.3
1.6
|
L
 -19.1%
H
1.3
1.8
|
L
 -33%
H
1.3
2.5
|
L
 -9.9%
H
1.3
5.0
|
L
 -93.9%
H
1.2
42.2
|
L
 -96.7%
H
1.2
146.2
|
L
 -91.9%
H
0.8
146.2
|
| Sunshine Biopharma Inc |
|
5.3
|
1.1
|
L
H
1.1
1.1
|
L
 11.3%
H
1.0
1.1
|
L
 -6.9%
H
1.0
1.2
|
L
 -10%
H
1.0
1.3
|
L
 -17.6%
H
1.0
2.4
|
L
 -98.0%
H
0.1
140
|
L
 -100.0%
H
0.1
6280
|
L
 -100.0%
H
0.1
224000
|
| Scilex Holding Co |
|
56.5
|
8.0
|
L
 -15.4%
H
7.5
9.6
|
L
 -6.9%
H
7.5
12.3
|
L
 12.8%
H
4.2
12.3
|
L
 -5.3%
H
4.2
12.3
|
L
 63.8%
H
3.9
34.3
|
L
 48.9%
H
0.2
34.3
|
L
 -19.3%
H
0.2
34.3
|
L
H
0.2
34.3
|
| Scynexis Inc |
|
76.3
|
1.0
|
L
 -2.0%
H
1.0
1.0
|
L
 3.2%
H
0.9
1.0
|
L
 4.4%
H
0.9
1.1
|
L
 26.3%
H
0.7
1.1
|
L
 2.1%
H
0.6
1.3
|
L
 -67.9%
H
0.6
3.9
|
L
 -86.2%
H
0.6
10.3
|
L
 -97.6%
H
0.6
55.1
|
| Seer Inc (Class A) |
|
103.5
|
1.9
|
L
 -0.5%
H
1.9
1.9
|
L
H
1.8
2.1
|
L
 9.9%
H
1.7
2.1
|
L
 5.0%
H
1.7
2.2
|
L
 -0.5%
H
1.7
2.4
|
L
 -48.1%
H
1.5
5.7
|
L
 -95.3%
H
1.5
45.9
|
L
H
1.5
86.6
|
| Selecta Biosciences Inc |
|
1,263.6
|
8.2
|
L
 -2.2%
H
7.9
8.5
|
L
 26.1%
H
6.0
8.5
|
L
 30.8%
H
5.8
8.5
|
L
 25.7%
H
5.6
9.3
|
L
 -20.5%
H
5.6
15.6
|
L
 -20.5%
H
5.6
15.6
|
L
 -20.5%
H
5.6
15.6
|
L
 -20.5%
H
5.6
15.6
|
| Shuttle Pharma Holdings Inc |
|
3.9
|
0.7
|
L
 -9.0%
H
0.7
0.8
|
L
 -29%
H
0.7
1.1
|
L
 -4.1%
H
0.7
1.2
|
L
 -56.4%
H
0.5
1.6
|
L
 -89.6%
H
0.5
11.3
|
L
 -99.7%
H
0.5
550
|
L
H
0.5
25252
|
L
H
0.5
25252
|
| SIGA Tech Inc |
|
339.3
|
4.7
|
L
 0.6%
H
4.7
4.9
|
L
 4.4%
H
4.5
4.9
|
L
 2.8%
H
4.3
4.9
|
L
 -29.4%
H
4.3
7.0
|
L
 -10.3%
H
4.3
9.6
|
L
 -20.2%
H
4.2
12.8
|
L
 -35.5%
H
4.2
27.0
|
L
 425.6%
H
0.6
27.0
|
| SILO Pharma Inc |
|
6.8
|
0.4
|
L
H
0.4
0.4
|
L
 -6.7%
H
0.4
0.5
|
L
 16.7%
H
0.4
0.7
|
L
 35.5%
H
0.2
0.7
|
L
 -48.8%
H
0.2
1.1
|
L
 -80.9%
H
0.2
4.5
|
L
 -96.6%
H
0.2
496
|
L
 -99.2%
H
0.2
496
|
| Solid Biosciences Inc |
|
695.8
|
7.1
|
L
 -1.8%
H
6.9
7.3
|
L
 0.3%
H
6.8
7.5
|
L
 -8.7%
H
6.8
8.9
|
L
 8.4%
H
5.2
8.9
|
L
 109.8%
H
2.4
8.9
|
L
 32.1%
H
1.8
15.1
|
L
 -89.8%
H
1.8
73.7
|
L
H
1.8
822.6
|
| Sol-Gel Tech Ltd |
|
225.7
|
69.5
|
L
 -2.6%
H
67.6
71
|
L
 -2.6%
H
67.6
80.5
|
L
 -6.5%
H
67.4
84.2
|
L
 5.7%
H
60.6
98.0
|
L
 807.8%
H
6.6
98.0
|
L
 1858.9%
H
0.3
98.0
|
L
 621.4%
H
0.3
98.0
|
L
H
0.3
98.0
|
| Soleno Therapeutics Inc |
|
2,759.8
|
53.0
|
L
 0.0%
H
52.9
53.0
|
L
 0.3%
H
52.8
53.0
|
L
 1.3%
H
52.2
53.0
|
L
 27.5%
H
29.4
53.0
|
L
 -28.2%
H
29.4
90.3
|
L
 1264.7%
H
3.7
90.3
|
L
 233.0%
H
0.9
90.3
|
L
 -39.1%
H
0.9
117.8
|
| SELLAS Life Sciences Grp Inc |
|
909.7
|
4.9
|
L
 -4.3%
H
4.9
5.1
|
L
 5.6%
H
4.7
5.2
|
L
 8.8%
H
4.2
5.5
|
L
 32.2%
H
3.5
6.1
|
L
 186.6%
H
1.4
6.1
|
L
 193.5%
H
0.5
6.1
|
L
 -37.0%
H
0.5
15.1
|
L
 -100.0%
H
0.5
74703
|
| Summit Therapeutics Inc |
|
13,311.2
|
17.2
|
L
 -3.9%
H
16.8
18.2
|
L
 -17.7%
H
15.1
22.4
|
L
 -8.2%
H
15.1
29.2
|
L
 14.4%
H
14.6
29.2
|
L
 -29.1%
H
13.8
31.0
|
L
 690.3%
H
1.5
36.9
|
L
 188.2%
H
0.7
36.9
|
L
 100.1%
H
0.7
36.9
|
| Syndax Pharma Inc |
|
1,820.1
|
20.5
|
L
 -0.5%
H
20.2
20.8
|
L
 -0.4%
H
19
21.6
|
L
 -15.4%
H
19
25.4
|
L
 -2.2%
H
19
25.6
|
L
 93.1%
H
8.6
25.6
|
L
 2.4%
H
8.6
25.6
|
L
 34.4%
H
8.6
29.9
|
L
 41.8%
H
3.4
29.9
|
| Soligenix Inc |
|
3.2
|
0.3
|
L
 -6.1%
H
0.3
0.3
|
L
 -8.8%
H
0.3
0.4
|
L
 -72.8%
H
0.3
1.4
|
L
 -72.6%
H
0.3
1.4
|
L
 -83.6%
H
0.3
6.2
|
L
 -98.2%
H
0.3
85.3
|
L
 -99.9%
H
0.3
324.0
|
L
 -100.0%
H
0.3
2136.0
|
| Sonoma Pharma Inc |
|
4.6
|
1.2
|
L
 -0.8%
H
1.2
1.2
|
L
 11.3%
H
1.1
1.3
|
L
 -49.1%
H
0.9
2.9
|
L
 -61.1%
H
0.9
3.1
|
L
 -61.1%
H
0.9
6.9
|
L
 21.6%
H
0.1
6.9
|
L
 -83.6%
H
0.1
13.4
|
L
 -97.4%
H
0.1
74.2
|
| Synaptogenix Inc |
|
46.0
|
6.2
|
L
 -4.4%
H
6.1
6.9
|
L
 27.5%
H
4.8
6.9
|
L
 3.7%
H
3.8
6.9
|
L
 55.6%
H
3.5
7.2
|
L
 152.5%
H
2.1
12.0
|
L
 616.3%
H
0.1
12.0
|
L
 -24.1%
H
0.1
14.5
|
L
H
0.1
14.5
|
| Sensei Biotherapeutics Inc |
|
31.9
|
23.8
|
L
 -8.7%
H
23.8
27.2
|
L
 -16.0%
H
23.8
33
|
L
 -28.8%
H
23.8
34.7
|
L
 168.2%
H
8.7
36.8
|
L
 199.2%
H
5.3
36.8
|
L
 -27.1%
H
5
38.8
|
L
 -89.9%
H
5
302.4
|
L
H
5
530
|
| Senti Biosciences Inc |
|
30.5
|
1.0
|
L
 1.0%
H
1.0
1.1
|
L
H
0.9
1.1
|
L
 7.7%
H
0.8
1.2
|
L
 5.4%
H
0.8
1.2
|
L
 -70.3%
H
0.8
3.9
|
L
 -90.5%
H
0.8
16.9
|
L
H
0.7
87.7
|
L
H
0.7
87.7
|
| Spruce Biosciences Inc |
|
152.9
|
56.6
|
L
 -2.3%
H
55.6
57.4
|
L
 1.9%
H
54.9
60.3
|
L
 -10.2%
H
51.4
74
|
L
 -21.9%
H
48.1
86.9
|
L
 963.4%
H
4.4
240
|
L
 -67.2%
H
4.3
446.3
|
L
 -95.2%
H
4.3
1214.3
|
L
H
4.3
2670
|
| SciSparc Ltd |
|
3.9
|
6.7
|
L
 5.3%
H
6.2
7.1
|
L
 -25.6%
H
6.2
8.9
|
L
 87.2%
H
3.0
9.0
|
L
 9.1%
H
3.0
9.0
|
L
 -88.5%
H
3.0
80.1
|
L
 -99.8%
H
3.0
4471.7
|
L
H
3.0
41769
|
L
H
3.0
41769
|
| Spero Therapeutics Inc |
|
145.3
|
2.5
|
L
 -0.8%
H
2.5
2.6
|
L
 -0.8%
H
2.4
2.6
|
L
 -3.8%
H
2.4
2.9
|
L
 3.7%
H
2.1
2.9
|
L
 325.4%
H
0.6
3.2
|
L
 28.7%
H
0.5
3.2
|
L
 -80.3%
H
0.5
19.9
|
L
H
0.5
23.6
|
| ARS Pharma Inc |
|
893.7
|
9
|
L
 -3.0%
H
8.8
9.4
|
L
 14.8%
H
7.7
9.6
|
L
 7.3%
H
7.7
9.6
|
L
 -10.3%
H
7.2
10.1
|
L
 -35.8%
H
6.7
18.9
|
L
 42.6%
H
2.6
18.9
|
L
 -67.9%
H
2.6
35.6
|
L
H
2.6
63.4
|
| SeqLL Inc |
|
74.7
|
1.5
|
L
 -0.7%
H
1.4
1.5
|
L
 -15.3%
H
1.2
1.8
|
L
 -55.4%
H
1.2
3.4
|
L
 -56.8%
H
1.2
4.6
|
L
 -42.7%
H
1.2
5.3
|
L
 246.5%
H
0.3
35.4
|
L
H
0.2
35.4
|
L
H
0.2
35.4
|
| Sarepta Therapeutics Inc |
|
2,195.9
|
20.8
|
L
 -9.7%
H
20.1
22.7
|
L
 0.6%
H
20.1
23.5
|
L
 -8.8%
H
18.4
23.7
|
L
 12.4%
H
15.5
23.9
|
L
 -55.5%
H
10.4
44.1
|
L
 -84.1%
H
10.4
173.3
|
L
 -72.1%
H
10.4
173.3
|
L
 17.5%
H
10.4
181.8
|
| Scholar Rock Holding Corp |
|
5,541.6
|
46.5
|
L
 -1.4%
H
45
49.9
|
L
 0.3%
H
45
49.9
|
L
 -4.8%
H
45
51.6
|
L
 -2.5%
H
38.8
51.6
|
L
 58.5%
H
27.1
51.6
|
L
 492.5%
H
5.6
51.6
|
L
 57.0%
H
4.3
51.6
|
L
H
4.3
70
|
| Surrozen Inc |
|
361.7
|
30.8
|
L
 -9.9%
H
30.5
35
|
L
 -2.6%
H
30.5
35
|
L
 12.2%
H
25.1
35
|
L
 34.9%
H
21.6
35
|
L
 211.9%
H
5.9
35
|
L
 4941.0%
H
0.3
35
|
L
H
0.3
35
|
L
H
0.3
35
|
| Stoke Therapeutics Inc |
|
1,939.6
|
32.8
|
L
 -1.5%
H
31.8
33.0
|
L
 1.1%
H
31.8
35.2
|
L
H
31.8
37.4
|
L
 1.2%
H
29.9
40.2
|
L
 274.7%
H
8.5
40.2
|
L
 174.4%
H
3.4
40.2
|
L
 4.5%
H
3.4
41.6
|
L
H
3.4
71.6
|
| Sutro Biopharma Inc |
|
659.9
|
39.8
|
L
 5.7%
H
36.5
40.3
|
L
 12.6%
H
34.4
40.3
|
L
 66.3%
H
23.4
40.3
|
L
 156.6%
H
13.9
40.3
|
L
 319.3%
H
6.7
40.3
|
L
 -27.3%
H
5.2
61.3
|
L
 -78.5%
H
5.2
237
|
L
H
5.2
283
|
| Shattuck Labs Inc |
|
473.1
|
6.3
|
L
 -6.3%
H
6.0
6.7
|
L
 -11.7%
H
6.0
7.8
|
L
 -7.7%
H
6.0
8.3
|
L
 66.1%
H
3.7
8.3
|
L
 619.5%
H
0.7
8.3
|
L
 131.9%
H
0.7
11.8
|
L
 -80.4%
H
0.7
32.5
|
L
H
0.7
60.5
|